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General abstract
Late-onset Alzheimer’s disease (LOAD) is a heritable disorder. It is invariably 
characterised by a decline in cognitive abilities, however, marked variation in 
behavioural symptoms and age at onset are observed between sufferers. This 
clinical heterogeneity may be genetically modified, hence, may provide a 
productive avenue of exploration for those seeking to unravel the genetic aetiology 
of LOAD. This thesis employed a sequential three stage approach to search for 
loci implicated in the development of genetically influenced features of the 
disease.
Behavioural symptoms in 1,120 unrelated individuals with LOAD were assessed 
using the Neuropsychiatric Inventory. The 12 symptom domain scores were 
subjected to principal components analysis. Three interpretable components were 
identified, comprising: “frontal lobe dysfunction”, “psychosis” and “mood”. These 
components remained stable when taking account of disease severity.
The familiality of clinical variation was assessed. Affected siblings from 388 
families were characterised in terms of aggression, psychosis and mood 
disturbances. Age at onset data were available for affected siblings from 458 
families. Familial clustering was found for age at onset, psychosis, aggression and 
mild depression, with the strongest evidence noted for age at onset and psychosis. 
Major depression and a combined phenotype of depression with anxiety showed 
limited evidence of familial aggregation.
Covariate linkage analysis was employed to search for loci which may influence 
clinical variation in LOAD. This included a sample of 513 affected relative pairs. 
Increases in LOD were observed with age at onset (chromosome 1, 2,12,19 and 
21), aggression (chromosome 9), psychosis (chromosome 7 and 15) and minor 
depression (chromosome 21).
Understanding factors associated with behavioural symptoms and age at disease 
onset may lead to the achievable goal of disease modification. These findings 
support the hypothesis that clinical variation in AD is genetically modified, setting 
the stage for future linkage and association studies.
1
Chapter 1 
General Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and is the 
primary cause of dementia in elderly populations. It is estimated that AD accounts 
for about two thirds of subjects with dementia (Nussbaum and Ellis 2003) and that 
it afflicts approximately 15 million individuals worldwide (Fratiglioni et al. 1999). In 
the United States alone it is estimated that as many as 4.5 million individuals are 
currently suffering with AD (Hebert et al. 2003). In England and Wales there are 
thought to be approximately 180,000 new cases of dementia each year (Matthews 
and Brayne 2005).
Aside from the obvious detrimental effects to sufferers, AD also causes severe 
distress for family members and caregivers, along with placing a huge burden on 
the economy (Lowin et al. 2001). In the United Kingdom, the direct costs of AD are 
between 7 and 14 billion pounds per year (Lowin et al. 2001), whilst in the United 
states the total annual cost has been estimated at around $76 billion (Rice et al. 
1993). Current projections suggest that the number of elderly people will double in 
the next generation, resulting in more than a billion people over the age of 60 by 
2025 in Europe alone (Taket 1992). Given that AD is age dependent, the 
escalating growth of the elderly population, particularly in the oldest age group, 
means that the economic and societal costs of the disease will increase over the 
coming years (Villareal and Morris 1999). Herbert and colleagues (2003) 
estimated that, baring a cure, the number of individuals with AD in the United 
States will increase almost threefold by 2050, to over 13 million people. The 
predicted increase in the prevalence will undoubtedly have an enormous impact 
on society (Souetre et al. 1999).
There is currently no cure for AD. Cholinesterase inhibitors and A/-methyl d- 
aspartate receptor-targeted therapies are, at present, the only treatments available 
in the UK. These forms of medication provide modest benefits to cognition, 
activities of daily living and behaviour, and can provide temporary stabilisation of 
the rate of decline (Desai and Grossberg 2005). However, they do not benefit all
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AD sufferers and their positive affects are usually temporary (Cummings and Cole 
2002). As such, there is an urgent need for more effective therapeutic 
interventions. Even treatments which reduce the incidence of AD by only 1 % 
would offset the projected increase in costs due to an aging population 
(Brookmeyer et al. 1998). It is therefore essential that we gain a comprehensive 
understanding of its aetiology. Such an understanding could lead to the 
achievable goal of disease-modification. In recent years major advances in 
understanding the causes and pathogenesis of AD have arisen from molecular 
genetic research and this powerful tool will undoubtedly continue to provide 
important conceptual and practical advances. Therefore, gaining a more complete 
understanding of the genetic contribution to AD must be a priority, as it will provide 
a strong platform for the development of future preventative and therapeutic 
strategies.
1.1 Clinical definition of Alzheimer’s disease
The diagnosis of AD is difficult. To date there are no specific neuroimaging or 
biological markers for the disease. Histopathological examination of brain tissue at 
post mortem is the only way to diagnose AD definitively. However, even this is 
problematic, as only 50% to 60% of individuals meeting neuropathological criteria 
for AD will have experienced cognitive decline during life (Knopman et al. 2003).
Diagnosis of AD is generally based on physical examination, patient history and 
detailed cognitive assessment. These approaches serve to compare each 
individual against a series of inclusion criteria and also allow competing causes of 
dementia to be systematically excluded (e.g. vascular dementia, dementia with 
lewy bodies etc.). These approaches can be complimented by the use of 
neuroimaging which generally serves to identify vascular contributions to dementia 
and rule out potentially treatable causes (Kantarci and Jack 2003). Typically, AD is 
characterised by an insidious onset and gradual decline in cognition and functional 
abilities (Desai and Grossberg 2005). An initial phase of forgetfulness is usually 
accompanied by difficulty learning, recalling new information and progressive 
language disorder, from anomia in the early stages to complete aphasia as the 
illness progresses. Visuospatial difficulties can often become apparent,
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manifesting as geographical disorientation or difficulty with copying figures in 
cognitive testing (Cummings and Cole 2002). Furthermore, deficits in executive 
function usually occur over the course of the illness (Baudic et al. 2005; Rainville 
et al. 2002). Motor disturbances are common in the later stages of disease 
development, including gait changes, rigidity and seizures (McKhann et al. 1984). 
The advanced stages of the disease are characterised by total dependence on 
others for assistance in activities of daily living. At this point patients often lose all 
semblance of speech and are frequently bed bound (Villareal and Morris 1999). 
Without treatment those with AD usually survive for between 7 and 10 years after 
onset of symptoms (Bracco et al. 1994; Larson et al. 2004).
DSM-IV (American Psychiatric Association, 1994) and the National Institute of 
Neurological and Communication Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Associations (NINCDS-ADRDA) (McKhann et al. 
1984) criteria are generally used in both research and clinical settings to make a 
diagnosis of Alzheimer’s disease. These criteria were mainly developed to attain 
uniformity of classification for research and treatment purposes (Clarfield and 
Foley 1993). They both require deficits in memory and one other area of cognition, 
including aphasia, apraxia, agnosia and executive functioning, further stipulating 
that these difficulties should cause significant decline in functional abilities and 
activities of daily living. DSM-IV and NINCDS-ADRDA criteria also stipulate that 
the illness should be characterised by an insidious onset and gradual decline in 
cognitive and functional abilities, and that competing causes of dementia are ruled 
out. NINCDS-ADRDA guidelines specify separate criteria for possible and definite 
AD. A diagnosis of possible AD is reserved for those with an atypical course of 
illness or individuals who might have some other co-morbid illness that can lead to 
dementia but that is not considered to be the primary cause of the disease.
Definite AD is reserved for cases where pathological evidence is available, either 
by autopsy or brain biopsy, which shows an excess abundance of neurofibrillary 
tangles and senile plaques compared to what would be expected among healthy 
age matched individuals (McKhann et al. 1984).
The reliability and validity of DSM and NINCDS-ADRDA criteria for AD have been 
found to be good. To assess the inter-rater reliability of diagnostic criteria for AD
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O’Conner and colleagues (1996) compared diagnoses of 100 elderly people, with 
a variety of diagnoses, within and between five research centres based in 
Australia, Germany, the Netherlands, United Kingdom and United States. The 
within centre inter-rater reliability, using DSM criteria for AD, was high, whilst 
between centre reliability was reported to be moderate to good. To assess the 
validity of these diagnostic criteria a number of studies have attempted to confirm, 
via autopsy, diagnoses made using NINCDS-ADRDA and DSM criteria during life. 
In general, the accuracy of clinical diagnosis relative to neuropathology has been 
reported to be between 86% and 93% (Becker et al. 1994; Gearing et al. 1995; 
Holmes et al. 1999). However, despite the validity of the diagnostic criteria it is still 
notable that ‘pure AD’ only accounts for between 50% and 60% of all dementia 
cases, with a further 20% to 30% showing AD pathology in conjunction with other 
pathological lesions (Desai and Grossberg 2005; Gearing et al. 1995; Holmes et 
al. 1999).
Both DSM-IV and NINCDS-ADRDA criteria support a cut-off of 65 to differentiate 
between early- and late- onset AD. Both early- and late- onset forms of AD are 
often categorised as sporadic or familial (Ashford and Mortimer 2002). The term 
familial AD is usually reserved for cases in which a clear pattern of autosomal 
dominant inheritance is observed, or for cases carrying genetic mutations known 
to cause early-onset forms of the disease. Familial cases usually present with the 
disease before 65 years of age. Sporadic, or non-familial AD, which constitutes 
around 95% of cases of the disease, includes those in which no clear mode of 
inheritance is observed (Ashford and Mortimer 2002).
The neuropathological hallmarks of the disease include extracellular deposits of p- 
amyloid in senile plaques, neurofibrillary tangles of phosphorylated tau protein, 
neuron degeneration and synaptic loss (Cummings and Cole 2002; Kamboh 
2004). The current criteria for pathological diagnosis of definite AD require the 
presence of both senile plaques and neuropathological tangles (Reagan Institute 
Working Group on Diagnostic Criteria for the Neuropathological Assessment of 
Alzheimer’s Disease 1997). The main constituent of the extracellular senile 
plaques is the 42 amino-acid amyloid p peptide (AP) that is derived from the 
amyloid precursor protein (APP) (Kamboh 2004). The APP protein is present in
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almost all tissues, and undergoes three alternative steps of cleavage by a-, p- and 
y-secretase enzymes. When cut by a-secretase and then y-secretase, APP 
generates a harmless peptide. However, when cut by p-secretase and then y -  
secretase, APP generates peptides of 39 to 43 amino acids, of which Ap-42 
accounts for about 10%. Ap-42 is neurotoxic and involved in the formation of 
senile plaques in AD brains (Selkoe 2001). Tangles are the second major 
histopathological feature of AD. They contain paired helical filaments of 
abnormally phosphorylated tau protein which occupy the cell body and extend into 
the dendrites. Senile plaques and neurofibrillary tangles can occur independently 
of one another (Selkoe 2001). AD is also characterised by reduction in synaptic 
density and loss of neurons. Neuronal loss or atrophy in the nucleus basalis, locus 
ceruleus and raphe nuclei of the brainstem leads to deficits in cholinergic, 
noradrenergic and serotonergic transmitters, respectively (Cummings and Cole 
2002). Synaptic loss is the best current pathologic correlate of cognitive decline, 
and synaptic dysfunction is evident long before synapses and neurons are lost 
(Coleman et al. 2004).
1.2 Epidemiology of late-onset Alzheimer’s disease
AD accounts for between 45% and 76% of cases of dementia in those over 65 
years of age (Bachman et al. 1992; Gautrin et al. 1990; Kokmen et al. 1989;
Ostbye and Crosse 1994; von Strauss et al. 1999). It is estimated that between 2.3 
and 4.5 million individuals are currently suffering with AD in the United states 
(Brookmeyer et al. 1998; Hebert et al. 2003). In England and Wales it is estimated 
that there are approximately 180,000 new cases of dementia each year (Matthews 
and Brayne 2005). Perhaps the most notable risk factors for late-onset Alzheimer’s 
disease (LOAD) are a family history of dementia and the presence of the 
Apolipoprotein (APOE) e4 allele. Numerous population based twin studies have 
been conducted and generally support a heritability estimate of around, or in 
excess of, 60% (Bergem et al. 1997; Gatz et al. 1997; Raiha et al. 1996), whilst 
family based studies consistently find the presence of one or more affected family 
members to be a strong risk factor for the disease (Fratiglioni et al. 1993; Jarvik et 
al. 1996; Martinez et al. 1998; Sleegers et al. 2004; van Duijn et al. 1991). Twin 
and family studies of late-onset AD are discussed in more detail in sections 3.1.2
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and 3.1.3. Despite displaying substantial heritability, APOE is currently the only 
gene to show consistent association with LOAD. The association between APOE 
and AD will be discussed in section 1.3. In addition to genetics, numerous other 
risk factors have been reported, of which increasing age, female gender and low 
levels of education are the most consistent and will be discussed briefly in this 
chapter. Other, less well supported, risk factors have been reported, including 
smoking (Bowirrat et al. 2001; Lee 1994; Letenneur et al. 1994b), head injury 
(Launer et al. 1999; Nicoll et al. 1995; Canadian Study of Health and Aging 1994), 
depression (Devanand et al. 1996; Speck et al. 1995), cardiovascular risk factors 
(Luchsinger et al. 2004) and oestrogen replacement therapy (Henderson et al. 
1994; Schmidt et al. 1996). However, a full review of these is beyond the scope of 
this introduction.
1.2.1 Aging and late-onset Alzheimer’s disease
Increasing age is the most notable non-genetic risk factor for AD. Numerous 
studies have aimed to estimate the risk attributable to aging. Comparisons 
between these studies are hampered by the use of different methodology and 
study populations. Some have sought to determine the prevalence of AD (e.g. the 
proportion of affected individuals in the population at a specific point in time), 
according to age and other risk factors. Alternatively, others have focused on 
disease incidence over time (e.g. the number of newly acquired cases among 
previously healthy individuals over a given period of time). In theory, cumulative 
incidence at specific ages should equal the age specific prevalence.
Prevalence estimates have tended to vary across studies. The Rotterdam study, 
employed a cross sectional, population based, design incorporating 7,528 
participants from a suburb of Rotterdam (Ott et al. 1995). The prevalence of AD 
was estimated to be 0.9%, 7.4% and 26.8% among those in the 65 to 74, 75 to 84 
and £ 85 year age groups respectively. These estimates are somewhat lower than 
those reported elsewhere. For example, in a population based study of all 
individuals aged 65 years or older in three urban Chicago neighbourhoods, Hebert 
and colleagues (2003) reported a steady rise in AD prevalence from around 5%
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among those between 65 and 74 years of age, to nearly 50% in those aged 85 
years or older.
Some have suggested that the increasing risk of AD with age may be exaggerated 
by studies looking at the age specific prevalence rates, as prevalence is 
determined by both incidence and duration of the disease. Hence, differential 
survival within specific age groups could affect the age distribution of dementia 
prevalence (Drachman 1994). As such longitudinal based studies which focus on 
the incidence of AD may be better placed to delineate the relationship between 
aging and dementia.
A number of larger, multi centre and meta-analyses have been performed, which 
are likely to provide the most reliable and informative sources of data. Recently, 
Matthews and Brayne (2005) reported data from the MRC-CFAS study, in which 
individuals from England and Wales were assessed longitudinally for 2 years.
They found that the incidence of AD rose with age, from 7.4 per 1,000 person 
years at 65 to 69 years of age to 84.9 per 1,000 person years in those aged over 
85. These findings are comparable with other large population based analyses of 
AD incidence. For example, Jorm and Jolley (1998) performed a meta-analysis 
using data from 23 published studies, concluding that incidence rates for both 
dementia and AD rose exponentially up to the age of 90 years. Incidence rates 
differed according to ethnicity and with diagnostic criteria for dementia, with lower 
incidence in Eastern Asians, but were largely comparable to those reported by 
Matthews and Brayne (2005). Similarly, consistent results were reported by the 
authors of the European studies of dementia network (EURODEM) (Launer 1992). 
EURODEM was formed in 1988 to harmonise protocols used in a number of 
population based follow up studies on incident dementing illness. In 1999, 
analyses of 528 incident dementia patients were presented, incorporating over 
28,000 years of person follow up (Launer et al. 1999). Of these, 352 patients were 
diagnosed with AD. They reported that disease incidence increased steeply with 
age, from 2.5 per 1000 person years at 65 years of age to 85.6 in those aged 90+ 
years.
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Further to these larger studies, findings from numerous population based samples 
at single sites have been used to determine age specific incidence rates for AD in 
a variety of populations, including American rural (Ganguli et al. 2000) and urban 
communities (Bachman et al. 1993; Fillenbaum et al. 1998; Havlik et al. 2000; 
Hebert et al. 1995; Kawas et al. 2000; Newman et al. 2005; Tang et al. 2001), 
Canada (Canadian Study of Health and Aging 1994), Italy (Di Carlo et al. 2002), 
Nigeria (Hendrie et al. 2001), Sweden (Fratiglioni et al. 1997; Guo et al. 1999; von 
Strauss, 1999), Rotterdam, Holland (Ott et al.), Cambridge, UK (Paykel et al. 
1998), Australia (Waite et al. 2001) and Japan (Yoshitake et al. 1995).
On the whole most studies report incidence rates of between 1 and 7.4 per 1000 
person years in those aged around 65, raising to between 20 and 85 per 1000 
person years among those aged over 85. There is some variation in incidence 
rates reported in these studies. For example, compared to findings elsewhere, 
lower levels of AD were reported in the Framingham Study (Bachman et al. 1993) 
and in a study of community dwelling Italians (Di Carlo et al. 2002). Variable 
incidence rates could be attributable to differences in study design, population 
sampling methods, diagnostic criteria or real geographical incidence variations.
For example, the study of an Italian population, reported by Di Carlo and 
colleagues, employed a two stage assessment approach, in which all individuals 
were screened using the mini mental state examination (MMSE). Those who 
scored below a certain cut-off were referred for further diagnostic evaluation. 
However, such an approach assumes perfect screening test sensitivity (Rogan 
and Gladen 1978). This is a particular problem as the MMSE is known to have low 
sensitivity for cognitive decline, especially in the early stages of disease 
development (Cummings and Cole 2002). Furthermore, they did not correct for 
educational level. Those with a higher education generally perform better on 
cognitive tests (Qiu et al. 2001; Stem et al. 1994b), increasing the possibility that 
those with a high education could have been falsely recorded as not having 
dementia. It is advantageous to perform detailed evaluations with a random 
sample of those who pass and fail initial screening, thus, the proportion of ‘false 
negatives’ can be estimated and adjusted for (Matthews and Brayne 2005). In 
addition, a number of studies have used different diagnostic criteria and reported 
contrasting response rates, which further hinders comparisons between findings.
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In the Framingham study only those with moderate to severe dementia were 
considered, which is likely to explain the relatively low incidence of AD reported. It 
should also be noted that non participation in population based samples is likely to 
bias incidence estimates. Participation is likely to be biased towards those not 
suffering with dementia. As such, one would expect lower participation rates to be 
associated with an underestimation of dementia prevalence. However, moderate 
to high participation rates have generally been reported, usually between 70% and 
80%.
Despite these methodological concerns, there is a general consensus that the risk 
of AD increases exponentially with age, with incidence rates approximately 
doubling every five years up to 90+ years of age. Kukull and colleagues (2002) 
plotted the incident rates per 1000 person years against age for 7 independent 
population studies. Although, incidence rates differed between studies, the slope 
of the lines plotting incidence against age were remarkably similar, confirming that 
age is a strong risk factor for AD. Increasing risk with age could be taken to imply 
that the disease is inevitable in those who live long enough. However, some have 
hypothesised that there is an ‘extreme survivor’ effect, where the risk of 
developing AD begins to reduce after a certain age (Ritchie and Kildea 1995). 
Analyses of this hypothesis are problematic as most studies do not include 
sufficient numbers of very old people to draw reliable conclusions. Studies which 
have included adequate numbers of those aged over 80 and 90 years have 
reported contradictory findings. Ritchie and colleagues (1995) carried out a meta­
analysis of nine epidemiological studies of senile dementia, including samples of 
elderly individuals over 80 years of age. They reported that the rate of increase in 
dementia prevalence reduced after the age of 80 years, levelling of around 40% at 
approximately 95 years of age. However, these estimates were based on varying 
forms of dementia. Studies which have differentiated between AD and vascular 
dementia, seem to show that the age related increase in risk is stronger in AD 
(Ruitenberg et al. 2001; von Strauss et al. 1999). Studies which have specifically 
sought to investigate age specific incidence of AD among the very elderly have 
generally not reported a reduction in risk among the those aged over 90 
(Gussekloo et al. 1995; von Strauss et al. 1999). For example, Von Strauss and 
colleagues (1999) assessed the prevalence of AD among the very elderly in the
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Kungsholmen study. They examined 1,424 individuals aged over 77 years and 
identified 358 cases of dementia, of which 274 were considered to have AD. They 
found that the risk of AD developing rose exponentially even after the age of 85, 
with those aged 95 or over being approximately 9 times more likely to develop AD 
compared to those aged less than 84 years. However, they did provide some 
evidence that the risk of AD began to plateau after the age of 90 among males. 
This observation has been noted elsewhere. Miech and colleagues (2002) 
reported that among the Cache County population the incidence of AD increased 
exponentially until ages 85 to 90 years, but appeared to decline after 93 years in 
men and 97 years in women. However, the majority of incidence studies have 
shown an increase in risk of dementia after the age of 90 (Jorm and Jolley 1998; 
Matthews and Brayne 2005; Paykel et al. 1998), although a number of these have 
been limited to small numbers of nonagenarians.
1.2.2 Gender and late-onset Alzheimer's disease
Female gender has been reported as a risk factor for AD. However the findings 
are somewhat contradictory. In general AD is more prevalent in females; however 
these estimates are largely biased by the differential life expectancy among males 
and females. Epidemiological population based studies have reported differing 
results regarding the effect of gender on AD risk. A number of studies have 
reported different incidence rates among males and females. Brayne and 
colleagues (1995) performed a 2.4 year follow up of a cohort aged 75 years and 
over. They reported that the incidence of AD was 1.5 and 3.3 per 1000 person 
years among males and females, respectively. Likewise, Fratiglioni and colleagues 
(1997) reported a positive association between gender and AD risk in the 
Kungsholmen study, finding increased incidence rates for AD at all ages in women 
compared to men. This effect became more notable with increasing age. In total, 
women were found to be over 3 times more likely to develop AD than males. 
Hagnell and colleagues (1992) also reported a significant association between 
gender and lifetime risk of developing AD (25.5% among males, compared to 
31.9% among females)
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Several studies have reported no difference in the prevalence of dementia 
according to gender. For example, no notable sex differences were found in the 
Framingham study (Bachman et al. 1993), the Rochester population based study 
(Rocca et al. 1998), in a population based study of a French community 
(Letenneur et al. 1994a), or in the studies reported by Ganguli and colleagues 
(2000) and Paykel and colleagues (1994). These studies have generally included 
no more than 2,000 participants, followed up for only 2 to 4 years, hence 
prevalence estimates are likely to be imprecise (Ruitenberg et al. 2001). This is 
particularly problematic in the later age groups, with the majority of these studies 
incorporating only a small number of participants in the later stages of life. Also 
follow up was often hampered by incomplete response rates due to refusal and/or 
death of participants.
Larger studies, have offered useful insights into the relationship between gender 
and AD. For example, Reitenburg and colleagues (2001) assessed the 
relationship between gender and AD risk in the population based Rotterdam study. 
They included a cohort of nearly 8,000 individuals over 55 years of age at baseline, 
and completed one follow up after 3 to 4 years with almost 80% of participants, 
and a further follow up 4 to 6 years later with over 60% of participants. They 
reported that the incidence of AD for males and females was generally similar. 
However, in those aged 90 to 94 years the incidence rate of AD among males and 
females was 11% and 53%, respectively. In those aged >95 years the incidence 
rate was 86% among females, whereas no males were reported to develop AD in 
this age group. As such, females were found to have over a five-fold increase in 
risk of developing AD after the age of 90, compared to males. These differences 
could not be explained by differential response rates. Similarly, in the EURODEM 
study, 528 incident cases of dementia were identified (Launer et al. 1999). 
Significant gender differences in the incidence of AD were reported in those aged 
above 85 years. At 90 years of age, the incidence rate among women was 81.7%, 
compared to just 24.0% in men. These findings suggest that the differential risk to 
males and females may be restricted to very old age.
1.2.3 Education and late-onset Alzheimer's disease
Low levels of education have been reported to increase the risk of developing AD.
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Katzman (1993) proposed that education might enhance the brains reserves by 
increasing synaptic density in the neocortical association cortex. Others have 
extended the cognitive reserve hypothesis to incorporate the possible beneficial 
effects of mental activity throughout the lifespan, taking into account other lifestyle 
and occupational factors associated with mental activity (Stern et al. 1994b).
The effect of education on AD risk has been examined in a number of population 
based longitudinal studies. For example, in the Rotterdam study, Ott and 
colleagues (1995) found that the relative risk of dementia decreased in a dose 
dependent manner, with increasing educational status. The effect could not be 
explained by the confounding effect of cardiovascular disease. Likewise in the 
Kungsholmen study, Qui and colleagues (2001) followed a dementia free cohort of 
1,296 individuals over 75 years of age, identifying 109 cases of AD. Low levels of 
education were associated with over a two-fold increase in risk for disease 
development. Findings from the EURODEM study also suggest that less time in 
education increases risk of AD, but only among females (Launer et al. 1999). This 
effect remained unchanged after accounting for the confounding effects of 
cardiovascular disease or stroke. The gender specific association could have 
reflected a lack of power in this study as only 96 males were available for 
hypothesis testing. Further epidemiological longitudinal studies (Canadian Study 
of Health and Aging 1994; Di Carlo et al. 2002; Mortimer et al. 2003; Schmand et 
al. 1998; Zhang et al. 1990) and cross sectional studies (Hill et al. 1993; Katzman 
1993; Mortel et al. 1995; Risch 2000; Stern et al. 1994b) have reported an 
association between AD and education.
These findings suggest that education related factors, operating in childhood, 
could be associated with cognitive function in later life and the subsequent 
development of AD. Indeed, Plassman and colleagues (1995) have provided 
strong evidence that intelligence and education in early adulthood correlate with 
cognitive function in later life. They combined data regarding education and 
intelligence, assessed on enrolment into the US armed forces in the 1940’s, with 
cognitive function in a group of elderly male twins. Cognition in later life was 
correlated with both intelligence and education assessed in early adulthood.
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Despite the preponderance of evidence suggesting that education is associated 
with AD, a number of large studies have failed to find a relationship (Cobb et al. 
1995; Fratiglioni et al. 1991; Paykel et al. 1994). A firm association between AD 
and education is difficult to establish for a number of reasons. There are numerous 
lifestyle factors which differ according to education (Winkleby et al. 1992) which 
are likely to bias findings if not successfully accounted for. Perhaps the most 
obvious confounding variable would be socioeconomic status (SES). Most studies 
show a moderate to high correlation between education and SES (Evans et al. 
1997b; Winkleby et al. 1992). However, studies which have simultaneously 
assessed the effect of education and SES on AD have generally concluded that 
education remains a strong predictor of AD development after controlling for SES. 
For example, Evans and colleagues (1997b) investigated the effect of education, 
occupational prestige and income on AD risk, concluding that education was the 
strongest predictor of disease development. Low income and lower occupational 
status were both associated with AD risk in individual analysis, however were not 
additionally predictive after controlling for education. Likewise, De Ronchi and 
colleagues (1998) tested the association between education and AD, after 
controlling for occupational level, in a sample of 495 elderly subjects with middle to 
high SES, among which a large proportion had received no formal education. 
Those with no education were reported to have a four-fold increase in risk of 
developing AD, compared to those who had been educated. This effect was 
particularly strong in those between 61 and 69 years of age. More recently, Karp 
and colleagues (2004) have extended their earlier work (Qiu et al. 2001), by 
determining whether their previously reported association between educational 
level and AD could be explained by occupation based socioeconomic status. In 
univariate analysis education was a strong predictor of AD development, 
associated with over a three-fold increase in risk. This effect remained significant 
after controlling for socioeconomic status. Low levels of education were associated 
with an increased AD risk in both those with a low and high SES. However, one 
report has suggested that occupational level is a stronger predictor of disease 
development than education (Bonaiuto et al. 1995). However, the sample used in 
this analysis was relatively small, comprising only 48 cases and 96 matched 
controls; hence interpretation of these findings should be made with caution.
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The relationship between education and AD is complicated by issues surrounding 
the diagnosis of the disease. Those with a higher education perform better on 
neuropsychological tests, thus are less likely to be diagnosed with dementia (Qiu 
et al. 2001; Stern et al. 1994b). A number of positive findings to date have 
originated from studies which have aimed to determine the incidence of AD within 
given populations (Di Carlo et al. 2002; Launer et al. 1999; Mortimer et al. 2003;
Ott et al. 1995; Qiu et al. 2001; Schmand et al. 1998; Zhang et al. 1990). These 
studies largely rely on relatively basic means of cognitive screening. Those who 
perform poorly on screening are generally referred for further diagnostic evaluation. 
As such, those with a low education are more likely to be evaluated extensively, if 
indeed they do perform worse on screening tests. However, given these limitations, 
the majority of studies appear to show an association between education and AD. 
This would suggest that increasing education either directly, or indirectly, reduces 
the risk of developing AD, maybe by increasing cognitive reserves.
Research into risk factors for AD has been plagued with inconsistent results, 
owing largely to methodological variations between studies (Hendrie 1998). A 
large number of studies have relied on cross sectional, case-control, designs, 
which are hindered by case ascertainment biases and differential survival. As 
discussed in sections 1.2.1 to 1.2.3 numerous population based studies have been 
conducted, which may provide more useful insights. However, population based 
methods still suffer from problems related to sample stratification, and the extent to 
which findings from specific populations can be generalised to the wider 
population is often not clear. There are numerous difficulties inherent in the search 
for risk factors for AD. For example, information about risk factors may be 
systematically biased between cases and controls. On the whole data regarding 
AD sufferers generally comes from an informant, or proxy. It is possible that the 
proxy of an AD case may recall previous medical history differently to the proxy of 
a control, or the control themselves (Launer et al. 1999). Also, studies are often 
biased as it is difficult to ascertain whether a particular risk factor is associated 
with the disease per se or whether it is associated with increased survival after the 
onset of dementia. In summary, it would appear that increasing age is the only 
non-genetic factor, which is widely acknowledged to increase risk of developing
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AD, whilst female gender and low levels of education are perhaps the next most 
consistent contributory factors to the disease.
1.3 A brief overview of the genetics of Alzheimer’s 
disease
The most significant genetic advances have come from the rare autosomal 
dominant forms of AD, characterised primarily by lower ages at onset compared to 
LOAD. To date, mutations in three genes including the gene encoding APP on 
chromosome 21 (Goate et al. 1991), presenilin 1 (PSEN1) on chromosome 14 
(Sherrington et al. 1995) and presenilin 2 (PSEN2) on chromosome 1 (Levy-Lahad 
et al. 1995b; Rogaeva et al. 1995) have been found to cause AD in families with 
early-onset autosomal dominant forms of the disease. Together, mutations in 
these genes account for approximately 50% of early onset AD cases, with the 
main contribution from PSEN1 (Tandon et al. 2000). The identification of these 
genes has provided useful insights in understanding the biological mechanisms in 
AD as a whole. For example, most of the pathogenic mutations in the APP and 
presenilin genes are associated with abnormal processing of APP, which leads to 
the overproduction of toxic A042 found in senile plaques (Kamboh 2004).
However, these genes are not believed to be implicated in the more common form 
of late-onset AD.
As mentioned in section 1.2 and discussed further in sections 3.1.2 and 3.1.3, 
LOAD is thought to have a substantial genetic component, with twin studies 
reporting heritability estimates of around 60% (Bergem et al. 1997; Gatz et al. 
1997; Raiha et al. 1996). To date, the Apolipoprotein gene (APOE), located on 
chromosome 19, is the only widely acknowledged gene associated with LOAD. 
APOE has three major isoforms (apoE2, apoE3 and apoE4), which differ in amino 
acid sequence at two sites, codon 112 and 158.These isoforms are coded for by 
alleles, APOE £2, £3 and e4. In normal populations the e3 allele is the most 
frequent, whilst £4 occurs slightly more often than the £2 allele (Hendrie 1998).
The £4 allele increases the risk of LOAD in a dose dependent manner, whilst £2 is 
thought to be protective (Farrer et al. 1997). The association between APOE and 
AD was first reported in a series of publications in 1993 (Corder et al. 1993;
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Saunders et al. 1993; Schmechel et al. 1993). Saunders and colleagues (1993) 
reported an association between the APOE z4 allele and AD using a small 
prospective series of sporadic AD cases and spouse controls, which replicated in 
a sample of autopsy confirmed cases. Authors from the same group reported that 
the APOE s4 allele was associated with both late-onset familial and sporadic forms 
of AD, increasing risk for the disease from 20% to 90% and reducing the age at 
onset (AAO) from 94 to 68 years with increasing £4 alleles (Corder et al. 1993). 
They concluded that homozygosity for the APOE £4 allele was almost sufficient to 
cause AD by 80 years of age. Around the same time, the same group also 
reported that the £4 allele was associated with increased A(3 deposition in senile 
plaques, which are a major neuropathological feature of AD (Schmechel et al. 
1993).
Taken together these findings provided strong evidence that the APOE gene was 
implicated in the development of LOAD. Since then hundreds of studies, using 
divergent populations, have demonstrated an association between AD and the 
pathogenic £4 allele. The findings in relation to APOE have been remarkably 
consistent with only a few failing to find an association, largely in selective 
populations. An excellent review of these findings can be found at: 
http://www.ncbi.nlm.nih.qov/entrez/dispomim.cqi?id=107741. alternatively, Raber 
and colleagues (2004) and Ashford and colleagues (2002) have also provided 
reviews.
The strength of the relationship varies among epidemiological studies, however 
the APOE £4 allele is generally not found to be necessary nor sufficient to cause 
AD. For example, in the Framingham study cohort, comprising 1,030 elderly 
individuals, Myers and colleagues (1996) reported that 45% of £4 homozygotes 
had not developed dementia by the age of 80. In addition, they reported that about 
50% of AD in their cohort was not attributable to APOE genotype. Likewise, in a 
further population based study Evans and colleagues (1997) found that APOE only 
accounted for a small proportion of the incidence of AD. Indeed, they reported that 
if the allele did not exist or had no effect on disease risk, the incidence would be 
reduced by only 13.7%. These findings refute claims that the £4 allele is either 
necessary or sufficient to cause AD. It should be noted that epidemiological
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samples often require study populations in which enough individuals will develop 
AD for the study to be economically and practically viable, as such populations are 
often restricted to those over 65 years of age. However, many individuals with one 
or more APOE e4 alleles are likely to develop AD at a younger age than the study 
criterion. Also, many such studies are based on samples that are dementia free at 
onset. Those with AD risk alleles are therefore more likely to be excluded from the 
study, which could lead to an underestimation of the APOE effect. In general, 
estimates of population risk attributable to APOE are between 20% to 57% 
(Nalbantoglu et al. 1994; Seshadri et al. 1995; Slooter et al. 1998).
The APOE z2 allele is reportedly protective against AD (Bickeboller et al. 1997; 
Corder et al. 1994; Talbot et al. 1994). Despite being nearly as common as the e4 
allele in the general population, there are relatively few AD patients studied with 
the e2 allele (Raber et al. 2004). Talbot and colleagues (1994) presented evidence 
that the e2 allele may confer protection to AD, and that its effect is not simply due 
to the absence of the £4 allele. These findings have been replicated by others, for 
example Corder and colleagues (1994) found that the risk of AD was lowest in 
subjects with the e2/£3 genotype, reporting that although a substantial proportion 
of AD is due to the presence of the e4 allele, up to 23% of AD was attributable to 
the absence of APOE e2 in their sample.
The neuropathological pathway by which APOE increases the risk of developing 
AD is not well understood. A number of studies have reported that the APOE £4 
allele is associated with increased senile plaque and neurofibrillary tangle 
formation in brains of AD sufferers studied at autopsy (Ghebremedhin et al. 2001). 
Furthermore, Bennett and colleagues (2003) found that after controlling for the 
effect of AD pathology, including senile plaques and neurofibrillary tangles, the 
association between APOE and AD no longer remained, suggesting that the £4 
allele is related to AD through an association with the pathological hallmarks of the 
disease, rather than via some other mechanism. In addition to these findings the 
APOE e4 allele has been associated, in a dose dependent manner, with elevated 
rate of hippocampal atrophy in longitudinally assessed patients (Mori et al. 2002).
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The effect of the APOE £4 allele is thought to reduce with increasing age, with 
some authors suggesting that is has little effect on risk of developing AD after 90 
years of age (Farrer et al. 1997; Meyer et al. 1998). However, in a sample of 109 
cases and 303 controls aged over 85 Skoog and colleagues (1998) reported the 
APOE £4 allele remained predictive of AD. Numerous studies have reported a 
lower AAO among those with increasing numbers of APOE £4 alleles (Corder et al. 
1993; Lucotte et al. 1994). Indeed, Meyer and colleagues suggested that APOE 
genotype does not appear to influence whether subjects will develop AD, but 
rather when susceptible individuals will develop the disease. However, others 
have reported that APOE explains <10% of the variance in AAO (Slooter et al.
1998). The £4 allele is also thought to reduce AAO among some, but not all, 
familial forms of early onset AD (Levy-Lahad et al. 1995a). In addition to the z2 
and £4 alleles, polymorphisms in the APOE promoter region have been implicated 
with the disease, however the results of these associations are often contradictory 
(Bullido et al. 1998; Lambert et al. 2002; Lambert et al. 1998; Song et al. 1998; 
Wang et al. 2000).
Despite the robust association between APOE and AD, the £4 allele is neither 
necessary nor sufficient to cause the disease. Several studies have indicated that 
a number of other genes are implicated in the development of LOAD (Jarvik et al. 
1996; Martinez et al. 1998; Steffens et al. 2000). Tremendous effort has been put 
into identifying these genes. Linkage analysis offers a means of identifying regions 
which are likely to contain disease loci. To date, findings from linkage analysis 
studies of LOAD have generally been inconclusive, with perhaps the most 
convincing region of linkage located on chromosome 10 (Bertram et al. 2000; 
Ertekin-Taner et al. 2000; Farrer et al. 2003; Li et al. 2002; Myers et al. 2000). A 
further explanation of linkage analysis is presented in section 4.1.2 of this thesis 
and linkage findings in relation to late-onset AD are discussed in sections 4.1.4 
and 4.1.5. Numerous functional and positional candidate genes have been 
identified. Functional candidate genes are those which have a known biological 
function which could be implicated in the development of AD (e.g. those that are 
involved in the production, degradation and clearance of Ap within the brain), 
whereas positional candidate genes are those located in genetic regions identified 
through linkage analyses. Most studies have been restricted to genes which are
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both functional and positional candidates for AD (e.g. functional candidate genes 
within regions of linkage). Like linkage studies, results from association analyses 
have generally been negative, inconclusive or contradictory. Since the year 2000, 
it is estimated that over 200 publications, reporting positive associations in over 50 
genes with AD have been published (Becker et al. 2004). However, very few of 
these associations have positively replicated when analysed in independent 
samples, increasing the possibility that they are ‘false positives’ (Brookes and 
Prince 2005). In general, it would appear that LOAD is not likely to be due to a 
mutation in a single gene. However, it is more probable that a number of genes, 
interacting with environmental risk factors, cause AD (Brookes and Prince 2005).
A full review of association studies with AD as a whole is beyond the scope of this 
thesis, although reviews are provided by Brookes and Prince (2005), Bertram and 
Tanzi (2004) and Kamboh (2004).
Association and linkage studies of LOAD are plagued by issues of locus 
heterogeneity and phenocopies. Heterogeneity is the term used when identical 
phenotypes arise from different mutations at the same or different loci, whereas 
the term phenocopies refers to subjects with clinically indistinguishable non- 
genetic forms of the disease. Rare genetic variation may be associated with a 
small proportion of cases, and therefore undetectable using current experimental 
designs (Pritchard 2001). It is possible that those linked to specific susceptibility 
loci could display phenotypically distinguishable forms of AD (e.g. as observed in 
those carrying mutations for early-onset AD). Thus, the challenge for geneticists is 
to identify the phenotype which is associated with variation in a particular gene 
(Freimer and Sabatti 2003). Clinical variation commonly observed in AD may offer 
a suitable candidate to identify genetically homogenous forms of the disease.
1.4 A brief overview of clinical variation observed in 
late-onset Alzheimer’s disease
The clinical phenotype of LOAD is invariably associated with deficits in several 
areas of cognition. As noted in section 1.1 deficits in memory and two other areas, 
including aphasia, apraxia, agnosia and executive functioning, are generally 
required to formulate a diagnosis of probable AD occurring to DSM-IV (American
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Psychiatric Association 1994) and NINCDS-ADRDA (McKhann et al. 1984) 
criteria. However, a number of behavioural symptoms are commonly displayed by 
disease sufferers. The following quote is taken from the case report of the first 
incidence of what is known as Alzheimer’s disease:
‘Sometimes she greets the doctor as if he were a visitor... on other 
occasions she screams that he wants to cut her open... on others yet 
she fears him as a threat to her honor as a woman... she seems to 
have auditory hallucinations. Often she screams for many hours in a 
horrible voice’ (Alzheimer 1907)
The description was of a 51-year-old woman who presented with focal cognitive 
deficits, but also delusions of jealousy and auditory hallucinations (Alzheimer 
1907). Behavioural disturbances in AD can include affective symptoms, agitation, 
aggression and psychosis (Burns et al. 1990a, b, c). The type, severity and 
prevalence of behavioural symptoms vary greatly and they are not generally 
believed to be an inevitable consequence of disease progression (Cummings 
2000; Sweet et al. 2003). As such they are not a diagnostic requirement for 
probable AD.
There is controversy about how best to categorise behavioural symptoms. DSM-IV 
guidelines suggest the use of additional coding to encapsulate AD with depressive 
mood and AD with delusions. However, specific guidelines for the diagnosis and 
classification of behavioural symptoms in AD are not available. Behavioural 
problems are associated with many serious consequences, including increased 
functional deficits (Stern et al. 1994a), cognitive impairment (Jeste et al. 1992), 
increased rate of decline (Neumann et al. 2001; Wilson et al. 2000), earlier 
institutionalisation (Borson and Raskind 1997; Steele et al. 1990), and increased 
caregiver distress (Donaldson et al. 1998; Craig et al. 2005a). As such, gaining a 
more comprehensive understanding of their aetiology is essential.
Another notable aspect of clinical variation in AD is AAO. Symptoms of AD can 
present at anytime from 30 to 90+ years of age. Despite sharing major clinical and 
neuropathological features a distinction is often made between those with disease
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onset before and after the age of 65. Those with a disease onset less than this are 
widely termed as ‘early onset AD’, which is often taken to represent a distinct 
disease ‘sub-phenotype’ (Raskind et al. 1995; Whitehouse 1995). However, the 
classification of early onset AD as a clinical subtype remains controversial. 
Evidence for this dichotomy comes from numerous studies which have reported 
clinical differences between those with early- and late- onset AD. For example, 
early onset forms of the disease have been found to be characterised by shorter 
survival, more rapid cognitive deterioration, more severe language disturbances 
and more severe AD related neuropathology (Koss et al. 1996; Sevush et al. 1993; 
Villareal and Morris 1999). The most compelling evidence for a distinction between 
early- and late-onset AD comes from genetic studies. As already noted in section 
1.3 genetic mutations which cause autosomal dominant AD are almost entirely 
restricted to those with an early age of disease onset (Villareal and Morris 1999). 
Others have hypothesised that further categorisation by AAO may be useful for 
genetic studies of AD. For example, Olson and colleagues (2001) have reported 
evidence that suggests those with a disease onset over the age 80 years may be 
linked to a genetic locus on chromosome 21.
It is clear that Alzheimer’s disease is a clinically heterogeneous disorder.
Currently, little is known about the underlying causes of the clinical differences 
observed in AD. Gaining a more comprehensive understanding may aid both the 
study of the clinical heterogeneity and AD as a whole. A more detailed overview of 
the clinical variation observed in AD can be found in sections 2.1.1 to 2.1.3 of this 
thesis.
1.5 General aims and outline of this thesis
Genetic and epidemiological studies of LOAD rely largely on comparisons made 
between ‘cases’, diagnosed to published criteria for AD, and healthy elderly 
individuals. Implicit in such an approach is the concept that LOAD is clinically 
homogeneous and can be defined categorically as either present or absent. 
However, LOAD is a clinically heterogeneous illness and increasing attention is 
now being paid to utilizing defined subgroups in the hope of unpicking the complex 
aetiology of the illness (Olson et al. 2001; Pericak-Vance et al. 2000; Sweet et al. 
2003)..
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Clinical variation in the disease phenotype offers a means of characterising sub­
phenotypes or limiting the effect that ‘phenocopies’ have on genetic analyses. 
Using aspects of clinical variation to identify sub-phenotypes has proved 
successful in identifying genes for other complex disorders (Rioux et al. 2001; Van 
Eerdewegh et al. 2002), whilst the categorisation by AAO proved crucial to the 
identification of mutations which cause early onset forms of AD (Lendon et al. 
1997).
The aim of this thesis is to investigate the underlying genetic aetiology of the 
clinical variation observed among AD sufferers. It is important to consider clinical 
variation from two distinct standpoints. First, clinical variation could identify distinct 
‘sub-phenotypes’, or more homogeneous forms of the disease. Under such a 
model, genetic variation would increase disease risk but only within a specific sub 
group of sufferers, for example, among the very elderly. Alternatively, genetic 
variants may act as ‘disease modifiers’. According to such a model, genetic 
variation would not increase the risk of developing AD, but could influence disease 
processes and presentation in the presence of neurodegeneration owing to 
genetic variation at another locus, or environmental influences.
Two aspects of clinical variation will be considered in this thesis. First, behavioural 
symptoms, which represent a substantial problem in AD (Cummings 2000). 
Second, age at disease onset, which has already been used to define clinical 
homogeneous subsets of the disease, will be investigated. Both age at disease 
onset and behavioural symptoms may fluctuate as a result of genetic variation or 
may act as clinical markers for disease sub-phenotypes.
In this thesis a three stage approach to identifying genes which are implicated in 
the clinical heterogeneity observed in AD is presented. In the first stage, the 
emphasis is placed upon characterising behavioural disturbances. As already 
noted, a wide variety of symptoms are common among AD sufferers and a number 
of these can often appear in tandem. This represents a methodological problem to 
studies aiming to delineate their underlying causes (Borson and Raskind 1997). 
The evidence to date suggests that certain symptoms in AD occur more frequently
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together than one would expect by chance and could, therefore, represent 
behavioural components (Frisoni et al. 1999). In chapter 2 of this thesis data 
regarding 12 common symptoms, assessed using the Neuropsychiatric Inventory 
(Cummings 1997), in a large sample of 1,120 AD cases, will be subjected to 
principal components analysis. The primary aim of this study is to elucidate 
behavioural components which will be useful in further genetic analyses, under the 
assumption that behavioural problems may reflect differing manifestations of 
common underlying neuropathology. This approach has the further advantage of 
reducing the dimensionality of the data. This is particularly beneficial in this 
exploratory investigation as it reduces the number of statistical tests required in 
subsequent analyses. Before proceeding to investigate the genetic underpinnings 
of behavioural components, or age at disease onset, it is important to determine if 
they are likely to be subject to genetic influence. In chapter 3 of this thesis, the 
familiality of AAO and behavioural components will be assessed using a large 
sample of affected sibling pairs. Familial clustering of age at disease onset and 
behavioural components would suggest that they are genetically modified and 
provide justification for future genetic studies.
In chapter 4, aspects of clinical variation which show evidence of being genetically 
influenced will be used to test for linkage using a regression based method of 
covariate analysis. Linkage analysis provides a means of locating regions which 
are likely to harbour genes which increase susceptibility to a particular phenotype. 
As noted in section 1.3 and discussed in more detail in sections 4.1.4 and 4.1.5 
linkage studies have yielded a number of regions which could harbour genes that 
increase susceptibility to AD. However, studies to date have been characterised 
by a lack of consistency and failure to replicate positive findings (Bertram and 
Tanzi 2004). Incorporating covariates into linkage analysis has two main 
advantages. First, genetic variation which does not increase susceptibility to the 
disease, but rather modifies its progression can be identified. Second, covariate 
linkage analysis allows for locus heterogeneity owing to the covariates. Using 
partly overlapping samples, Myers and colleagues (2002) and Blacker and 
colleagues (2003) have reported two of the largest genome screens for LOAD to 
date. In chapter 4, data from these two studies is combined to provide a large 
sample of relative pairs, well characterised in terms of phenotypic variation,
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genotyped on a dense grid of markers. The identification of regions harbouring loci 
which increase susceptibility to genetically modified aspects of clinical variation will 
set the stage for future linkage and association studies.
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Chapter 2
Phenotypic characterisation of late-onset 
Alzheimer’s disease
2.1 Introduction
2.1.1 Clinical presentation of late-onset Alzheimer's disease.
Alzheimer’s disease (AD) is characterised by an insidious onset and progressive 
decline in memory and cognitive abilities (McKhann et al. 1984). Individuals with 
AD show fluctuations in the severity of cognitive impairment over days or weeks, 
but over a number of years the pattern is one of unavoidable decline (Mohs 2005). 
Rate of disease progression varies, however on average one would expect to 
observe progression from disease onset to terminal stages in 7 to 10 years 
(Larson et al. 2005; Jost and Grossberg 1995; Knopman et al. 1988).
Symptoms of AD can present from the age of 30 up to 90+ years of age. DSM-IV 
(American Psychiatric Association 1994) criteria for the diagnosis of Alzheimer’s 
disease supports the widely used, but somewhat arbitrary, cut-off of 65 years for 
distinguishing between early- and late- onset AD. The early-onset form of the 
disease is usually familial and follows an autosomal dominant pattern of 
inheritance with a high penetrance. Mutations in the gene encoding the Amyloid 
Precursor Protein (Goate et al. 1991), Presenilin 1 (PSEN1) (Sherrington et al. 
1995) and the Presenilin 2 (PSEN2) (Levy-Lahad et al. 1995b) genes account for 
around 50% of early-onset AD cases (Tandon et al. 2000). AD prevalence 
increases exponentially between the ages of 60 and 90 (Jorm and Jolley 1998). 
The late-onset form of AD (LOAD) accounts for around 99% of all cases of the 
disease (Rocca et al. 1991).
Disease progression in AD is associated with decline in numerous areas of 
cognition, including deficits in short term memory, attention (Petersen et al. 2001), 
aphasia (Carlomagno et al. 2005; Grossman et al. 2004), visuospatial ability 
(Henderson et al. 1989; Lineweaver et al. 2005) and executive functioning
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(Cummings 2000). Increasing disease severity and cognitive impairment are also 
associated with a notable and catastrophic decline in functional abilities and 
activities of daily living (Harwood et al. 2000; Matsuda and Saito 2005). Long-term 
memory, general intelligence, vocabulary, reading ability, perceptual abilities and 
the capability to perform previously well-learned activities, are more severely 
affected in the later stages of disease development (Mohs 2005). These changes 
are widely believed to be invariable consequences of disease progression, with 
AD sufferers eventually losing all semblance of cognitive function (Cummings 
2000; Mohs 2005; Morris et al. 1989).
A wide range of behavioural symptoms can also occur during the illness, including 
delusions, hallucinations, agitation, depression, apathy and irritability. Such 
symptoms are common but vary greatly among disease sufferers (Cummings
2000). A number of studies have attempted to determine the prevalence of these 
symptoms in AD. Depression, anxiety and apathy are widely reported to be the 
most common behavioural symptoms (Lyketsos et al. 2000; Mega et al. 1996;
Craig et al. 2005a). Depressive symptoms occur more frequently in AD than they 
do in the healthy population (Burns et al. 1990c). However, the relationship 
between depression and AD is a complex one. Such symptoms are common in the 
early stages of the disease and increased prevalence rates of depression have 
even been reported in the pre-clinical stages of AD (Gatz et al. 2005a). However, 
it is unclear whether depression is a preclinical symptom, occurring before the 
onset of cognitive decline, or whether it acts as a risk factor for AD. The 
relationship between AD and depression is further complicated as cognitive 
deficits are often associated with depression in the absence of dementia (Abas et 
al. 1990), which can make the distinction between depression and AD difficult, 
especially in the early stages of disease development. Although symptoms of 
depression are common in AD they often occur in the absence of a major 
depressive episode (Purandare et al. 2001), with the prevalence of dysthymia 
being approximately double that of major depression. Starkstein and colleagues 
(1997) performed longitudinal assessments with a consecutive series of AD 
patients and found major depression to be a longer lasting mood change. Those 
who had dysthymia were less likely to be depressed after 18 months of follow up 
than those who met criteria for major depression at study entry.
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Apathy is also among the most common behavioural disturbances observed in 
patients with AD (Craig et al. 2005a). It is broadly defined as a loss of motivation 
and manifests in behaviours such as diminished initiation, poor persistence, lack of 
interest, indifference, low social engagement, blunted emotional response and lack 
of insight. Apathy often becomes apparent early in the clinical course and has 
been shown to increase in severity in tandem with worsening cognitive abilities 
(Mega et al. 1996). Prevalence estimates indicate that around a half of AD cases 
experience symptoms of apathy (Starkstein et al. 1995; Weiner et al. 2005; Craig 
et al. 2005a), however it has been suggested that as many as 92% of patients in 
the later stages of disease development will have displayed apathetic behaviour at 
some point during their illness (Mega et al. 1996). There is a considerable overlap 
between symptoms associated with depression and apathy, for example loss of 
interest or pleasure and fatigue could be used as indicators for both symptoms. 
However, certain behaviours are specific to either apathy or depression; for 
example, suicidal ideation and pessimism are indicators of depression whereas 
poor persistence and indifference are more in coupling with apathy (Landes et al.
2001). As such it is possible for trained observers to delineate between the two 
symptoms in most cases. There is evidence that the close association noted 
between apathy and depression results from the symptoms sharing similar 
neurobiological underpinnings, rather than being due to an overlap in non-specific 
symptoms (Landes et al. 2001). However, there are numerous reports where 
depression is present in patients without symptoms of apathy, and vice versa 
(Marin et al. 1994), therefore they can be viewed as distinct and discriminable 
symptoms.
Anxiety can take numerous forms in AD. In its mildest form it manifests as 
irrational avoidance of places or situations and worry when left alone. In its more 
severe form it can be devastating, causing nervousness resulting in 
hyperventilation, shaking and marked increases in heart rate. As such it can 
impact on the patient’s ability to function socially and in activities of daily living. 
Increased anxiety occurs in up to 70% of AD patients during the course of their 
illness (de Toledo et al. 2004; Ferretti et al. 2001; Teri et al. 1999) and is 
associated with worsening abilities to perform activities of daily living (Teri et al.
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1999). It is frequently viewed as synonymous with other behaviours, notably 
agitation and aggression, or as a component of a broader syndrome, such as 
psychosis or depression (Mega et al. 1996; Mintzer et al. 2001). However, several 
studies have reported anxiety to occur as a distinct syndrome in up to 45% of 
patients (Burns et al. 1990d; Mega et al. 1996; Teri et al. 1999).
Psychotic symptoms are commonly experienced by AD sufferers, especially in the 
later stages of disease development (Paulsen et al. 2000; Sweet et al. 2003). 
Delusions, misidentification syndromes and hallucinations are the common types 
of psychotic symptoms displayed (Cummings 2000). A wide variety of delusions 
have been reported, including persecutory delusions, delusions of infidelity, 
delusions of abandonment and delusions that deceased individuals are still living 
(Sweet et al. 2003; Tariot et al. 1995). Misidentification delusions are also frequent 
in AD patients, for example the belief that a family member is someone else, or 
that one’s home is not one’s own. Delusions in AD are typically non-bizarre and 
simple, and seem to differ somewhat from the more complex and bizarre delusions 
seen in patients with schizophrenia (Jeste and Finkel 2000). They are reported to 
occur in between 16% to 70% of AD patients (Bassiony and Lyketsos 2003). 
Hallucinations are less common, occurring in around 7% to 30 % of patients 
(Marin et al. 1997). They can occur in any sensory modality, but visual and 
auditory hallucinations are more common (Jeste and Finkel 2000; Tariot et al. 
1995) occurring in around 19% and 12% of patients, respectively (Bassiony and 
Lyketsos 2003). In addition to problems arising from population heterogeneity, 
prevalence estimates for delusions and hallucinations vary greatly due to 
differences in how AD and symptoms are diagnosed. Population based studies (de 
Toledo et al. 2004; Steinberg et al. 2003) and studies which assess symptom 
development longitudinally (Cohen-Mansfield et al. 1998; Deutsch et al. 1991; 
Lopez et al. 1991; Paulsen et al. 2000; Rosen and Zubenko 1991) are more likely 
to provide accurate estimates of symptom prevalence. Reviewing this literature it 
seems likely that delusions occur in around 45% of patients, whereas 
hallucinations are less common, occurring in approximately 25% of AD sufferers.
Other common symptoms which occur during the course of AD are agitation, sleep 
disruption, appetite disturbances and disinhibition. Agitation, with aggressiveness
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and physical combativeness, is of particular concern as it represents one of the 
most challenging behaviours observed in the course of AD (Rabins et al. 1982; 
Reisberg et al. 1987; Ryden 1988). Between 30% to 70% of patients display 
notable symptoms of agitation (Mirakhur et al. 2004; Senanarong et al. 2004), 
which become more prominent in the moderate to severe stages of disease 
development (Chen et al. 1998; Levy et al. 1996a). Sleep and appetite 
disturbances have afforded less attention in the literature to date. Sleep 
disturbances can take the form of insomnia, early morning awakening and waking 
many times during the night. The relationship between sleep disturbances and AD 
is complicated as normal aging is often associated with disruption in circadian 
rhythm (Harper et al. 2005). However, sleep disturbances in AD occur more 
frequently than in the normal aging population, affecting around 18% to 53% of 
patients (Aalten et al. 2003; Harper et al. 2005; Mirakhur et al. 2004). As with 
many behavioural disturbances sleep disruption becomes more apparent in 
concert with increasing functional and cognitive decline (McCurry et al. 2004). 
Eating disturbances can take the form of alterations in food preferences, appetite 
and eating habits. These symptoms are more common in frontotemporal type 
dementia (FTD) (Bozeat et al. 2000), with one report suggesting that some form of 
eating disturbance is an invariable component of FTD (Ikeda et al. 2002). They are 
less marked in AD, occurring in 24% to 63% of patients (Aalten et al. 2003; Bozeat 
et al. 2000; Ikeda et al. 2002; Mirakhur et al. 2004).
Disinhibition is one of the least studied behavioural symptoms occurring in AD. It 
can take numerous forms, including abnormal motor behaviour, hypomania, loss 
of insight, egocentrism, and poor self-care (Starkstein et al. 2004). Once present it 
has been shown to be persistent through the course of the disease (Starkstein et 
al. 2004). Cross sectional studies suggest that between 12% and 30% of patients 
experience symptoms of disinhibition (Aalten et al. 2003; Frisoni et al. 1999).
It is clear that behavioural symptoms represent a significant problem in AD. As 
already highlighted, they occur in a substantial proportion of cases. They are also 
associated with many serious consequences for the patient, caregivers and the 
wider society. Many behavioural symptoms, including apathy, psychosis and 
agitation (Jeste et al. 1992; Landes et al. 2001; Stern et al. 1994a; Teri et al. 1990)
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are associated with increased functional and cognitive deficits (Craig et al. 2005a). 
High levels of behavioural disturbance are reported to be associated with 
increased rate of decline in AD (Jeste et al. 1992; Levy et al. 1996a; Neumann et 
al. 2001; Wilson et al. 2000), which suggests that such symptoms may be a 
marker for a more severe and aggressive subtype of the disease. Behavioural 
symptoms are also associated with increased caregiver distress (Donaldson et al. 
1998; Craig et al. 2005a). Shin and colleagues (2005) reported a negative 
correlation between caregiver quality of life and agitation, anxiety, disinhibition, 
irritability and a global measure of behavioural disturbance. Others have reported 
sleep problems to be among the most troublesome behaviours for caregivers 
(Gaugler et al. 2000; Hope et al. 1998). Psychosis, aggression and sleep 
disturbances are among the primary reasons for institutionalisation of AD patients 
(Gaugler et al. 2000; Magni et al. 1996). This is of particular concern as nursing 
home placement necessitates a difficult psychosocial adjustment for older adults 
and their families (Gaugler et al. 1999) and is also associated with massive 
economic costs, which are a significant burden to the wider society (Gaugler et al.
2000).
2.1.2 Factors associated with behavioural symptoms in late-onset 
Alzheimer's disease.
It is important to consider variables which are associated with clinical variation in 
AD. To date the aetiology and pathophysiology of behavioural disturbances are 
largely unknown (Cummings 2000; Esiri 1996), however, numerous biological and 
clinical correlates have been reported with individual behavioural symptoms.
The relationship between global measures of cognitive function and behavioural 
symptoms is widely reported, whilst the relationship between behavioural 
symptoms and selective aspects of cognition is less studied (Spalletta et al. 2004). 
Numerous symptoms, including psychosis, anxiety and agitation have been shown 
to be associated with general measures of cognitive impairment (Levy et al.
1996a; Paulsen et al. 2000; Porter et al. 2003; Turvey et al. 2001). However, such 
associations are not reported in all studies (Marin et al. 1997; Migliorelli et al. 
1995a; Migliorelli et al. 1995b). Behavioural symptoms have also been associated
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with increased rate of decline (Burns et al. 1990b; Neumann et al. 2001; Rosen 
and Zubenko 1991; Spalletta et al. 2004). The relationship between behavioural 
problems and cognitive impairment could point towards the existence of a more 
aggressive form of the disease, characterised by a more rapid decline in cognition 
and excess behavioural symptoms. However, others have reported that cognition 
and behavioural symptoms represent independent dimensions of AD (Spalletta et 
al. 2004; Wobrock et al. 2003), suggesting that different neurobiological systems 
could be implicated in the pathogenesis of cognitive and behavioural disturbances 
seen in AD. Discrepancies between studies could result from the different aspects 
of cognition measured. It is possible that only certain cognitive abilities are 
associated with particular behavioural symptoms, if these are not assessed in a 
particular study then the association will be missed. Indeed, studies which have 
looked at specific forms of cognitive deficit have reported associations between 
psychotic symptoms and frontally mediated cognitive abilities such as 
conceptualisation, verbal fluency and abstraction (Flynn et al. 1991; Jeste et al. 
1992; Perez-Madrinan et al. 2004). Behavioural symptoms that increase in 
prevalence among patients with greater cognitive impairment may be linked with 
the cholinergic dysfunction associated with AD (Cummings and Back 1998).
The prevalence and severity of a number of symptoms have been shown to vary 
as a function of both age at disease onset and current age. For example, anxiety 
(Porter et al. 2003), misidentification syndromes (Burns et al. 1990b) and 
depression (Lawlor et al. 1994) are reportedly more common in those with a 
younger AAO. Whereas increased psychosis, less agitation and less depression 
have been shown to be associated with increasing age (Levy et al. 1996a). Small 
but inconsistent gender differences have been reported with individual behavioural 
symptoms and global measures of behavioural disturbance (Landes et al. 2001; 
Ott et al. 1996). Some have suggested that increased behavioural problems, in 
particular agitation, are more common among females (Levy et al. 1996a). 
However, others have found that symptoms such as delusions and 
misidentification syndromes are more common among males (Burns et al. 1990a, 
b).
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Behavioural problems are likely to be a manifestation of underlying structural brain 
damage (Fairburn and Hope 1988), however the neuropathology of behavioural 
symptoms is far less understood than the neuropathology of the cognitive deficits 
observed in AD, or even mild cognitive impairment (MCI) (Kordower et al. 2001). A 
relatively small number of patients have been comprehensively assessed in life to 
allow the study of neuropsychiatric symptoms in relation to autopsy findings. In the 
few available studies, only a small number of brain regions were investigated and 
only a few neuropathological and neurochemical parameters were assessed 
(Cummings 2000). Studies using magnetic resonance imaging (MRI), computed 
tomography (CT) and single photon emission tomography (SPECT) have identified 
areas of the brain associated with behavioural symptoms, however there is 
currently little consensus among the findings (Cummings 2000). This 
heterogeneity requires further investigation in larger, well characterised, samples. 
A full review of the neuropathological and neurochemical studies of behavioural 
symptoms in AD is beyond the scope of this thesis, however comprehensive 
reviews are provided by Cummings and colleagues (2000) and Mcllroy and Craig 
(2004).
Evidence that certain symptoms result from specific neuropathological deficits can 
also be gleaned from studies comparing the prevalence rates of behavioural 
symptoms across different forms of dementia. For example, there is a suggestion 
that depression is more common in vascular dementia and that delusions occur 
more frequently in AD (Lyketsos et al. 2000), whereas visual hallucinations are 
more common in dementia with Lewy bodies (DLB) (Geser et al. 2005). 
Frontotemporal dementia is characterised by changes in eating preference, 
increased levels of disinhibition, apathy and stereotyped behaviours (Ames et al. 
1994; Bozeat et al. 2000). It is plausible and likely that the differing profile of 
behavioural changes observed between dementia types is a direct consequence 
of differential neuropathological changes associated with the different diseases.
Genetics of behavioural symptoms in AD have received increased attention over 
the last 10 years. A number of positive associations have been reported, for 
example polymorphisms in the serotonin and dopamine receptor genes have been 
significantly associated with psychotic symptoms in AD (Assal et al. 2004; Holmes
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et al. 1998a; Holmes et al. 2001; Lam et al. 2004; Nacmias et al. 2001; Sweet et 
al. 1998), however, such associations have failed to be replicated elsewhere 
(Craig et al. 2004b). A few studies have reported relationships between 
Apolipoprotein E (APOE) genotype and depressive symptoms (Ballard et al. 1997; 
Ramachandran et al. 1996; Scarmeas et al. 2002), although the majority found no 
relationship (Craig et al. 2005b; Forsell et al. 1998; Gabryelewicz et al. 2002; 
Holmes et al. 1998b; Levy et al. 1999; Steffens et al. 2003). On the whole the 
study of behavioural genetics in AD is in its infancy and the findings to date are 
inconsistent. This thesis is primarily concerned with genetic variation which is 
associated with clinical heterogeneity observed in AD.
It is important to consider clinical variation, including the presence or absence of 
behavioural symptoms, from two distinct standpoints. First, clinical variation may 
identify ‘sub-phenotypes’, or less heterogeneous forms of AD, which have a 
distinct aetiology from AD in general. Early onset forms of familial AD provide a 
primary example of this, with both AAO and disease duration differing between 
those carrying the PSEN1, PSEN2 and APP early onset AD mutations (Lippa
1999). Under the ‘sub-phenotype hypothesis’ genetic variation that increases risk 
of developing a particular sub-phenotype (e.g. AD with psychosis) is unlikely to 
increase risk of developing other distinct types of AD (e.g. AD without psychosis). 
Behavioural symptoms are a good candidate for defining homogeneous disease 
sub-phenotypes. Although common, such symptoms are very rarely reported to 
occur in all patients and as such it would appear that they are not merely a 
consequence of increasing disease severity. It therefore follows that patients from 
clinically heterogeneous groups may be affected by differing underlying 
aetiologies, or may show variable distribution of burden in brain pathology (Larner 
2005). This level of heterogeneity suggests that Alzheimer’s disease, as currently 
defined, may more closely resemble a syndrome with multiple contributing 
aetiologies rather than a disease with a unitary cause (Zubenko 1997). To such 
ends psychosis (Sweet et al. 2003) and depression (Zubenko 1997) have been 
suggested as symptoms which may mark disease sub-phenotypes that could be 
useful for further analysis.
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An alternative hypothesis is that genetic variation may influence the phenotypic 
expression of the disease without being directly involved in its aetiology. According 
to such a model, genetic variation would not increase the risk of developing AD but 
alter aspects of the clinical presentation in the presence of neurodegeneration 
resulting from other genetic and/or environmental causes. For example, 
polymorphisms in the serotonin and dopamine receptor genes have been 
significantly associated with psychotic symptoms in AD (Assal et al. 2004; Holmes 
et al. 1998a; Holmes et al. 2001; Lam et al. 2004; Nacmias et al. 2001; Sweet et 
al. 1998), but do not appear to increase the risk of developing AD itself. Such 
genetic variation could also increase the prevalence of similar symptoms in other 
disorders. Indeed, there is growing evidence that genetic variation can modify 
clinical presentation across disease boundaries. For example, AAO in both AD 
and Parkinson’s disease have been linked to the same region of chromosome 10 
(Li et al. 2002), whilst linkage has been shown to the same region of chromosome 
6 in studies looking at AD with psychosis (Bacanu et al. 2002), bipolar disorder 
(McQueen et al. 2005) and schizophrenia (Levinson et al. 2000). These findings 
are largely preliminary, it therefore remains to be seen if these genomic regions 
actually contain genetic variation which influences disease presentation across 
these diseases.
The traditional approach of classifying psychiatric disorders as categorical, 
homogeneous entities have been questioned in other psychiatric illnesses, 
including depression (Korszun et al. 2004; Parker 2000), schizophrenia (Hallmayer 
et al. 2005) and bipolar disorder (Fisfalen et al. 2005). The analysis of disease 
sub-phenotypes has already proven successful in identifying genes for other 
complex disorders. For example, the inclusion of bronchial hyperresponsiveness 
as a covariate in linkage analysis of asthma refined the linkage region and resulted 
in the identification of ADAM33 as the first susceptibility gene which increases risk 
of developing asthma (Van Eerdewegh et al. 2002). Likewise, studies of Crohn’s 
disease have used reduced AAO to define a disease subtype in linkage analysis 
and succeeded in reducing their LOD-1 regions from 50cM to 5cM (Rioux et al.
2001). As a result increasing attention is now being paid to defining and analysing 
sub-phenotypes. These studies have primarily relied on clinical variation of
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disease, or co-morbid illness, to identify distinct sub-phenotypes. For many 
diseases this approach is in its infancy.
In order to effectively study both the disease modifying gene and the sub­
phenotype hypotheses it is important to accurately characterise the clinical 
differences observed within AD and then demonstrate familial aggregation. To 
date, there is little consistency between studies aiming to identify the correlates of 
behavioural symptoms in AD. Some have argued that these inconsistencies arise 
from the number of symptoms that can appear in tandem in some patients, which 
leads to methodological problems (Borson and Raskind 1997). Frisoni and 
colleagues (1999) hypothesised that the many behavioural symptoms observed in 
AD represent a lesser number of underlying components, and that symptoms of 
the same component are more likely to co-occur. This is supported by the 
numerous reports of symptoms which are observed together more commonly than 
would be expected by chance. For example, agitated behaviour is often 
associated with delusions and hallucinations (Burns et al. 1990d; Lyketsos et al. 
1999; Ott et al. 1996; Rapoport et al. 2001), whilst others have reported that 
depressive symptoms are associated with both aggression (Lyketsos et al. 1999) 
and psychosis (Holmes et al. 1998b). The identification of behavioural components 
has many benefits. First, they could be beneficial to the management and 
treatment of behavioural symptoms (Lawlor and Bhriain 2001), as they may help 
clinicians in their choice of treatment since groups of related symptoms are likely 
to respond to the same therapeutic intervention (Aalten et al. 2003; Lawlor and 
Bhriain 2001; Street et al. 2001). Second, the existence of components may point 
to possible common underlying neurobiological determinants that cut across a 
number of dementia subtypes and even other disease entities. Studying such 
components may offer vital clues about the underlying pathology of AD and could 
provide more consistent findings than looking at individual symptoms.
Factor analysis offers a means of assessing whether certain behavioural 
symptoms occur more frequently together, and is useful for detecting behavioural 
components present in AD. It assumes that behavioural components exist and that 
some symptoms, and not others, characterise these components. Cluster analysis 
and latent class analysis offer alternative methods of characterising behavioural
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symptoms. Both of these types of analyses examine the relationship between the 
chosen variables and then place participants into particular groups or classes. 
Factor, cluster and latent class analysis all have the advantage that they reduce 
the dimensionality of the observed data, which has practical benefits for 
researchers as they produce a smaller set of variables which require analysis.
Such approaches also allow pertinent questions to be asked of the data, for 
example should delusions and hallucinations be viewed as separate entities, or do 
they make up a broader behavioural component of psychosis. Cluster and latent 
class analysis are well suited to studying the sub-phenotype hypothesis, as they 
place participants into groups which are optimally different. However, they are less 
compatible with studying disease modifying hypotheses, especially if one assumes 
that phenotypic variation is a quantitative trait which exists in the whole study 
population. Factor analysis is less concerned with sorting participants into groups 
or classes. Instead it provides a means of reducing a large number of variables 
into a smaller number of underlying components, under the assumption that the 
original variables are in some way related and represent differing manifestations of 
a common underlying cause. Participants can then be scored quantitatively 
against each component. As such factor analysis provides information which can 
be used to inform the study of sub-phenotypes, but does not preclude investigation 
of disease modifying hypotheses.
2.1.3 Factor analysis studies of behavioural symptoms in late-onset 
Alzheimer's disease.
Numerous studies have used methods of factor and cluster analysis to identify 
behavioural components in AD (Aalten et al. 2003; Amer-Ferrer et al. 2005; 
Devanand et al. 1992; Frisoni et al. 1999; Fuh et al. 2001; Gauthier et al. 2005; 
Harwood et al. 1998; Haupt et al. 1998; Hope et al. 1997; Mack et al. 1999; Marin 
et al. 1997; Matsuoka et al. 2003; McShane 2000; Mirakhur et al. 2004; Moran et 
al. 2004; Ott et al. 1996; Spalletta et al. 2004). Analyses have been based upon a 
variety of different scales used to characterise behavioural symptoms, of which the 
Neuropsychiatric Inventory (NPI) (Cummings 1997) is the most common.
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A summary of the factor analytic studies performed using the NPI to assess AD 
patients can be seen in figure 2.1.
Frisoni et 
al, 1999
Fuh 
et al, 
2001
Aalten 
et al, 
2003*
Spalletta 
et al, 2004
Mirakur 
et al, 2004
Amer- 
Ferrer et 
al, 2005
Gautheir 
et al, 
2005
n
Delusions 
Hallucinations 
Agitation/Aggression 
Depression/Dysphoria 
Anxiety 
Euphoria 
Apathy 
Disinhibition 
irritability 
Aberrant Motor Behaviour
162 95 146 240 435 90 252
Sleep disturbances 
Appetite abnormalities
Figure 2.1 Summary of factor analytic studies using the NPI to study behavioural symptoms in AD. 
Each column represents a component, with "shaded" symptoms loading onto that component. The 
studies presented by Frisoni, Fuh, Spalletta and Amer-Ferrer used the earlier 10 item version of the 
NPI which does not assess sleep and appetite disturbances.
* Results from sub-analysis using just cases with probable AD presented.
Frisoni and colleagues (1999) used the 10 item version of the NPI and reported 
dimensions o f ‘mood’ (containing items depression/dysphoria, anxiety and apathy), 
‘psychosis’ (containing items agitation, hallucinations, delusions and irritability) and 
‘frontal behavioural features’ (containing items relating to disinhibition and 
euphoria). Fuh and colleagues (2001) used the Chinese version of the NPI (Leung 
et al. 2001) and reported a three-factor solution, with factors defined as ‘mood and 
psychosis’ (including items relating to delusions, hallucination, 
depression/dysphoria, anxiety and aberrant motor behaviour), ‘psychomotor 
regulation’ (that included hallucinations, agitation, euphoria and irritability) and 
‘social engagement’ (which included disinhibition and apathy). However, the 
samples used by Frisoni and colleagues and Fuh and colleagues were relatively 
small (n=162 and n=95 respectively) and no corrections were made for either 
disease duration or severity, which are known to influence the occurrence of 
behavioural symptoms (Finkel 2001). Also, Fuh and colleagues used a sample of 
patients still in their home environment or living with family. This is likely to have 
biased their findings, as those with more severe and frequent behavioural
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symptoms often create a greater burden for caregivers (Kaufer et al. 1998) and 
are more likely to be placed in residential or nursing care (Steele et al. 1990).
Aalten and colleagues (2003) used the 12 item version of the NPI in a sample of 
199 individuals suffering with various types of dementia. They performed separate 
analyses for the whole sample, those in the mild to moderate and more severe 
stages of dementia. They reported a three-factor solution, which comprised factors 
described as hyperactivity (including agitation, euphoria, disinhibition and aberrant 
motor behaviour), mood/apathy (depression/dysphoria, apathy, anxiety, night time 
behaviours and eating abnormalities) and ‘psychosis’ (including delusions and 
hallucinations). Slight differences were reported in the mild and severe groups. In 
those with mild dementia, aberrant motor behaviour loaded higher with the 
‘mood/apathy’ factor, not with ‘hyperactivity’, whereas, sleep disturbances were in 
the ‘psychosis’ factor, rather than the ‘mood/apathy’ factor. It is possible that these 
symptoms may be more related to the severity of dementia. The sample consisted 
of individuals with differing dementia diagnoses. Using a sub sample of 146 cases 
diagnosed with probable AD, factor loadings similar to the mild dementia group 
were reported.
Spalletta and colleagues (2004) analysed the factor structure of the NPI, taking 
into account cognitive function, in a sample of 240 AD patients. They proposed 
that the variance contained in the NPI could be accounted for by five factors, 
including ‘hyperactivity’, ‘psychosis’, ‘anxiety’, ‘mood’ and ‘mood/anxiety’.
However, they selected factors based on eigenvalues greater than 0.8. Using an 
eigenvalue cut-off of 1, fewer factors were used to account for the common 
variance in the NPI and the symptom loadings were increasingly comparable to 
those reported elsewhere. In a much smaller sample comprising 90 AD patients, 
Amer-Ferrer and colleagues (2005) reported that the NPI comprised three 
components, including psychosis, affective and discontrol syndromes. In their 
study, hallucinations and delusions loaded together to form the ‘psychosis’ 
syndrome, depression/dysphoria, anxiety and euphoria formed the ‘affective’ 
syndrome whilst agitation, irritability and disinhibition made up a ‘discontrol’ 
component. The compounding effect of disease severity was not controlled for in 
the studies reported by Spalletta and colleagues and Amer-Ferrer and colleagues.
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Using the same sample as used in their earlier study (Craig et al. 2005a), Mirakhur 
and colleagues (2004) have reported the largest factor analysis of the NPI using 
AD patients (n=465). Four components were identified representing ‘affect’ 
(including depression/dysphoria, anxiety, irritability and agitation), ‘physical 
behaviour’ (comprising symptoms of apathy, aberrant motor behaviour, sleep and 
appetite disturbance), ‘psychosis’ (including delusions and hallucinations) and 
‘hypomania’ (including disinhibition and euphoria). Of particular note was the high 
loading of items relating to aggression/agitation within a depressive symptom 
factor, which had not previously been observed in factor analytical studies using 
the NPI. In the study by Mirakhur and colleagues no allowance was made for 
disease severity, although patients were required to have suffered with dementia 
for greater than 3 years, with a mean disease duration at assessment of 5.7 years. 
Hence, these data offer a fair reflection of symptom development over the lifetime 
of the illnesss. Furthermore, the component solution was stable to various 
methods of rotation, indicating that they are unlikely to represent artefacts of a 
single rotation.
Finally, Gauthier and colleagues (2005) used the NPI to assess behavioural 
symptoms in response to memantine. They reported three factors labelled 
‘hyperactivity’ (comprising symptoms of agitation/aggression, 
depression/dysphoria, anxiety, irritability, apathy and eating disturbances), 
‘psychosis’ (including delusions and hallucinations) and ‘mood/apathy’ (with high 
loadings in elation, disinhibition and apathy). These results were largely 
comparable to those reported elsewhere, with hallucinations and delusions 
forming a psychosis factor and depression/dysphoria and anxiety loading highly 
together onto a separate factor. In coupling with a number of previous studies 
disinhibition and euphoria loaded highly together, this indicates that a behavioural 
component characterised by lack of control may exist. The sample used in this 
analysis differed somewhat from those used elsewhere as all participants were in 
the moderate to severe stages of disease severity. This is likely to have biased 
their results, however it increases the likelihood that participants will have passed 
through the period of risk for developing many behavioural symptoms, increasing 
the reliability of the resulting factor loadings. In all of the analyses using the NPI 
most symptoms had high factor loading. Also, each study reported a core set of
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symptoms which loaded onto conceptually similar factors across analyses, for 
example hallucinations and delusions consistently formed one factor, as did 
depression/dysphoria and anxiety. This supports the hypothesis that components 
of behavioural symptoms exist.
Similar findings have been observed in factor analytic studies based on 
instruments other than the NPI (Devanand et al. 1992; Haupt et al. 1998; Hope et 
al. 1997; Marin et al. 1997; Matsuoka et al. 2003; McShane 2000; Ott et al. 1996). 
Hope and colleagues (1997) used the Present Behavioural Examination to assess 
97 participants with either AD or vascular dementia. Three behavioural 
components were revealed, representing ‘over activity’, ‘aggressive behaviour’ and 
‘psychosis’ (including items relating to anxiety, persecutory delusions and 
hallucinations). In an extension to this study, including 104 participants they 
reported these components remained stable over a 24 month period (McShane
2000). Behavioural symptoms vary in AD and vascular dementia (Lyketsos et al.
2000), therefore combining patients with differing diagnoses is likely to affect the 
factor structure in such analyses. Using the dementia behaviour disturbance 
scale, Ott and colleagues (1996) assessed 125 cases with probable AD and 
reported components labelled ‘antisocial’, ‘disorientation’, ‘apathy’, ‘amnesia’, 
‘agitation’ and ‘reclusiveness’. It is difficult to draw comparisons between this and 
other studies as several common behavioural symptoms were not assessed in 
their sample, including delusions and hallucinations.
A number of studies have used the BEHAVE-AD (Reisberg et al. 1996) scale to 
assess behavioural symptoms in AD. The BEHAVE-AD assesses a narrower 
range of symptoms than the NPI (for example, it does not cover symptoms relating 
to changes in appetite or irritability) however, different types of delusions, 
hallucinations, aggression and depressed mood are rated separately, for example 
delusions of abandonment are rated independently from paranoid delusions.
Haupt and colleagues (1998) performed factor analysis of the BEHAVE-AD using 
data from a limited sample of 48 patients with probable AD and reported four 
behavioural components. These components represented ‘depression’, ‘apathy’, 
‘psychotic symptoms/aggression’ (including items relating to delusions, 
hallucinations and aggressive behaviour) and ‘misidentifications/agitation’.
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Interestingly, the factor structure remained stable over 3 weeks of assessments. 
However, it should be noted that the sample used in this analysis is considerably 
smaller than recommended for performing factor analyses (Kline 1994). In a larger 
sample of 151 AD sufferers, assessed using the BEHAVE-AD rating scale, 
Harwood and colleagues (1998) reported five behavioural components, 
characterised by ‘agitation and anxiety’, (agitation, anxiety of upcoming events and 
other anxieties), ‘psychosis’ (delusions of theft, suspiciousness/paranoia and 
visual hallucinations), ‘aggression’ (verbal aggressiveness, physical 
threats/violence, fear of being left alone and other delusions), ‘depression’ 
(tearfulness and depressed mood) and ‘activity disturbance’ (wandering and the 
delusion that one's house is not one's home). It is notable that the sample used in 
this analysis comprised entirely outpatients and relatively low levels of cognitive 
impairment were reported. As such the prevalence of behavioural symptoms in 
this sample was lower than reported elsewhere (Aalten et al. 2003; Cummings 
1997; Moran et al. 2004), therefore the factor structure obtained cannot be 
generalised to the broader population of AD sufferers, especially those in the later 
stages of the disease. Similarly, Moran and colleagues (2004) used the BEHAVE- 
AD to assess a sample of 240 AD patients in the mild stages of the disease. They 
performed latent class analysis and defined three classes, characterised by low 
behavioural disturbances; affective disturbance and anxiety; and aggression, 
delusions and agitation. However, the sample was not large enough in this study 
to perform latent class analysis therefore analyses were restricted to a subset of 
the items covered by the BEHAVE-AD.
It is difficult to draw comparisons between studies which have used different rating 
scales and different study populations. However, it is notable that a number of 
studies using rating scales other than the NPI have identified the behavioural 
component representing psychosis. Also, in the study by Moran and colleagues 
anxiety was found to load onto the same behavioural component as depression, 
which is consistent with several studies which have used the NPI. Harwood and 
colleagues found anxiety to load onto the same behavioural component as 
agitation, which has been reported elsewhere (Gauthier et al. 2005; Mirakhur et al. 
2004; Spalletta et al. 2004). The finding of similar behavioural components across 
samples, using different rating scales, increases the possibility that robust
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behavioural components have been identified. However, there are numerous 
inconsistencies between the component structures in factor analytical studies 
reported to date. These differences could emerge from the use of different sample 
populations and relatively small sample sizes for factor analytical purposes. It is 
notable that the majority of studies performed to date have not taken account of 
disease severity when performing factor analyses. It is likely that a proportion of 
those in the early stages of the disease will go onto display new behavioural 
symptoms as their illness develops. Also, almost all symptoms increase in 
prevalence and severity with worsening disease progression (Cummings 2000), as 
such correlations between symptoms will be inflated if disease severity is not 
accounted for. This will undoubtedly affect the factor structure obtained in such 
analyses. Indeed, it would appear that ambiguous symptoms, which do not load 
reliably onto any factor, are dependent on the stage of dementia. Given the 
limitations of previous investigations, further studies are required which rely on 
large, adequately powered, samples in which behavioural symptoms have been 
carefully characterised. Furthermore, it is unclear to what extent current findings 
are biased by the confounding effects of disease severity. As such, future studies 
may provide more reliable results if this confounding variable is suitably accounted 
for.
2.1.4 Study design and aims
Behavioural symptoms may fluctuate as a result of genetic variation or may act as 
clinical markers for disease sub-phenotypes. To identify genetic variation 
associated with such symptoms it is essential that they are well characterised. The 
evidence from the foregoing literature review, regarding behavioural symptoms in 
AD, supports the view that they are common and may reflect differing underlying 
neuropathology. In addition, the evidence to date suggests that certain symptoms 
in AD occur more frequently together and could, therefore, represent behavioural 
components. Future analyses may be better served by focusing on these 
components rather than individual symptoms. Methods of identifying behavioural 
components to date have relied on samples which are generally underpowered to 
perform such analysis, which could account for differences in the results between 
studies.
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In this chapter, the NPI is subjected to principal components analysis using data 
from the largest sample studied to date, comprising data from 1,120 AD sufferers. 
Factor analytic studies are largely dependent on the variables that are measured. 
The Neuropsychiatric Inventory provides data from a broad range of symptoms 
and was therefore selected to assess behavioural problems in this study. In 
addition, direct comparisons with previous research are facilitated by using the 
NPI, as it has been widely used elsewhere. The majority of studies to date have 
not taken account of disease severity when performing factor analyses. Almost all 
behavioural symptoms increase in prevalence during the later stages of disease 
development (Cummings 2000). Hence, the confounding effect of disease severity 
is likely to affect the component structure obtained in factor analyses. This is a 
particular problem in cross-sectional studies. Incorporating disease severity as a 
covariate in such analysis will limit the effect that it has on the component 
structure. Two methods of incorporating disease severity will be used in this 
analysis. First, it will be controlled for when calculating the correlation matrix 
between all symptoms included in the principal components analysis. This has the 
effect of removing the shared variance between all variables which is attributable 
to disease severity. Second, separate analysis will be performed for those in the 
mild to moderate and those in the moderately severe to severe stages of 
dementia. As the prevalence of behavioural symptoms largely increase with 
advancing disease progression, those assessed in the early stages of disease 
development may still harbour a moderate risk of going on to develop particular 
symptoms. As such, analysis of those in the later stages may provide more 
reliable results.
Numerous correlates of individual symptoms have been reported, however the 
findings to date have been largely inconsistent. Analyses may be better served by 
focusing on behavioural components rather than individual symptoms. As such, 
supplementary analysis will be performed to investigate the relationship between 
cognitive function, gender, AAO, APOE genotype, age, years in education and 
family history of dementia.
In summary, this chapter is primarily concerned with three aims, outlined below:
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1) To identify components which represent the variety of behavioural symptoms 
commonly observed among AD sufferers.
2) To perform supplementary analyses controlling for the potential confounding 
effect of disease severity.
3) To investigate the relationship between behavioural components with clinical, 
demographic and genetic variables.
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2.2 Methodology
2.2.1 Participants
A total of 1,120 individuals diagnosed with late-onset probable AD were used for 
the analysis. The sample comprised individuals ascertained from both community 
and hospital settings in the UK and Ireland, collected as part of the National 
Alzheimer’s Research Initiative, funded by the Medical Research Council and the 
Alzheimer’s Research Trust. AD sufferers were ascertained by four collaborating 
centres, comprising: Cardiff University School of Medicine, Cardiff; Institute of 
Psychiatry, London; Trinity College, Dublin; and Cambridge University,
Cambridge, who contributed data on 420, 272, 125 and 303 participants, 
respectively. Data collectors from all centres received comprehensive training on 
all aspects of the assessment battery before the study commenced. A two-day 
training exercise was held at the Institute of Psychiatry, led by Professor Simon 
Lovestone. Regular meetings were held between contributing centres and futher 
training days were organised periodically to train additional data collectors.
The author (PH) was involved in co-ordinating data collection between the 4 
centres, including the facilitation of communication between centres, organising 
regular meetings, training and supervision of data collectors, obtaining and 
collating clinical information. The author also performed assessments with 270 AD 
sufferers and/or their informant between July 2001 and December 2004. Ethical 
permission was obtained from the Multi-centre Research Ethics Committee 
(MREC), relevant local ethics committees and NHS trusts.
All individuals were Caucasian and diagnosed with probable AD in accordance 
with the National Institute of Neurological and Communication Disorders and 
Stroke and the Alzheimer’s disease and Related Disorders Associations 
(NINCDS-ADRDA) clinical diagnostic criteria for AD (McKhann et al. 1984). All 
diagnoses were made based on a semi-structured interview, with known validity 
for AD pathology (Holmes et al. 1999) (i.e. positive predictive value of 92%) which 
included: 1) The Mini Mental State Examination (Folstein et al. 1975); 2) The 
Cambridge Mental Disorders of the Elderly Examination (CAMDEX; informant 
interview) (Roth et al. 1986); 3) The Blessed Dementia Scale (Blessed et al.
1968); 4) The Bristol Activities of Daily Living Scale (Bucks et al. 1996); 5)
46
Webster Rating Scale (Webster 1968); 6) Global Deterioration Scale (Reisberg et 
al. 1982); 7) Cornell Scale for Depression in Dementia (Alexopoulos et al. 1988a); 
8) Neuropsychiatric Inventory (12 Item version) (Cummings 1997). Interviews were 
primarily conducted with the AD sufferer’s next of kin in their own home. All 
informants were required to have a regular contact with the AD sufferer and be 
familiar with their illness.
2.2.2 Measures
The Neuropsychiatric Inventory (NPI) (Cummings 1997) was used to assess the 
prevalence and severity of behavioural symptoms in all participants. The NPI is an 
informant-based rating scale which evaluates 12 common behavioural symptoms 
in AD including delusions, hallucinations, agitation, depression/dysphoria, anxiety, 
euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, night-time 
behaviour disturbances, and appetite/eating abnormalities. The severity of each 
symptom is rated categorically from 0-3, with anchor points for ‘does not occur’ (0), 
‘mild’ (1), ‘moderate’ (2) and ‘severe’ (3). The frequency with which the symptom 
occurs is rated categorically from 0-4, with points for ‘never’ (0), ‘less than once 
per week’ (1), ‘about once per week’ (2), ‘several times per week’ (3) and ‘once or 
more per day’ (4). Frequency and severity scores are then multiplied to give an 
overall domain score for each symptom ranging from 0 to 12. Content validity, 
concurrent validity, inter-rater reliability, and test-retest reliability of the NPI are 
well established and it is commonly used in both research and clinical settings 
(Cummings 1997).
The Mini Mental State Examination (MMSE) (Folstein et al. 1975) is a widely used 
measure of cognitive function consisting of 20 questions. The maximum score is 
30, with scores of 24 or below being indicative of cognitive impairment. The global 
severity of dementia in all individuals was rated using the Global Deterioration 
Scale (GDS) (Reisberg et al. 1982). The GDS is a well established scale used to 
stage the magnitude of functional and cognitive deficits in dementia. Scores range 
from 1 to 7, with anchor points for ‘no cognitive decline’ (1), ‘very mild’ (2), ‘mild’
(3), ‘moderate’ (4), ‘moderately severe’ (5), ‘severe’ (6) and ‘very severe’ (7) 
cognitive decline. To aid subsequent analysis participants were divided into two
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groups based on the severity of their illness at assessment; the groups comprised 
mild to moderate (GDS 2-4) and moderately severe to severe (GDS 5-7) stages of 
dementia. Age at onset (AAO) was used in supplementary analyses and was 
defined as the age at which first symptoms of Alzheimer’s disease were observed 
by friends or family.
A detailed family history was obtained from all participants or their next of kin 
where necessary. Individuals were characterised as having a positive family 
history if at least one first degree relative was reported as being diagnosed with 
dementia. Those individuals with a family history of dementia were further 
partitioned into those with a family history of AD, where at least one family 
member was reported to have been diagnosed specifically with AD. Individuals 
were classified as having no family history of dementia if all their first degree 
relatives were reported to be cognitively intact and at least two first degree 
relatives had lived passed the AAO in the AD patient. Individuals were classified 
as unknown if they had missing data, were adopted, if any first degree relatives 
had memory problems but were not formally diagnosed with dementia, or if they 
had less than 2 first degree relatives who had lived passed their age at disease 
onset. All participants, or their informant, were asked about the total number of 
years spent in full time education. This included basic schooling, further education, 
apprenticeships, technical college and higher education.
2.2.3 APOE genotyping
A subset of 878 individuals had APOE genotypes available. Genotyping was 
performed using standardised methods (Saunders et al. 1993). For the purposes 
of statistical analysis individuals were categorised as either having no (x / x), one 
(£4/ x) or two (e4/e4) e4 alleles.
2.2.4 Statistical analysis
The prevalence of the 12 behavioural symptoms among those in the mild to 
moderate stages of dementia were compared to the reported prevalence among 
those with moderately severe to severe AD by constructing 2x2 contingency tables 
and applying the chi-square goodness of fit test with one degree of freedom. NPI
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domain scores (frequency x severity) were considered to be ordinal therefore 
Kendall's tau-b was used to test the association between disease severity and 
‘domain scores’ on the NPI. Due to the number of tests employed here Bonferroni 
significance criteria were applied. The association between disease severity and 
prevalence for each of the twelve symptoms on the NPI was assessed (24 tests in 
total) therefore the Bonferroni-adjusted criterion for significance was 0.002.
Domain scores for each section of the NPI were used to test the component 
structure of the NPI and determine clusters of symptoms which occur together. As 
symptom domain scores were considered to be ordinal polychoric correlations 
were calculated using the POLYCHOR function in SAS 8.02 (SAS Institute Inc., 
1999-2001). The resulting NPI polychoric correlation matrix was submitted to 
Principal Components Analysis (PCA). PCA is a method of reducing a large 
number of variables into a smaller number of underlying components, under the 
assumption that the original variables are in some way related and represent 
differing manifestations of a common underlying cause. Three criteria were used 
to select the number of components to retain in further rotated analyses, including 
eigenvalues greater than 1, inspection of the scree plot and theoretical relevance 
of the resulting components (Kline 1994). Selecting eigenvalues greater than 1 
was proposed by Kaiser (1960) and ensures that each component extracts as 
much, or more, variance from the correlation matrix as would be expected from 
any one of the original variables. Non-orthogonal rotation of the components was 
conducted as orthogonal rotation methods (such as varimax rotation) maximise 
loadings onto components in a way which does not allow for inter correlations 
between components. Orthogonal rotation was considered inappropriate for this 
analysis as some relationship would be expected between components due to the 
underlying disease process in AD. Absolute component loadings greater than, or 
equal to, 0.4 were deemed substantial and used in the interpretation of 
components. Cronbach’s a coefficients were used to assess the internal 
consistency of the factors.
A number of behavioural symptoms occur later in the illness; therefore separate 
analyses were performed for the sample as a whole, those in the mild to moderate 
stage of disease development and those in the moderately severe to severe
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stages of the illness. To further investigate the relationship between disease 
severity and the component structure, supplementary analyses were performed. 
First order polychoric correlations were calculated for the 12 NPI domains, 
controlling for GDS. The resulting correlation matrix was then submitted to PCA as 
described above.
T-tests were performed to compare component scores, derived from PCA using 
the full sample, of those in the mild to moderate stages of dementia (GDS 2-4) 
with those in the moderately severe to severe stages (GDS 5-7) of disease 
development. Linear regression analysis was used to determine the relationship 
between individual component scores derived from PCA with gender, AAO, age at 
assessment, level of cognitive functioning (as measured by the Mini Mental State 
Examination (Folstein et al. 1975)), years in education and the number of APOE 
z4 alleles. A separate analysis was performed to assess the relationship between 
family history of dementia and AD with the component scores as a substantial 
proportion of the sample were classified as ‘unknown’ for family history.
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2.3 Results
2.3.1 Characteristics of the sample
Basic characteristics of the sample can be found in Table 2.1.
Table 2.1 Basic characteristics of the sample used in the principal components analysis 
(n=1120).
Range
Gender n (%)
Male 334 (29.8) -
Female 786 (70.2) -
GDS n (%)
Mild to Moderate 2-4 434 (38.7) -
Moderately Severe to Severe 5-7 686 (61.3) -
APOE Genotype n (%)
2/2 6 (0.7) -
2/3 36 (4.1) -
2/4 31 (3.5) -
3/3 299 (34.1) -
3/4 399 (45.4) -
4/4 107(12.2) -
Family History of dementia, n (%)
Positive family history of dementia 171 (15.3) -
Negative family history of dementia 259 (23.1) -
Unknown 690 (61.6) -
Mean age at assessment, years (sd) 81.2 (6.5) 6 2 - 9 9
Mean age at onset, years (sd) 75.4 (6.8) 6 0 - 9 3
Mean number of years in education (sd) 10.4 (2.7) 0 - 2 3
Mean disease duration, months (sd) 69.5 (44.9) 3 - 3 1 2
Mean MMSE Score (0 - 30) (sd) 12.8 (9.0) 0 - 2 8
Mean NPI Total (0 -144) (sd) 30.5 (22.2) 0-112
Table 2.2 shows descriptive statistics for the NPI in the full sample, those in the 
mild to moderate stages of disease development (GDS 2-4) and those in the 
moderately severe to severe (GDS 5-7) stages of dementia. Apathy, 
depression/dysphoria and agitation/aggression were the most commonly reported 
symptoms occurring in 73.2%, 56.8% and 56.1% of patients, respectively. 
Euphoria was the least common behavioural disturbance, apparent in only 10.5% 
of patients. All symptoms were more prevalent in the moderately severe to severe 
patients, compared to those in the mild to moderate stages of dementia (p<0.002),
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with the exception of depression/dysphoria (x2(1)= 1-369, p=0.242) and anxiety 
(x2(1)= 2.025, p=0.155). Similarly, all symptoms showed increased domain scores 
in the moderately severe to severe patients, compared to those in the mild to 
moderate stages of dementia (p<0.002), with the exception of 
depression/dysphoria (7= 0.069, n = 1120, p=0.009), euphoria (r= 0.073, n=1120, 
p=0.008) and anxiety (r = 0.064, n = 1120, p=0.018).
Table 2.2 Prevalence and severity of the Neuropsychiatric Inventory symptom domains in the full 
sample, those in the mild to moderate and moderately severe to severe stages of dementia.
Item
Full Sample: 
GDS 2-7 
(n=1120)
Mild to moderate patients: 
GDS 2-4 
(n=434)
Moderately severe to 
severe patients: GDS 5-7 
(n=686)
Mean domain 
score (sd)
% of patients 
with symptom
Mean domain 
score (sd)
% of patients 
with symptom
Mean domain 
score (sd)
% of patients 
with symptom
Delusions 2.5 (3.7) 44.8 1.1 (2.4) 27.4 3.5 (4.1) 55.8
Hallucinations 1.2 (2.7) 24.2 0.4 (1.3) 11.3 1.7 (3.2) 32.4
Agitation/Aggression 2.9 (3.8) 56.1 1.5 (2.7) 39.4 3.8 (4.0) 66.6
Depression/Dysphoria 2.6 (3.5) 56.8 2.2 (3.2) 54.6 2.9 (3.5) 58.2
Anxiety 2.1 (3.3) 40.2 1.6 (2.7) 37.6 2.2 (3.6) 41.8
Euphoria 0.4 (1.5) 10.5 0.3 (1.2) 7.6 0.5 (1.7) 12.4
Apathy 5.3 (4.2) 73.2 3.4 (3.5) 61.8 6.3 (4.2) 80.5
Disinhibition 1.3 (2.6) 31.4 0.7 (1.7) 22.6 1.8 (3.1) 37.0
Irritability 2.4 (3.5) 43.0 1.6 (2.8) 37.1 2.8 (3.8) 46.8
Aberrant Motor Behaviour 3.2 (3.8) 51.8 1.7 (2.9) 33.9 4.0 (4.0) 63.1
Sleep disturbances 3.2 (4.0) 50.4 1.8 (3.0) 35.3 4.2 (4.3) 60.1
Appetite abnormalities 3.5 (4.1) 52.9 2.7 (3.6) 44.5 4.3 (4.3) 58.2
2.3.2 Principal components analysis
Inspection of the scree plot, shown in figure 2.2, indicated that either a one, three 
or five component solution could be appropriate for these data. Eigenvalues 
derived from the principal components analysis (PCA) can be seen in Table 2.3. 
Three components had an eigenvalue which exceeded the cut-off of one and each 
of these components represented clinically meaningful domains, hence a three 
component solution was deemed most appropriate for these data.
The matrix of the component loadings from the PCA, rotated to oblimin criteria, is 
presented in Table 2.4. Loadings greater than 0.4 were deemed substantial and 
included in the following interpretations.
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Table 2.3 Eigenvalues and percentage o f variance explained for 
components in the fu ll sam ple principal components analysis
Com ponent Eigenvalue % of Variance
1 4.23 35.22
2 1.09 9.11
3 1.08 9.01
4 0.93 7.77
5 0.93 7.71
6 0.79 6.58
7 0.67 5.59
8 0.57 4.74
9 0.52 4.35
10 0.46 3.83
11 0.39 3.27
12 0.34 2.81
The first component identified accounted for 35.2% of the variance and 
represented ‘frontal lobe dysfunction’, with agitation/aggression, euphoria, apathy, 
disinhibition, irritability, aberrant motor behaviour, sleep and appetite disturbances 
loading onto this component. The second component reflects ‘psychosis’, 
accounting for 9.1% of the variance in the correlation matrix. Delusions and 
hallucinations loaded highly onto this component, sleep disturbances also had a 
moderate loading on this factor. Component three, ‘mood’, accounted for 9.0% of 
the variance. Reliability analysis found that if sleep disturbances were removed 
from the ‘psychosis’ component the Cronbach’s a increased slightly from 0.593 to
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0.611. Whereas, if they were removed from the ‘frontal lobe dysfunction5 
component Cronbach’s a decreased from 0.725 to 0.692. This suggests that sleep 
abnormalities are more associated with the ‘frontal lobe dysfunction’ component 
than with ‘psychosis’.
Table 2.4 Component loadings for the Neuropsychiatric Inventory in the full sample 
(n=1120).
Item Component 1: Component 2: Component 3:
"Frontal Lobe" "Psychosis" "Mood"
Delusions 0.83
Hallucinations 0.81
Agitation/Aggression 0.53
Depression/Dysphoria 0.87
Anxiety 0.75
Euphoria 0.69
Apathy 0.52
Disinhibition 0.77
Irritability 0.54
Aberrant Motor Behaviour 0.53
Sleep disturbances 0.43 0.41
Appetite abnormalities 0.51
Eigenvalue 4.23 1.09 1.08
% of Variance 35.2 9.1 9.0
NB: Absolute values less than 0.4 are not shown
A secondary analysis was performed controlling for the effect of disease severity. 
The component structure was largely analogous to the one reported above. The 
only notable differences were that apathy loaded with depression/dysphoria and 
anxiety, rather than the frontal lobe dysfunction, whilst the loading for appetite 
disturbances on the frontal lobe dysfunction reduced to 0.324. The matrix of the 
component loadings from the PCA, rotated to oblimin criteria, controlling for 
disease severity can be found in appendix 2a.
To further investigate the relationship between dementia severity and the 
component structure, separate analyses were performed for those in the mild to 
moderate stages of dementia (GDS 2-4) and those in the moderately-severe to 
severe stages (GDS 5-7). In the mild to moderate group (n=434) four eigenvalues 
exceeded the cut-off of one, however the scree plot (figure 2.3) indicated that a 
three-component solution may also be compatible. To aid comparison between the
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analyses of those in the mild to moderate stages and the full sample both the 
three- and four-component solutions are reported here.
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Component loadings for the three-component solution can be seen in table 2.5. 
Component one of the three-component solution accounted for 34.3% of the 
variance and included delusions, hallucinations, agitation/aggression, irritability 
and sleep disturbances. Apathy loaded with anxiety and depression/dysphoria to 
make up component two, explaining 10.2% of the variance in the correlation 
matrix. Component three explained 9.3% of the variance and contained items 
relating to euphoria, disinhibition and aberrant motor behaviour. Appetite 
disturbances did not have a substantial loading on any component. The four- 
component solution differed slightly; delusions and hallucinations loaded with 
aberrant motor behaviours, sleep and appetite disturbances. Irritability and 
agitation/aggression loaded together onto component two. Depression/dysphoria, 
anxiety and apathy again loaded together onto component three. The fourth 
component was made up of euphoria and disinhibition and explained 8.8% of the 
variance in the correlation matrix. Component loadings for the four-component 
solution in the mild to moderate group can be seen in table 2.6.
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Table 2.5 Component loadings for the Neuropsychiatric Inventory in mild to moderate 
AD cases (n=434). Three-component solution.
Item Component 1 Component 2 Component 3
Delusions 0.73
Hallucinations 0.67
Agitation/Aggression 0.72
Depression/Dysphoria 0.82
Anxiety 0.75
Euphoria 0.86
Apathy 0.46
Disinhibition 0.42
Irritability 0.71
Aberrant Motor Behaviour 0.41
Sleep disturbances 0.61
Appetite abnormalities
Eigenvalue 4.11 1.22 1.11
% of Variance 34.3 10.2 9.3
A/S; Values less than 0.4 are not shown
Table 2.6 Component loadings for the Neuropsychiatric Inventory in mild to moderate AD cases 
(n=434). Four-component solution.
Item Component 1 Component 2 Component 3 Component 4
Delusions 0.60
Hallucinations 0.79
Agitation/Aggression 0.83
Depression/Dysphoria 0.80
Anxiety 0.70
Euphoria 0.87
Apathy 0.45
Disinhibition 0.47
Irritability 0.88
Aberrant Motor Behaviour 0.42
Sleep disturbances 0.58
Appetite abnormalities 0.67
Eigenvalue 4.11 1.22 1.11 1.04
% of Variance 34.3 10.2 9.3 8.8
NB: Values less than 0.4 are not shown
In the moderately severe to severe group (n = 686) three components had 
eigenvalues greater than the cut-off of one and inspection of the scree plot (figure 
2.4) indicated that a three component was appropriate. The three-component 
solution produced a comparable structure to that obtained in the full sample. The 
only notable difference was that the loading for sleep disturbances on component
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two reduced from 0.412 to 0.398. Component loadings for the NPI among patients 
in the moderately severe to severe stages of AD can be seen in table 2.7.
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Figure 2.4 Scree plot from principal components analysis 
using cases with moderately severe to severe AD
Table 2.7. Component loadings for the Neuropsychiatric Inventory in moderately 
severe to severe AD cases (n=686).
Item Component 1 Component 2 Component 3
Delusions 0.82
Hallucinations 0.80
Agitation/Aggression 0.60
Depression/Dysphoria 0.86
Anxiety 0.69
Euphoria 0.54
Apathy 0.62
Disinhibition 0.70
Irritability 0.58
Aberrant Motor Behaviour 0.56
Sleep disturbances 0.40
Appetite abnormalities 0.47
Eigenvalue 3.66 1.29 1.08
% of Variance 30.5 10.8 9.0
A/S; Values less than 0.4 are not shown
2.3.3 Component score analysis
Component scores derived from PCA were used to determine the relationship 
between behavioural components of the NPI and disease severity, gender, AAO, 
cognitive function, age at assessment, years in education and the number of
57
APOE £4 alleles. Component scores were positively skewed; therefore log 
transformations were performed to normalise the data before further analyses. The 
distribution of component scores for each component, before and after 
transformation, can be found in appendix 2b. Significant differences were 
observed between those in the mild to moderate and moderately severe to severe 
stages of dementia for the frontal lobe dysfunction (t(1118)= -12.484, p<0.001), 
psychosis (t(1118)= -13.168, p<0.001) and mood (t(1118)= -3.023, p<0.003) 
components. The mean transformed component scores can be seen in table 2.8. 
Component scores were higher in those with moderately severe to severe 
dementia compared to those in the earlier stages of disease development, 
indicating that participants in the early stages still harbour a moderate risk of going 
on to develop particular symptoms. It was considered that this might influence the 
findings when looking for features associated with the component scores, hence 
only data relating to participants in the moderately severe to severe stages of 
dementia were considered in further analyses.
Table 2.8 Mean transformed component scores for those in the mild to moderate and moderately 
severe to severe stages of dementia.
Mild to moderate patients: Moderately severe to severe patients:
Component GDS 2-4 (n=434) GDS 5-7 (n=686)
Mean sd Mean sd
Frontal lobe dysfunction 0.41 0.36 0.72 0.42
Psychosis 0.69 0.24 0.95 0.36
Mood 0.54 0.40 0.62 0.45
Linear regression models were used to simultaneously assess the effect of clinical 
variables on component scores. The following variables were entered into the 
model at step 1: gender, AAO, age at assessment, years in education and number 
of APOE £4 alleles. Backward removal was used to remove variables that did not 
explain a significant proportion of variance in component scores. Due to the 
obvious relationship between cognitive function and disease duration in AD (r 
(1116) = -0.437, p < 0.001 in this dataset), the effect of illness duration was 
controlled when assessing the relationship between cognitive function and 
component scores. This was done by entering disease duration at step 2 before 
cognitive function (MMSE) was entered at step 3.
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The linear regression analysis used to assess the impact of clinical variables on 
the frontal lobe dysfunction scores can be seen in table 2.9.
Table 2.9 Linear regression model for frontal lobe dysfunction component scores as 
predicted by age at onset, gender, age at assessment, APOE e4 status, years in education 
and MMSE (controlling for disease duration) (n=499).
Bf R2 R2 Change Sig.
Step 1 Age at onset (years) -.011 .038 .038 <.001
Step 2 Disease Duration (years) -.010 .042 .004 .149
Step 3 MMSE .007 .110 .065 <.001
Excluded variable(s)
Gender * -076 .089
Age at assessment (years) .121 - - .123
Years in Education (years) -.080 - - .070
APOE £4 status ** - - - -
£4 / x .038 - - .393
£4 /  £4 .050 - - .264
Dependent Variable = Component 1 Scores - Frontal lobe dysfunction
* Unstandardised regression coefficient
* Gender: 0 = Female, 1 = Male
** reference group = No APOE zA alleles (x /  x)
AAO was significantly associated with ‘frontal lobe dysfunction’ component scores 
(p = -0.011, p < 0.001). Higher scores were found with an earlier AAO. AAO 
explained 3.8% of the variance in component 1 scores. After controlling for 
disease duration cognitive function significantly improved the prediction of 
component scores, explaining 6.5% of the variance ( R 2increase = 0.065, p < 0.001). 
Higher component scores were found among those with more severe cognitive 
impairment. Neither gender (p = -0.076, p=0.089), age at assessment (p = 0.121, 
p=0.123) nor APOE e4 status significantly predicted ‘frontal lobe dysfunction’ 
component scores. Those with more years in education (p = -.080, p=0.070) 
showed a trend towards lower component scores which did not meet criteria for 
statistical significance. Given the sample size it is reasonable to assume that years 
in education does not have a notable effect on the frontal lobe dysfunction 
component in this sample.
Table 2.10 shows the linear regression analysis used to assess the impact of the 
clinical variables on ‘psychosis’ component scores.
59
Table 2.10 Linear regression model for the psychosis component scores as predicted by 
age at onset, gender, age at assessment, APOE e4 status, years in education and MMSE  
(controlling for disease duration) (n=499).
Bf R2 R2Change Sig.
Step 1 Disease Duration (years) .003 .002 .002 .384
Step 2 MMSE -.012 .056 .054 <.001
Excluded variable(s)
Gender * -.068 .127
Age at onset (years) .011 - - .831
Age at assessment (years) .017 - - .704
Years in Education (years) -.049 - - .277
APOE e4 status ** - - - -
e 4 / x -.046 - - .308
e4 / e4 .044 - - .328
Dependent Variable = Component 2 Scores - Psychosis
f Unstandardised regression coefficient
* Gender: 0 = Female, 1 = Male
** reference group = No APOE e4 alleles (x / x)
Neither gender (p = -0.068, p=0.127), AAO (p = 0.011, p=0.831), age at 
assessment (P = -0.017, p=0.704), years in education (P = -0.049, p=0.277) nor 
APOE e4 status had a significant effect on ‘psychosis’ component scores. After 
controlling for disease duration, cognitive impairment explained 5.4% of the 
variance in component 2 scores ( R 2jnCrease = 0.054, p < 0.001). Higher psychosis 
component scores were found among those with more severe cognitive 
impairment.
Neither gender (P = -0.070, p=0.117), AAO (P = -0.058, p=0.240), age at 
assessment (p = -0.058, p=0.200), years in education (P = -0.045, p=0.312) nor 
APOE e4 status had a significant effect on ‘mood’ component scores. Cognitive 
impairment had a small effect on ‘mood’ scores (p = -0.010, p=0.050). Those 
presenting with more cognitive impairment, after controlling for disease duration, 
displayed higher mood component scores. However, the effect was small with 
cognitive impairment explaining only 1% of the variance in ‘mood’ component 
scores. A summary of the analysis can be seen in table 2.11.
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Table 2.11 Linear regression model for the mood component scores as predicted by age at 
onset, gender, age at assessment, APOE e4 status, years in education and MMSE 
(controlling for disease duration) (n=499).___________________________________
Bf R2 R2 Change Sig.
Step 1 Disease Duration (years) -.012 .003 .003 .188
Step 2 MMSE -.010 .011 .007 .050
Excluded variable(s)
Gender * -.070 .117
Age at onset (years) -.058 - - .240
Age at assessment (years) -.058 - - .200
Years in Education (years) -.045 - - .312
APOE e4 status ** - - - -
z4/x .038 - - .398
z4 / z4 .039 - - .385
Dependent Variable = Component 3 Scores - Mood
* Unstandardised regression coefficient
* Gender: 0 = Female, 1 = Male
** reference group = No APOE zA alleles (x / x)
A separate analysis was performed to assess the relationship between family 
history of dementia and diagnosed AD with the component scores. In the 
moderately severe to severe dementia group 176 individuals were classified as 
having at least one first degree relative with diagnosed dementia, 101 of these 
being reported as Alzheimer’s disease. 115 met criteria for no history of diagnosed 
dementia. The mean transformed component scores for those with no family 
history of dementia, those with a positive family history of diagnosed dementia and 
AD can be seen in table 2.12.
Table 2.12 Mean transformed component scores for those with no family history of 
dementia, those with >1 1st degree relative with diagnosed dementia and those with 
>1 1st degree relative with diagnosed AD
No family history Family history of Family history of
Component dementia (n=115) dementia (n=176)f AD(n=101)
Mean sd Mean sd Mean sd
Frontal lobe dysfunction 0.75 0.47 0.71 0.41 0.69 0.38
Psychosis 0.95 0.34 0.97 0.35 0.96 0.36
Mood 0.64 0.47 0.59 0.46 0.59 0.47
t  This group also contains those with a familiy history of diagnosed AD
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Those with a family history of dementia or AD showed a trend towards lower 
scores for the frontal lobe component, however, the differences were not 
significant, t(289)=1.197, p=0.232 and t(214)=1.420, p=0.157 respectively. There 
was no evidence that psychosis component scores differed in those with and 
without a family history of dementia, t(289)= -0.672, p=0.502, or diagnosed AD, 
t(214)= -0.214, p=0.831. Likewise, mood component scores did not differ among 
those with and without a family history of dementia, t(289)=0.777, p=0.438, or 
diagnosed AD, t(214)=.728, p=0.467.
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2.4 Discussion
2.4.1 Summary of findings
This is the largest study to date to assess the component structure of behavioural 
symptoms in AD. The findings show that behavioural symptoms are common and 
that the majority increase in prevalence and severity among patients in the later 
stages of dementia compared to those in the mild to moderate stages. Principal 
components analysis indicated that the twelve symptoms covered by the NPI 
represent three behavioural components: ‘frontal lobe dysfunction’, ’psychosis’ and 
‘mood’. These components remained stable after controlling for disease severity 
and in a separate analysis restricted to data from those in the later stages of 
disease development. The component structure differed somewhat when 
restricting analysis just to those in the mild to moderate stages of disease 
development. Higher scores on the frontal lobe dysfunction component were 
associated with a lower AAO, whilst both frontal lobe dysfunction and psychosis 
component scores were elevated in those with more severe cognitive impairment 
after controlling for disease duration. None of the behavioural components 
identified were associated with gender, current age, years in education, family 
history of dementia or number of APOE z4 alleles.
2.4.2 Discussion of behavioural symptoms and component structure
Apathy was the most frequent and severe symptom reported on the NPI, which is 
consistent with several other reports (Aalten et al. 2003; Frisoni et al. 1999; Mega 
et al. 1996; Spalletta et al. 2004; Craig et al. 2005a). In accordance with previous 
findings, high levels of depression/dysphoria and anxiety were reported (Aalten et 
al. 2003; Moran et al. 2004; Senanarong et al. 2004; Spalletta et al. 2004; Craig et 
al. 2005a). Euphoria was the least common symptom reported on the NPI. The 
prevalence and severity of agitation, disinhibition, irritability, aberrant motor 
behaviour, sleep and appetite disturbances reported in this sample were 
comparable to those reported elsewhere (Cummings 2000; Frisoni et al. 1999; Fuh 
et al. 2001; Craig et al. 2005a; Senanarong et al. 2004). Delusional behaviour and 
hallucinations were more common than in a number of previous studies 
(Cummings 2000; Spalletta et al. 2004) and were more in accordance with 
prevalence rates observed in AD patients residing in special units and nursing
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homes (Lange et al. 2004; Matsuoka et al. 2003). This may reflect the large 
proportion of cases in the moderate to severe stages of dementia represented in 
this sample.
The component structure obtained in this analysis is similar to those reported 
elsewhere. For example, Aalten and colleagues (2003) reported a factor labelled 
‘hyperactivity’ which contained items agitation, euphoria, disinhibition, irritability 
and aberrant motor behaviour, which was very similar to the ‘frontal lobe 
dysfunction’ component reported here. When a two-factor solution of the NPI was 
considered by Spalletta and colleagues (2004) a factor very similar to the ‘frontal 
lobe dysfunction’ component was reported, the only differences being the inclusion 
of anxiety and exclusion of euphoria. Frisoni and colleagues (1999) described a 
factor that contained items relating to disinhibition, euphoria, apathy and aberrant 
motor behaviour. In addition, Senanarong and colleagues (2004) recently reported 
strong correlations between items relating to agitation, irritability, disinhibition and 
aberrant motor behaviour which persisted after controlling for MMSE score. In the 
study by Fuh and colleagues (2001), the ‘frontal lobe dysfunction’ component 
found in this analysis was separated into two factors, with apathy and disinhibition 
loading onto a separate factor to agitation, euphoria and irritability. However, Fuh 
and colleagues used the 10-item version of the NPI and only included data from 
95 AD patients. The symptoms included in the ‘frontal lobe dysfunction’ 
component have also been reported to load together in other studies that have not 
used the NPI. For example, Ott and colleagues (1996) used the dementia 
behaviour disturbance scale, reporting that symptoms comparable to those 
represented by aberrant motor behaviour, sleep disturbances, appetite 
disturbances and apathy loaded onto one factor.
‘Psychosis’ represents the most consistent behavioural component reported to 
date. Symptoms of delusions and hallucinations have loaded together across all of 
the studies that have explored the factor structure of the NPI in samples of AD 
patients. Hallucinations and delusions have also loaded onto the same 
behavioural component in factor analyses of data from rating scales other than the 
NPI (Harwood et al. 1998; Hope, 1997; Haupt et al. 1992; Mack et al. 1999; 
McShane 2000). These symptoms have also been found to constitute a single
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component in a study of frontotemporal dementia (Mourik et al. 2004). In this 
analysis hallucinations and delusions made up an exclusive component, with the 
questionable inclusion of sleep disturbances. Other studies have reported items of 
irritability (Frisoni et al. 1999; Mourik et al. 2004), sleep disturbances (Aalten et al. 
2003; Matsuoka et al. 2003), agitation (Frisoni et al. 1999), depression/dysphoria 
(Fuh et al. 2001), anxiety (Fuh et al. 2001) and aberrant motor behaviours (Fuh et 
al. 2001) to load highly with ‘psychosis’.
The ‘mood’ component has been noted in a number of previous studies (Aalten et 
al. 2003; Amer-Ferrer et al. 2005; Frisoni et al. 1999; Gauthier et al. 2005; Lange 
et al. 2004; Mirakhur et al. 2004; Mourik et al. 2004). Also, using the BEHAVE-AD 
scale for determining presence of behavioural and psychological symptoms,
Moran and colleagues (2004) identified a class of AD patients whose illness was 
characterised by high incidence of depression and anxiety. A number of studies 
have found apathy to load highly with symptoms of depression and anxiety (Aalten 
et al. 2003; Frisoni et al. 1999), however these findings are not supported by this 
analysis.
On the whole it would appear that there are a core set of symptoms that 
consistently load together. For example, hallucinations and delusions; 
depression/dysphoria and anxiety; agitation, irritability, disinhibition, aberrant 
motor behaviour and euphoria. The fact that these symptoms load together across 
studies, using different samples, and a variety of rating scales, increases the 
probability that robust constructs have been identified and that behavioural 
components reflect an underlying pathophysiological process.
A number of symptoms do not appear to load consistently across or within studies. 
For example, Aalten and colleagues (2003) found that the assignment of the 
symptoms aberrant motor behaviour, sleep disturbances and anxiety to one 
particular component was questionable. The attribution of symptoms such as 
apathy, sleep and eating disturbances to behavioural components tends to be less 
reliable across studies. This may reflect the use of different samples, study 
designs and the relatively small numbers of patients included for factor analytical 
purposes. Also, studies using different scales are often difficult to compare.
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However, it may be that these ‘floating symptoms’ are more associated with 
disease severity or other unmeasured variables, which differ across studies.
Eleven of the twelve symptoms loaded exclusively onto one component, with 
many symptoms having very high loadings, increasing the reliability of the 
components. In addition, the three-component solution remained stable to different 
analytical methods, controlling for the confounding effect of disease severity, and 
when analysis was restricted to just those in the later stages of dementia. 
Differences were observed between those in the mild to moderate stages of 
dementia and those in the later stages of disease development. If one were to 
assume an underlying pathological cause for behavioural symptoms, analysis of 
those in the early stages might be unreliable as a large proportion of participants 
who had not displayed particular symptoms could still harbour a sizable risk of 
going on to develop them over the course of the illness. Hence, the component 
structure obtained among those in the later stages of the disease is likely to be 
more representative of symptom development over the lifetime of the illness. It 
should be noted that even though differences did occur between those in different 
stages of dementia, certain symptoms loaded together across the different 
analyses. For example, hallucinations and delusions reliably loaded together, as 
did euphoria, disinhibition and aberrant motor behaviour. Depression/dysphoria 
and anxiety also had high loadings onto the same component across the different 
analyses.
2.4.3 Discussion of component score analysis
None of the behavioural components were associated with gender, current age, 
years in education, family history of dementia or number of APOE e4 alleles. 
Findings in relation to APOE genotype are largely consistent with previous 
research. A small number of studies have reported a relationship between APOE 
genotype and specific behavioural symptoms in AD, such as aggression (Craig et 
al. 2004c), delusions (Scarmeas et al. 2002), depression (Ballard et al. 1997; 
Ramachandran et al. 1996) and psychosis (Ramachandran et al. 1996). However, 
the majority of studies have found no relationship (Craig et al. 2005b;
Gabryelewicz et al. 2002; Steffens et al. 2003). Therefore, it seems unlikely that 
APOE is implicated in the prevalence or severity of behavioural symptoms in AD.
66
Likewise, previous studies have reported relationships between gender and 
behavioural problems (Ott et al. 1996), however, these findings were inconsistent. 
The results from this analysis do not support a link between gender and 
behavioural components of AD. In addition, years spent in full time education was 
not related to any of the components.
Interestingly, higher scores on the frontal lobe dysfunction component were 
associated with a lower AAO. Although, only a small proportion of variance in 
component scores was attributable to AAO, suggesting it is likely to have little 
predictive value in determining which patients are likely to experience the 
symptoms represented in the frontal lobe component. The lack of relationship 
between current age and component scores has been shown before (Haupt et al. 
1998). However, in cross sectional studies it is difficult to draw conclusions from 
the analysis of age at assessment, as it is largely dependent on when patients 
were ascertained. Longitudinal studies which follow symptom development 
through the course of the illness are better placed to determine if behavioural 
disturbances vary as a function of age.
Frontal lobe dysfunction and psychosis component scores were both elevated in 
those with more severe cognitive impairment after controlling for disease duration. 
There is a general consensus that increased burden from behavioural symptoms 
is associated with lower cognitive ability, with the suggestion that such problems 
are also associated with an increased rate of cognitive deterioration (Ballard et al. 
1995; Drevets and Rubin 1989; McShane et al. 1997; Paulsen et al. 2000). This 
could implicate behavioural symptoms as a marker for a more rapid and 
aggressive form of the disease, which is supported by studies which have shown 
increased neuropathological burden in those with excess behavioural symptoms 
(Farber et al. 2000; Tekin et al. 2001b). It would also appear that behavioural 
disturbances do not directly lead to worsening cognitive impairment as the 
increased rate of decline has been shown to precede the onset of symptoms like 
psychosis in AD (Paulsen et al. 2000).
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2.4.4 Implications and future research
It is important to consider the validity and the possible underlying causes for 
components identified from this type of analysis. A number of symptoms in 
component one appear to be associated with frontal lobe function. Appetite 
disturbances, apathy, disinhibition, euphoria and aberrant motor behaviour are 
more common in FTD than AD, linking them with frontal lobe function (Levy et al. 
1996b). In addition, a higher burden of frontal lobe neurofibrillary tangles have 
been reported in patients with agitation (Cummings and McPherson 2001; Tekin et 
al. 2001b), whilst others have also observed associations between agitation and 
disinhibition with frontal lobe pathology (Chen et al. 1998; Sultzer et al. 1995;
Tekin et al. 2001a).
It has been hypothesised that psychotic symptoms in AD are underpinned by 
genetic influences (Sweet et al. 2003), indeed familial aggregation of psychosis in 
siblings with AD has been demonstrated (Sweet et al. 2002; Tunstall et al. 2000), 
with the odds of both AD and psychosis developing in siblings increasing over two­
fold if the proband has psychotic symptoms. Furthermore, polymorphisms in the 
serotonin and dopamine receptor genes have been significantly associated with 
psychotic symptoms in AD (Holmes et al. 1998a; Holmes et al. 2001; Nacmias et 
al. 2001; Sweet et al. 1998). Recently, a genome screen was performed using AD 
with psychotic symptoms as the phenotype of interest (Bacanu et al. 2002). One 
significant and two suggestive linkage peaks were identified, adding increased 
evidence to the hypothesis that psychotic symptoms are genetically modified. The 
genetic basis of behavioural components in AD will be discussed further in 
subsequent chapters of this thesis.
The co-occurrence of depression/dysphoria and anxiety is a finding that supports 
what is often observed clinically, suggesting that these symptoms are differing 
manifestations of a common underlying cause. An alternate hypothesis draws on a 
causal explanation, with one of the symptoms causing, or lowering the threshold 
for the expression of the other (Gorwood 2004). Middeldorp and colleagues (2005) 
reviewed twenty-three twin studies and twelve family studies which assessed the 
co-morbidity of anxiety disorders and depression. They concluded that twin studies
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provide evidence that the co-existence of anxiety disorders and depression is 
explained by a shared genetic vulnerability for both disorders. They also report 
that family studies show some support for this hypothesis. Such a scenario is 
referred to as pleiotropism, where a common gene is implicated in the vulnerability 
to distinct syndromes, or symptoms. Given that these symptoms also appear to 
make up a behavioural component in AD, genetic analyses may be facilitated by 
considering anxiety and depression in tandem, rather than treating them as distinct 
symptoms in hypothesis testing. However, it should be noted that Middeldorp and 
colleagues also found evidence from family studies which is consistent with the 
alternate hypothesis that anxiety is an epiphenomenon of depression (or vice 
versa).
These findings have implications for future research aiming to delineate factors 
associated with behavioural disturbances in AD. The reduction of symptoms into a 
smaller number of underlying components is likely to facilitate the identification of 
variables associated with behavioural problems (Frisoni et al. 1999). This thesis is 
primarily concerned with investigating the genetic aetiology of clinical differences 
observed between AD sufferers. Subsequent analyses will be guided by the three 
behavioural components identified in this chapter. This has a number of 
advantages, for example it reduces methodological problems arising from the 
number of symptoms which can co-occur among AD patients. Also, the 
identification of components reduces the dimensionality of the data, decreasing 
the number of statistical tests required in subsequent analyses. Before seeking to 
identify loci implicated in the development of behavioural components it is 
important to determine if they are likely to be genetically influenced. In chapter 3, 
results from the principal components analysis will be used to guide the 
classification of behavioural symptoms in a family based sample, to determine if 
such symptoms aggregate within families. Symptoms aggregating within families 
are more likely to be genetically influenced, and will be subjected to linkage 
analysis in chapter 4 to search for loci implicated in their aetiology.
2.4.5 Methodological critique
There are a number of methodological limitations in this area of research. First, 
this study uses a cross sectional design, hence the findings relate to the frequency
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and severity of the symptoms but do not take into account their stability over time. 
This study also relies on information obtained from an informant or caregiver, 
which could lead to bias if they lack or distort information. However, the NPI is a 
widely used scale with proven validity and reliability (Cummings and McPherson 
2001) and the informant interview is generally acknowledged to be the best way of 
assessing behavioural symptoms in AD. Studies of this type aim to identify 
behavioural components, however they are constrained to the variables that are 
measured and included in the analysis. This could potentially lead to 
misrepresentation of behavioural components as important variables may be 
omitted. However, the NPI covers a broad spectrum of behavioural symptoms 
common in AD and evidence suggests that cognitive impairment and behavioural 
aspects represent independent domains (Spalletta et al. 2004). It is also possible 
that the identification of frontal lobe and psychosis components could stem from 
the inclusion of cases with frontotemporal and lewy body type dementia in this 
sample. However, given that such cases are generally believed to make up a 
relatively small proportion of dementia sufferers (Neary et al. 2005; Zaccai et al. 
2005) this is unlikely to have substantially affected the results.
2.4.6 Conclusions
Moran and colleagues (2004) pointed out the umbrella term of ‘behavioural and 
psychological syndromes of dementia’ (BPSD) is too broad a target for treatment 
and research. Behavioural symptoms rarely occur in isolation, therefore targeting 
individual symptoms is probably too narrow an approach to take. Hence, the 
identification of components is vitally important both in terms of AD research and 
treatment. This is the most powerful study presented to date which has assessed 
behavioural disturbances in AD. Evidence for three components of behavioural 
symptoms was provided, representing frontal lobe dysfunction, psychosis and 
mood. These components may be subject to genetic variation. Before seeking 
such loci it is necessary to determine whether clinical heterogeneity in AD is likely 
to be genetically underpinned. In chapter 3 the familial aggregation of clinical 
variables will be assessed, guided by the components identified in this chapter.
70
Chapter 3 
Familial influences on clinical variation in late 
onset Alzheimer’s disease
3.1 Introduction
3.1.1 Heritability and familiality of phenotypic variation
As identified in chapter 2, AD is a clinically heterogeneous disorder, in which 
marked variation in AAO and variable presentation of behavioural symptoms are 
typical. Numerous authors have hypothesised that the clinical variation observed 
in AD (Sweet et al. 2003; Tunstall et al. 2000) and other psychiatric disorders 
(Fisfalen et al. 2005; Korszun et al. 2004; Wickham et al. 2002) may act as a 
marker for disease sub-phenotypes associated with increased genetic liability. 
Similarly, it has been suggested that the clinical presentation of AD may be 
modified by genetic variation that does not confer increased vulnerability to the 
disease as a whole.
Before proceeding to investigate either hypothesis it is necessary to understand 
what is implied by the term ‘phenotype’. The Oxford English dictionary defines the 
term as ‘the observable characteristics of an individual resulting from the 
interaction of its genotype with the environment’. As such the major task 
underlying psychiatric genetics is to identify the behavioral phenotype that 
fluctuates according to variations in one, or several, genes (Tsuang et al. 1993). 
To date, genetic studies of psychiatric disorders have largely relied on disease 
phenotypes categorized in accordance with standard diagnostic criteria and 
structured psychiatric interviews (Merikangas et al. 1989). Disease phenotypes 
defined in accordance with standard diagnostic criteria have been shown to be 
heritable in twin studies of numerous diseases, including Alzheimer’s disease (see 
section 3.1.2), schizophrenia (Cannon et al. 1998; Cardno et al. 1999) and bipolar 
disorder (Smoller and Finn 2003). However, limited success has been achieved in 
mapping genes for familial, non-Mendelian, diseases based on these phenotypes 
(Risch 2000). Some have argued that although diagnostic criteria are often found
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to be highly reliable, they have little biological validity. For example, Kendler 
(1990) proposed that making reliability a priority in the evaluation of psychiatric 
disorders might reduce validity. As such Leboyer and colleagues (1998) 
questioned whether modern definitions of clinical syndromes, which are currently 
considered as phenotypes, accurately reflect underlying genetic variation. They 
coined the term ‘candidate symptom approach’ as an analogy to the biologically 
used term ‘candidate gene’. The major goal for psychiatric geneticists following the 
‘candidate symptom approach’ is to identify, and accurately characterise, clinical 
(or ‘phenotypic’) characteristics associated with genetic variation.
Tsuang and colleagues (1993) proposed a number of specific guidelines for 
identifying phenotypic indicators. In summary, they argued that phenotypic 
variation should show some degree of stability, be specific to the disease of 
interest and have biological and clinical relevance in order to be useful for further 
genetic analysis. Tsuang and colleagues (1993), along with others (Lander and 
Schork 1994), have also stipulated that phenotypic variation must show clear 
familial transmission if it is to be considered useful for further genetic analyses 
(e.g. increased heritability, co-segregation or familial aggregation).
Twin and adoption studies are the gold standard in determining the extent to which 
phenotypic variation is genetically influenced (Cardno and McGuffin 2002). Twin 
studies require that the phenotype of interest is measured appropriately in 
monozygotic (MZ) and dizygotic (DZ) twins. Subsequent analyses can be 
performed to differentiate between effects resulting from individual specific 
environment, shared environment and genetic variation. Genetic effects are 
estimated by comparing the similarity, or concordance rates, of MZ twins, who 
inherit identical genes from their parents, with DZ twins, who share only 50% of 
their genes in common. If concordance rates are elevated in MZ twins it 
emphasises the importance of genetic effects. MZ and DZ are considered to be 
influenced equally by environmental conditions. As such genetic, individual 
environmental and shared environment effects can be estimated. However there is 
some evidence that the equal environment assumption may be invalid. For 
example, MZ twins socialise together more and others emphasise their similarities 
more frequently than is the case among DZ twins (Kendler and Gardner 1998).
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Furthermore, MZ twins are also exposed to increased pre-birth shared 
environment with around 65% being monochorionic, which never occurs among 
dizygotic twin pairs. This could affect growth rates and also increases the 
possibility of shared in utero viral infections (Cardno and McGuffin 2002). Adoption 
studies compare the risk of disease in adopted children of affected and unaffected 
biological parents. Alternatively, the disease risk is assessed in biological and 
adoptive relatives of affected adoptees. A less frequently used approach 
compares the risk of a disorder in adoptees who have affected biological parents 
and unaffected adoptive parents, with the risk among adoptees with unaffected 
biological parents and affected adoptive parents.
Familiality is concerned with the extent to which phenotypic variation clusters 
within families, for example do individuals within certain families present with 
clinical characteristics which are more alike than one would expect by chance. 
Familiality is often easier to assess as it is not dependent on the ascertainment 
and careful assessment of large twin based samples. It is important to remember 
that familiality represents the proportion of phenotypic variance accounted for by 
genetic and shared environmental effects, and is not directly comparable to 
genetic heritability (the proportion of phenotypic variance accounted for by genes 
alone). Tunstall and colleagues (2000) argued that sibling pairs are exposed to 
very little shared environment in later life, therefore familial effects are likely to 
reflect underlying heritability in studies of late life diseases, like AD. However, the 
role of early shared environment, for example influences from shared domestic 
experiences, school, peers and shared life events, cannot be assessed using 
familiality studies. Estimates of shared environment in twin studies assessing the 
heritability of AD have generally been low (Gatz et al. 1997; Pedersen et al. 2004; 
Pedersen et al. 2001; Raiha et al. 1996). However, two studies have reported 
considerable shared environment effects (Bergem et al. 1997; Breitner et al.
1995). This illustrates how common experiences among relatives can still play a 
role in phenotypic presentation even in later life, therefore interpretation of 
familiality studies should be made with caution. However, the majority of findings 
support the hypothesis that shared environment effects are limited in later life; 
hence familiality studies offer an appropriate means of identifying aspects of 
clinical variation in AD that are likely to be genetically influenced. On the whole,
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sibling pairs are easier to ascertain than twins. In addition, sibling pairs can be 
used for linkage analysis. This offers a distinct advantage over twin samples, 
allowing the direct assessment of the genetic epidemiology of clinical variation 
showing familiality. Monozygotic pairs are not informative for genetic linkage 
analysis, whilst samples of affected dizygotic twin pairs alone are rarely used as 
sufficient sample sizes are difficult to ascertain.
3.1.2 Twin studies of iate-onset Alzheimer’s disease
A number of twin studies have been performed to assess the heritability of Iate- 
onset Alzheimer’s disease, of which the majority have been of Scandinavian 
origin. Several early reports document monozygotic twin pairs who have remained 
discordant for over 15 years. However, these reports are of relatively little value as 
it is now widely acknowledged that LOAD arises from a combination of 
environmental and genetic risk factors, which are unlikely to demonstrate full 
penetrance. As such the goal of twin studies has generally been in determining the 
extent to which genetic heritability is implicated in AD.
In an early twin study of AD, Nee and colleagues (1987) did not report any 
evidence for heritability. They used a sample of 22 twin pairs and reported similar 
concordance rates among MZ and DZ twins. However, their study relied on 
volunteer twin pairs which is likely to have biased their results, making 
interpretation more difficult. This is perhaps illustrated in the over representation of 
MZ twins in their sample, with only 5 DZ pairs included. In addition, the average 
age of assessment was 70, which increases the likelihood that new cases of AD 
would develop in the years following the study.
A number of studies have reported population based approaches to twin studies. 
For example, Gatz and colleagues (1997) reported data from a population based 
sample of Swedish twins ascertained through an existing registry. They used twins 
who were reared apart, and a similar number of pairs who were reared together. A 
total of 781 twin pairs aged over 53 were considered in their study, along with an 
additional sample of 416 in which the co-twin was deceased. Just fewer than 1000 
individuals completed screening and subsequent clinical assessments, among
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which 75 were considered to be suffering with dementia. The relatively low 
prevalence of dementia probably represents the number of individuals under the 
age of 60 years included in their analyses; in fact the prevalence rate was much 
higher in a subset of their sample over 65 years of age. The concordance rate for 
MZ twins for AD was 67% compared to 22% among DZ twins, resulting in a 
heritability estimate of between 75% and 85%. The sample used was relatively 
small with only 10 MZ pairs and 30 DZ pairs in which one member had probable 
AD. In addition, the sample of twins was relatively young and the onset of new 
dementia in years succeeding the study was not taken into account in the analysis 
method used.
Gatz and colleagues (2005b) have recently extended this work, reporting 
preliminary analyses from the HARMONY study. They incorporated data from all 
twin pairs on the Swedish twin registry who were aged 65 years and over at 
baseline in 1998. As such it is more representative of the population as a whole 
and less effected by biases introduced by soliciting volunteers. In total the 
HARMONY cohort included 20,269 twins, of which 14,498 performed at least a 
basic telephone screen for cognitive decline. Consequently, a total of 4,537 twin 
pairs were assessed, with only one twin from each pair being assessed on 5,424 
occasions. The main reason for only one member of a pair participating was death 
of the co-twin before screening commenced. Of those screened by telephone 
2,139 twins were referred for clinical assessment, primarily because either they, or 
their twin, were considered to be cognitively impaired during telephone screening. 
The prevalence of dementia in the study population was estimated to be 7.7%, 
which is comparable with other studies. As such 187 and 288 demented 
monozygotic and dizygotic twins were ascertained, respectively. The concordance 
rate for AD among MZ twins was 59%, compared to 32% and 24% among like and 
unlike sex DZ twins respectively. It is interesting that the evidence for a genetic 
loading on AD remains stable in a very large population based study. However, it 
should be noted that more MZ twins were successfully ascertained as both 
members of DZ pairs were less likely to be living at the time of the study, which 
could have potentially biased these findings.
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Breitner and colleagues (1995) reported a twin study conducted in a sample of 
9,213 male twins ascertained in the USA through a registry of war veterans. Of 
these 2,888 (31 %) were either deceased, out of the country or untraceable. A total 
of 1,589 twins were thought to show signs of cognitive decline after telephone 
screening and were followed up in person. Those showing signs of other 
dementias (e.g. arising from multiple strokes or alcoholism) were excluded. As 
such, 90 twins were identified with suspected dementia, of which 38 met criteria 
for AD after assessment. The prevalence of AD in this sample was very low, 
estimated to be between 0.4% and 0.7%, which reflects the low age range of the 
sample ascertained (ranging from 62-73 years of age at baseline screening). The 
concordance rate for AD among MZ twins was 21% compared to 11% among DZ 
twins. These findings suggest a genetic component to AD, but the low prevalence 
of dementia, low age range of twins and lack of concordant pairs make 
interpretation difficult. Furthermore, the study was restricted to males, therefore 
the results cannot be generalised to the population as whole.
Raiha and colleagues (1996) reported another population based study using 
Finnish Twins. They studied birth records of all twins born before 1958 and still 
alive in 1967, identifying a total of 13,888 pairs. This twin registry was linked with 
hospital discharge records to identify those with dementia or related disease, 
yielding a total of 178 twins with confirmed dementia, primarily of the Alzheimer’s 
type. The pairwise concordance among MZ twins was 31% compared to 9% 
among DZ pairs, however this difference was not statistically significant. Wide 
confidence intervals were reported for the MZ and DZ concordance rates which 
could reflect a lack of power in this study. Also, it is likely that dementia sufferers in 
the Finnish population were under ascertained due to the inclusion of only those 
cases with a hospital discharge record. As such those with moderate to severe 
dementia, requiring hospitalisation, were more likely to be included in analyses. 
However, with adequate social support AD sufferers can remain in their home 
environment for many years without the need for medical treatment. This is 
probably reflected in the low incidence of dementia reported in this study.
However, it is unlikely that these selection biases operated according to zygosity; 
therefore they are unlikely to influence the conclusions drawn. In addition, the rate 
of AD was higher among MZ twins than in DZ pairs which could reflect
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ascertainment bias. Given these limitations, the use of medical records is 
particularly useful as it incorporates a long follow up time of twin pairs.
Bergem and colleagues (1997) matched data on 23,000 cognitively impaired 
individuals with 26,000 individuals on the Norwegian Twin Register. They identified 
151 ‘index cases’, of which 72 were suitable for further study (i.e. both twins were 
living and willing to participate). They assessed each twin pair using standardised 
diagnostic criteria and identified 29 concordant pairs in which both had dementia. 
They reported a concordance rate of 57% among MZ twins compared to 33% 
among DZ pairs. When restricting analyses to AD, the concordance rates were 
87% and 46% among MZ and DZ twins, respectively, corresponding to heritability 
estimate of between 55% and 61%. Furthermore, no evidence was found for a 
genetic component in the aetiology of vascular dementia. This supports the view 
that genetic variation plays a major role in AD susceptibility; whereas, vascular 
dementia is more likely to result from exposure to environmental risk factors.
It has been reported that concordant MZ twins are more likely to have a positive 
family history of dementia than discordant pairs (Rapoport et al. 1991). This is 
consistent with the hypothesis that concordant twins are genetically influenced. 
Steffens and colleagues (2000) have extended this research to determine if the 
increase risk to family members of concordant twins could be attributed to 
Apolipoprotein genotype (APOE) (discussed in section 1.3). They incorporated 
data from 15 concordant and 79 discordant twin pairs, reporting a positive family 
history in 21% and 9.5% of concordant and discordant twins respectively. This 
finding suggests a stronger genetic mode of disease transmission among 
concordant twins. In addition the effect is likely to be underestimated in these 
analyses, as relatives of concordant pairs were younger than those of discordant 
twins, as such the onset of new dementia among family members over the coming 
years is likely to be more marked for the concordant group. Tentative evidence 
was provided which suggests that the increased risk to family members of 
concordant twins is mediated, but not wholly explained, by APOE genotype. 
However, this analysis was not sufficiently powered to draw firm conclusions, as 
only one concordant twin pair did not possess an APOE e4 allele
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In addition to risk for AD as a whole, Barak and colleagues (2003) have reported a 
twin study which aimed to assess the heritability of cognitive impairment in late life. 
They ascertained and performed a basic telephone screen of cognitive function 
with 32 MZ and 18 DZ twin pairs aged between 65 and 86 years. They reported no 
differences in concordance rates for cognitive impairment, however there study 
was hindered by potentially imprecise measures of zygosity and the use of a 
rather crude measure of cognitive function.
Of particular concern for twin studies is the failure to detect all cases of dementia, 
which in general would require all members of a population to be assessed 
rigorously and longitudinally. This is beyond the means of most studies.
However, prevalence rates in twin studies have been largely comparable to those 
reported in population based surveys. Furthermore, the majority of studies find DZ 
concordance rates which are comparable to those reported among sibling pairs 
who also share half of their genes in common (van Duijn et al. 1991). In addition, it 
is unlikely that undetected and detected cases would differ in a way which would 
affect concordance. A similar problem derives from the Iate-onset nature of AD. 
Many genetically predisposed partners of affected twins may die of other causes 
before developing dementia. However, incomplete ascertainment of all affected 
twins is unlikely to differ according to zygosity, therefore it does not influence the 
conclusions which can be drawn from twin studies. Further methodological issues 
arise from the use of small sample sizes and the calculation of shared 
environment affects. Even in large studies, due to the relatively low prevalence of 
AD, sample sizes tend to be low. As a result wide confidence intervals are 
generally reported and the statistical power to identify group differences is limited. 
Also, as AD is age related, shared environment affects reported in twin analyses 
are often over estimated as twins share the same age. Despite these limitations, 
the evidence from twin studies is remarkably consistent. Perhaps the best 
evidence comes from the large population based studies of Scandinavian origin 
(Bergem et al. 1997; Gatz et al. 1997; Raiha et al. 1996), which generally support 
a heritability estimate of between 60% and 80%.
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3.1.3 Family studies of Iate-onset Alzheimer's disease
In addition to twin research, a number of studies have attempted to elucidate the 
proportion of AD risk attributable to genetic factors by assessing the familial 
aggregation of the disease. For example, Sleegers and colleagues (2004) 
investigated the epidemiology of dementia in a genetically isolated Dutch 
population in which they ascertained 122 patients with probable AD. They reported 
that individuals with AD were more closely related than healthy individuals. 
Consistent with what is already known, they reported that clustering was strongest 
among those with early onset forms of the disease. However, they found that over 
60% of Iate-onset AD sufferers had a family history of dementia, with the pattern of 
transmission being comparable with an autosomal dominant disease in 14% of 
Iate-onset AD cases. Others have reported family history of dementia to be a risk 
factor for Iate-onset AD. For example Van Duijn and colleagues (1991) reported 
that the relative risk of AD to first degree relatives of dementia sufferers was 3.5. 
The relative risk to first degree relatives reduced with increasing age at onset 
(AAO), however among those with AAO greater than 80 years there were still 
more participants with a family history of dementia compared to controls. This 
finding has been replicated elsewhere. Fratiglioni and colleagues (1993) assessed 
the risk of Iate-onset AD in relation to family history of dementia in a sample of 98 
cases and 216 healthy individuals. They reported that the presence of at least one 
first degree relative with dementia was associated with a three-fold increase in the 
risk of developing AD. Similarly, the Canadian Study of Health and Aging found 
those with a family history of dementia to have a two to three-fold increase in risk 
for AD (Canadian Study of Health and Aging 1994).
Given that the APOE e4 allele is widely believed to increase risk of developing 
LOAD in a dose dependent manner, it is reasonable to speculate that this could 
explain findings of heritability and familial clustering in AD. Jarvik and colleagues 
(1996) assessed the relationship between family history of dementia and AD, 
accounting for APOE genotype. Family history was assessed by asking informants 
of AD sufferers and non-demented controls about the prevalence of memory 
problems among their family members. They found that family history remained a
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significant predictor of AD status, regardless of APOE genotype (apart from e4 
homozygotes, of which almost all were affected). Payami and colleagues (1997) 
report similar findings, they performed longitudinal assessments over a total of 4 
years, with a sample of 114 healthy, cognitively intact, individuals aged 75 at 
baseline. Those with an APOE e4 allele and family history of dementia were found 
to have a nine-fold increase in disease risk compared to those without a family 
history. In a larger study, Martinez and colleagues (1998) collected family data for 
290 subjects with probable AD, performing clinical examinations with living 
relatives where possible. They reported that the APOE e4 allele increased lifetime 
risk of developing AD in a dose dependent manner, however, familial clustering of 
AD was largely due to factors other than APOE genotype. These findings are 
consistent with the conclusion that genetic variation which increases the risk of 
developing AD remains to be found.
Family based, non-twin, methods have a number of disadvantages. First, they 
cannot differentiate between shared environment and genetic effects, therefore 
increased familial risk could be attributable to environmental conditions common to 
members of the same family. Also, family history effects may be exaggerated due 
to healthy individuals being less likely to know about memory difficulties among 
other family members compared with informants of AD sufferers. However, they 
do have the particular advantage that a greater proportion of the population can be 
ascertained, providing more powerful samples for hypothesis testing. The 
evidence to date is largely consistent, suggesting a combination of environmental 
and genetic risk factors increase susceptibility to Iate-onset AD.
3.1.4 Heritability and familiality of age at onset in Alzheimer's disease
The familiality of clinical variation in AD has received very little attention. AAO 
represents perhaps the most studied clinical variation in relation to genetic 
influence. The effect that genetic variation can have on AAO is demonstrated 
clearly in the early onset forms of AD. Those harbouring presenilin 1, presenilin 2 
and amyloid precursor protein mutations show marked fluctuations in age at 
disease onset (Mullan et al. 1993), which corresponds largely to the specific 
mutation present in each family. It has been suggested that APOE e4 allele is
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associated with when, rather than if, Iate-onset AD develops (Meyer et al. 1998), 
with AAO reducing in a dose-dependent manner with increasing e4 alleles (Corder 
et al. 1993). However, a number of studies have reported that APOE does not 
account for all the genetic variation in AAO (Duara et al. 1996; Jarvik et al. 1996; 
Tunstall et al. 2000). Warwick Daw and Colleagues (2000) performed segregation 
analysis of Iate-onset AD families and estimated that between four and seven 
unidentified genes modify AAO , of which four were estimated to have an effect 
size greater than, or equal to, that of APOE. Furthermore, Tunstall and colleagues 
assessed the relationship between ages of onset among 106 affected sibling pairs. 
They reported a moderate relationship between ages at onset among siblings, 
which was not wholly accounted for by APOE genotype. It should be noted that as 
case finding in this sample relied on the identification of two or more affected living 
relatives, it generally excluded data from siblings who were either deceased or 
below the age of risk for developing dementia. As such the correlation between 
siblings may have been inflated. Li and colleagues (2002), using a much larger 
sample of 1121 individuals with AD from 449 families, estimated the ‘heritability’ of 
AAO in AD to be 42%, further supporting the notion that AAO is modified by 
genetic factors.
A number of studies have analysed familial risk to siblings, conditioning on the 
probands AAO (Silverman et al. 2005; Silverman et al. 2003; Wu et al. 1998b). 
They reported that the genetic risk to siblings decreases with increasing onset age 
in the proband. This supports the view that non-genetic, environmental influences 
have more of a role in very Iate-onset AD. As such, genetic studies of sporadic AD 
may be better served by analysis of those with an earlier disease onset. However, 
others have reported that genetic heritability does not differ significantly with age 
(Pedersen et al. 2004). As noted in section 3.1.2, Pederson and colleagues 
assessed the heritability of AD in a sample of Swedish twins, estimating that 48% 
of the liability to AD could be attributed to genetic variation. This estimate did not 
differ significantly between twins younger than 80 years of age and those aged 80 
and over at baseline. It should be noted that the actual heritability estimate among 
those aged younger than 80 years was 59%, compared to 40% in those aged over 
80. However, the sample used was relatively small. Consequently, large 
confidence intervals were reported for each heritability estimate. It is therefore
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unsurprising that no statistically significant differences were reported between the 
groups. It is interesting to note that increased heritability and familiality has been 
associated with lower age at disease onset in studies of schizophrenia (Sham et 
al. 1994), bipolar disorder (Strober et al. 1988), major depressive disorder 
(Weissman et al. 1984) and obsessive compulsive disorder (Pauls et al. 1995). 
This suggests that the genetic loading across a number of diseases is greater in 
cases with lower ages of onset, with later ages of onset being more influenced by 
other, environmental factors.
3.1.5 Heritability and familiality of behavioural features in Alzheimer's 
disease
In addition to AAO there is evidence that other aspects of the clinical phenotype in 
AD may be genetically modified. In 2000 Tunstall and colleagues reported the first 
study to directly assess the familial aggregation of behavioural symptoms 
observed in AD. They reported a significant correlation in current mood state, as 
measured by the Cornell scale for depression in dementia (Alexopoulos et al. 
1988a), in a sample of 86 sibling pairs with probable AD. They also reported 
excess pair wise concordance among siblings for symptoms of agitation. 
Symptoms of aggression and psychosis showed very slight increases in pairwise 
concordance among siblings, compared to what would be expected by chance. 
However, no formal significance testing of these increases was reported. These 
findings should be viewed with caution as the compounding effect of disease 
severity among siblings was not controlled for. This is particularly important in 
cross sectional studies of behavioural symptoms. As identified in chapter 2, most 
behavioural symptoms become more prevalent and severe in the later stages of 
disease development, therefore failure to account for severity of dementia could 
influence the findings from such analyses. The relationship between disease 
severity and behavioural symptoms could also induce another bias. Given that 
AAO has been shown to be correlated among sibling pairs (Tunstall et al. 2000), 
siblings of a similar age at assessment are likely to have suffered with dementia 
for around the same number of years. This increases the possibility that siblings of 
a similar age will be at a comparable stage of dementia at assessment. As 
behavioural symptoms vary as a function of disease severity this could falsely
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inflate correlations among pairs. Studies of this type, which assess symptom 
development cross sectionally should control for the confounding effect of disease 
severity.
Familial effects on depression are of particular interest as a number of studies 
have reported that individuals with a family history of an affective disorder are 
more likely to experience a depressive episode in the course of AD. Pearlson and 
colleagues (1990) assessed a sample of 122 AD sufferers. They found that those 
experiencing their first episode of major depression had significantly more first and 
second degree relatives with mood disorders than were reported among non­
depressed AD sufferers. This finding has been replicated elsewhere in larger 
samples, using differing methodology (Lyketsos et al. 1996; Strauss and Ogrocki 
1996). In these studies AD sufferers were generally excluded if their first episode 
of depression occurred before the onset of dementia. Butt and Strauss (2001) 
simultaneously analysed personal (e.g. previous lifetime history of depression 
before the onset of AD) and family history of depression in AD. They reported that 
both a personal lifetime history and a family history were risk factors for 
depression in AD, and that the increase in risk attributable to personal history of 
depression may be, in part, explained by familial influences. In sum, Butt and 
colleagues found that those with a family history of depression had a three-and-a- 
half-fold increase in risk of developing depressive symptoms, compared to AD 
sufferers without a family history of depression. Given these findings it is likely that 
those with a family history of mood disorders carry a previously unexpressed 
genetic risk for depression, which manifests in the presence of neurodegeneration 
observed in AD.
Familial aggregation of psychosis in AD has also been demonstrated (Bacanu et 
al. 2005; Sweet et al. 2002). Sweet and colleagues studied the relationship 
between psychotic symptoms in a sample comprising 461 affected siblings of 371 
probands with possible, probable or definite AD. They generated two 
classifications of psychosis. A broad definition required that patients had 
demonstrated either delusions or hallucinations at any time point during their 
illness, whereas a more restrictive classification required the presence of more 
than one psychotic symptom, or the presence of psychotic symptoms during more 
than one assessment. Using the broad definition, the odds of both AD and
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psychosis (AD+P) developing in siblings increased over two-fold if the proband 
had psychotic symptoms (Sweet et al. 2002). This effect remained stable after 
controlling for sibling age, AAO and disease severity. Furthermore, the effect 
appeared more marked in a separate analysis using the more restrictive definition 
of psychosis, with siblings of those with AD+P exhibiting over a three-fold increase 
in risk for developing psychotic symptoms, compared to if the proband was 
psychosis free. Sweet and colleagues have since followed up these results by 
categorising individuals as either non psychotic, having single or multiple psychotic 
symptoms (Bacanu et al. 2005). They estimated that the heritability for AD 
characterised by multiple psychotic symptoms was 61%, compared to 30% for 
AD+P defined by the occurrence of any psychotic symptoms. However, these 
estimates of heritability represent the upper limit as they assume that shared 
environment among siblings does not influence susceptibility to AD as a whole, or 
psychotic symptoms occurring during the illness. However, given these limitations, 
the heritability estimates of AD+P compare favourably with heritability estimates of 
both AD (Gatz et al. 1997) and schizophrenia (Cannon et al. 1998; Cardno et al. 
1999). These findings indicate two plausible scenarios. First, separate genetic 
vulnerabilities for AD and psychosis may exist. In such a case the genetic 
vulnerability to psychosis may manifest as a result of the neurodegeneration 
associated with AD. Alternatively, there may be a particular vulnerability to a 
refined phenotype of AD with psychosis.
Together with the earlier report by Tunstall and colleagues (2000) these remain 
the only studies to have investigated the familial aggregation of psychotic 
symptoms observed in AD. Independent replication in well characterised samples 
is necessary before firm conclusions can be drawn. Reviewing the broader 
literature it is interesting to note that familial influences on psychotic symptoms 
have also been reported in a number of other psychiatric disorders. For example, 
family history of psychosis has been identified as a risk factor for psychotic 
symptoms in Huntington’s disease (Tsuang et al. 2000), major depression 
(Leckman et al. 1984) and bipolar disorder (Potash et al. 2003; Potash et al.
2001). It could be that particular genetic variation which contributes major risk of 
developing psychotic disorders such as schizophrenia could be associated with 
psychosis in AD. Indeed, polymorphisms in dopamine and serotonin receptor
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genes, which have been implicated in the aetiology of schizophrenia, have been 
found to be associated with psychosis in AD (Holmes et al. 1998a; Nacmias et al. 
2001; Sweet et al. 1998).
3.1.6 Study design and aims
The vast majority of studies find that Iate-onset AD is a heritable disorder.
However, there is substantial clinical heterogeneity between disease sufferers, 
perhaps most notably in the age at disease onset and the development of 
behavioural symptoms. Evidence from the literature reviews presented in section
3.1.4 and 3.1.5 suggest that the clinical variation observed in AD is subject to 
genetic influence. However, there is a scarcity of studies which have looked at the 
familiality of clinical variation in AD using large, well characterised, samples. There 
are only three studies which have assessed the familiality of psychosis in AD 
(Bacanu et al. 2005; Sweet et al. 2002; Tunstall et al. 2000), of which two are 
largely overlapping. Whereas the analysis of familial aggregation of depression 
and agitation in AD has only been presented once (Tunstall et al. 2000). Further 
study is required to delineate aspects of clinical variation observed in AD which 
may be subject to genetic influence.
As identified in chapter 2 certain symptoms occur together more frequently than 
would be expected by chance. This suggests that certain behaviours may result 
from common underlying neurobiological determinants. Familial aggregation of 
behavioural disturbances in AD would suggest that this underlying neuropathology 
is genetically influenced, which manifests as an increased susceptibility to certain 
symptoms. If a number of symptoms are associated with the same underlying 
cause, studying the familiality of behavioural components may provide more 
consistent results. In chapter 2, three components were identified which 
represented the broad spectrum of behavioural disturbances commonly, but not 
inevitably, observed among AD sufferers. Specifically these were ‘frontal lobe 
dysfunction’, ‘psychosis’ and ‘mood’. These behavioural components are largely 
comparable with the three symptoms for which familiality has already been 
suggested (e.g. psychosis, depression and agitation).
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In this chapter, these behavioural components will be used to guide the 
classification of behavioural symptoms in a large sample of affected sibling pairs. 
For example, in the PCA presented in chapter 2, hallucinations and delusions 
loaded together, as did depression/dysphoria and anxiety. This supports the 
analysis of a broader syndrome of psychosis, rather than treating hallucinations 
and delusions as distinct entities. Likewise, symptoms of anxiety may be a 
differing manifestation of the underlying pathology associated with the 
development of depression in AD. As such, analyses of a combined depression 
and anxiety component may be more appropriate.
Family based samples offer an appropriate means of determining whether aspects 
of phenotypic variation are likely to be genetically influenced. Three such samples 
were available, comprising sibling pairs collected by the National Institute of 
Mental Health AD Genetic Consortium (‘NIMH Sample’), the Indiana Alzheimer 
Disease Centre (‘NIA Sample’) and a sample collected in the United Kingdom (‘UK 
Sample’). The NIMH sample is one of the largest publically available family based 
samples in the world which is accessible to those studying the genetics of AD.
Both the NIMH and UK families are well characterised, with standardised 
assessment batteries performed with most individuals. As such, detailed 
information regarding age at disease onset and the presence of behavioural 
symptoms are available for those in these families. The NIMH and UK samples 
have previously been used to investigate the familial clustering of clinical 
heterogeneity in AD. Tunstall and colleagues (2000) assessed the familial 
influence on AAO, mood disturbances, agitation, psychosis and aggression in the 
UK sample. However, they did not report significance levels for their findings in 
relation to behavioural symptoms. Furthermore, they did not control for the 
confounding effect of disease severity. Sweet and colleagues (2002) incorporated 
data from over 90% of the NIMH sample used in this chapter, however there study 
was restricted to psychotic symptoms. The NIMH sample has not previously been 
used to investigate the familial aggregation of age at disease onset, mood 
disturbances and aggression in AD. The NIA families were collected in a clinical 
setting primarily for genetic studies; as such data regarding behavioural symptoms 
is currently unavailable. However, data regarding AAO, suitable for investigating 
familiality, were available.
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This chapter presents the largest study to date which assesses the familiality of 
clinical variation in AD, focusing on the relationship between aggression, 
psychosis and mood disturbances among affected sibling pairs. In addition, the 
familiality of age at disease onset will be analysed. Previous findings and those 
reported in chapter 2 of this thesis suggest that behavioural symptoms may vary 
according to disease severity, AAO and gender. As such these variables will be 
controlled for when assessing the familiality of aggression, psychosis and mood 
disturbances. The APOE e4 allele is widely believed to reduce age at disease 
onset in a dose dependent manner. To determine whether further genes are likely 
to exist which influence AAO supplementary analysis will be performed removing 
the effect of APOE.
To summarise, the main aims of this chapter are:
1) To investigate the familiality of AAO in AD among affected sibling pairs.
2) To perform supplementary analyses investigating the familiality of AAO 
controlling for the effect of the APOE e4 allele.
3) To investigate the familiality of aggression, psychosis and mood 
disturbances in AD among affected sibling pairs, controlling for disease 
severity, AAO, current age and gender.
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3.2 Methodology
3.2.1 Sample description
Families were selected from those collected by the National Institute of Mental 
Health AD Genetic Consortium (referred to in this thesis as the ‘NIMH Sample’), 
the Indiana Alzheimer Disease Centre (referred to in this thesis as the ‘NIA 
Sample’) and a sample collected in the United Kingdom (referred to in this thesis 
as the ‘UK Sample’). A total of 452 families were selected using the following 
criteria: 2 or more siblings diagnosed with probable or definite AD according to 
NINCDS-ADRDA diagnostic criteria (McKhann et al. 1984) with onset ages greater 
than or equal to 65 years. To reduce potential genetic heterogeneity caused by 
ethnic origin only Caucasian families were selected.
A total of 287 families were selected from the NIMH sample, comprising 240 
affected sibling pairs, 37 affected sibling trios and 10 affected siblings quartets.
The NIMH Sample was ascertained in the United States by three collaborating 
centres, comprising: the University of Alabama, Birmingham; Harvard Medical 
School, Massachusetts and John Hopkins University, Baltimore. Participants were 
ascertained through systematic screening of patients in clinical settings and also 
via media advertising and local AD association referrals. Data collection began in 
1991 and continued until 1997. Participants in the NIMH sample were assessed 
using a detailed assessment battery which included the following scales: Bristol 
Activities of Daily Living Scale (Bucks et al. 1996), Mini-mental State Examination 
(Folstein et al. 1975), Brief Psychiatric Rating Scale (Overall and Gorman 1962), 
Hachinski Ischaemic Scoring System (Hachinski et al. 1975) and the CERAD 
Neuropsychological Battery (Morris et al. 1989).
A total of 101 families were selected from the UK sample, comprising 89 affected 
sibling pairs, 10 affected sibling trios and 2 families with four affected siblings. 
Siblings were ascertained through contact with clinical services. All participants 
were interviewed using an assessment battery which has been validated against 
post-mortem diagnosis and shows a positive predictive value of over 90% for 
detecting AD pathology (Holmes et al. 1999). Assessment scales included:
Blessed Dementia Scale (Blessed et al. 1968), Bristol Activities of Daily Living
88
Scale (Bucks et al. 1996), Manchester and Oxford Scale for Psychological 
Assessment of Dementia (MOUSEPAD) (Allen et al. 1996), the Behavioural 
Pathology in AD Rating Scale (BEHAVE-AD) (Reisberg et al. 1987), Cornell Scale 
for Depression in Dementia (Alexopoulos et al. 1988a), Mini-mental State 
Examination (Folstein et al. 1975), Webster Rating Scale (Webster 1968), 
Cambridge Mental Disorders of the Elderly Examination (CAMDEX; informant 
interview, physical examination sections and CAMCOG) (Roth et al. 1986) and the 
Global Deterioration Scale (Reisberg et al. 1982).
Sixty four families were selected from the NIA sample, comprising 56 affected 
sibling pairs and 8 affected sibling trios. All participants were ascertained in the 
United States by the Indiana Alzheimer Disease Centre. In the NIMH and UK 
samples diagnosis was based on semi structured interview, while in the NIA 
sample affection status was based on clinical diagnoses. The Clinical Dementia 
Rating Scale and the Global Deterioration Scale were used to stage disease 
progression in the NIMH and UK samples, respectively.
3.2.2 Definitions of clinical features of Alzheimer's disease
AAO was defined as the age which first symptoms of Alzheimer’s disease were 
observed and was available for subjects from the UK, NIMH and NIA samples. It 
was considered that the method of family selection outlined above would inflate 
the correlation between siblings, as they all had to have an AAO greater than 65 
years. To reduce this bias families were selected based on the proband having an 
AAO £ 65. Data for all available siblings were included in the analyses, regardless 
of AAO.
Clinical data were available for siblings from the UK and NIMH samples which 
allowed the categorisation of psychosis, mood and aggression to be made. 
Psychotic symptoms in subjects from the NIMH sample were assessed using the 
Brief Psychiatric Rating Scale (BPRS) (Overall and Gorman 1962), which 
assesses behavioural symptoms present at any time during an individual’s illness. 
Individuals were scored positive for psychosis if they scored highly on items 
relating to grandiosity, suspiciousness, unusual thought content or hallucinations.
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Those in the UK sample were assessed using the Manchester & Oxford 
Universities Scale for the Psychopathological Assessment of Dementia 
(MOUSEPAD) (Allen et al. 1996), which measures the presence of psychiatric 
symptoms at any point during the course of an individual’s illness. Subjects were 
classified as having psychosis if they demonstrated either two or more delusional 
symptoms or more than one type of hallucinatory behaviour. More caution was 
shown with regards to delusions in both samples as apparently delusional 
behaviour among AD sufferers is often a form of confabulation secondary to 
amnesia and therefore likely to have a different aetiology to other psychotic 
features.
Three variables were created to assess the familiality of mood, representing minor 
depression, major depression and depression with anxiety. Major Depression in 
subjects from the NIMH sample was defined in accordance with DSM-IV 
(American Psychiatric Association 1994) criteria for a ‘major depressive episode’. 
Subjects were defined as meeting criteria for major depression if they had been 
depressed for a period of two weeks and had displayed five or more of the 
following symptoms:
• Depressed mood most of the day.
• Diminished interest or pleasures in usual activities.
• Fluctuations in weight.
• Insomnia or hypersomnia.
• Psychomotor agitation or retardation.
• Fatigue or loss of energy.
• Feelings of worthlessness or excessive inappropriate guilt.
• Diminished ability to concentrate or indecisiveness.
• Recurrent thoughts of death, suicidal ideation.
In accordance with DSM-IV criteria, these symptoms had to cause clinically 
significant distress or impairment in social, occupational or other areas of 
functioning. Those meeting these criteria were classified as ‘AD with major 
depression’ (AD+MajD). Individuals who had not displayed any symptoms of 
depression were classified as ‘AD without depression’ (AD-MajD). Those who 
displayed depressive symptoms that did not meet criteria for major depression
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were excluded from familiality analyses of major depression (e.g. those displaying 
between 1 and 4 symptoms of depression). DSM-IV criteria for ‘major depressive 
episode’ can be found in appendix 3a.
The Cornell scale for depression in dementia (CSDD) (Alexopoulos et al. 1988a) 
was used to assess symptoms of depression in subjects from the UK sample. The 
CSDD is a 19-item, clinician administered depression scale that was developed 
specifically to measure depressive symptom severity in older adults. It has been 
validated in populations with and without dementia (Alexopoulos et al. 1988a, b). 
Each item is rated on a three point scale, with anchor points for absent (0), mild 
(1), and severe (2), providing a total summary score of 0 to 38, with higher values 
representing greater severity of depressive symptoms. A cut-off of 13 on CSDD 
was taken to be indicative of major depression as suggested by Alexapoulos and 
colleagues (Alexopoulos et al. 1988a). Those scoring less than 5 on the CSDD 
were classified as ‘AD without depression’ (AD-MajD). Those scoring between 5 
and 13 were excluded from familiality analyses of major depression. The Cornell 
scale for depression in dementia can be found in appendix 3b.
A broader definition of depression was utilised to assess cases in which 
depressive symptoms were present that did not meet criteria for major depression. 
Participants in the NIMH sample were classified as ‘AD with depression’ (AD+D) if 
they had experienced depressed mood for a period lasting two weeks or more. 
Those in the UK sample were classified as AD+D if they scored 5 or above on the 
CSDD. All other individuals with complete clinical data were classified as ‘AD 
without depression’ (AD-D).
The principal components analysis presented in chapter 2 identified a behavioural 
component including depression/dysphoria and anxiety. To assess familiality, a 
combined depression and anxiety component was defined in the siblings. DSM-IV 
criteria for a ‘major depressive episode’ and ‘generalized anxiety disorder’ were 
used to guide the classification of depression and anxiety, respectively. Major 
depressive episode was classified in accordance with the criteria noted above 
(AD+MajD). Anxiety was defined as a period of time lasting at least two weeks
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when anxiety and/or tension were present most of the time, and two or more of the 
following symptoms had occurred at the same time:
• Feeling anxious or tense (jittery, nervous, restless, uptight).
• Difficulty sleeping.
• Sweating, blushing, dizziness, palpitations or shortness of breath.
• Muscular tension.
• Excessive worrying.
• Fidgeting or being unable to sit still.
In accordance with DSM-IV criteria, these symptoms had to cause clinically 
significant distress or impairment in social, occupational or other important areas 
of functioning. Those meeting these criteria were classified as ‘AD with anxiety’ 
(AD+Anx). Individuals who had not displayed any symptoms of anxiety were 
classified as ‘AD without anxiety’ (AD-Anx). Those who had displayed symptoms 
of anxiety, but who did not meet the full criteria for AD+Anx were classified as 
unknown. DSM-IV criteria for ‘generalised anxiety disorder’ can be found in 
appendix 3c.
Classifications for AD with major depression and AD with anxiety were 
concatenated to produce a combined variable representing AD with depression 
and anxiety. Subjects who were classified as AD+MajD or AD+Anx were classified 
as having ‘AD with depression/anxiety’ (AD+DepAnx). Subjects who were 
classified as AD-MajD and AD-Anx were categorised as ‘AD without 
depression/anxiety’ (AD-DepAnx). All other subjects were excluded from analyses 
of depression and anxiety. Insufficient data were available for subjects from the 
UK sibling sample regarding symptoms of anxiety; therefore analyses of 
depression and anxiety were restricted to the NIMH sample.
The Principal components analysis presented in chapter 2 found a behavioural 
component which contained items relating to aggression/agitation, euphoria, 
apathy, disinhibition, irritability, aberrant motor behaviour, sleep disturbances and 
appetite abnormalities. Reliable and complete data were available from the UK 
and NIMH sibling samples regarding symptoms of aggression. However, the NPI 
was not used to assess the subjects in the family based samples. Therefore, data
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regarding euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, 
sleep disturbances and appetite abnormalities were limited. As such, data analysis 
was restricted to symptoms of aggression. Aggression had a moderate loading of 
0.53 on the frontal lobe component in PCA of the full sample in chapter 2. This 
increased to 0.60 when analysis was restricted to just those in the moderately 
severe to severe stages of dementia and increased further, to 0.66, in analysis 
controlling for the effects of disease severity.
Participants in the NIMH and UK samples were coded as ‘AD with aggression’ 
(AD+Aggr) if they had displayed unprovoked physical or verbal aggression. 
Symptoms of aggression in the NIMH sample were assessed by means of a semi 
structured interview, in which the informant was asked whether the subject had 
made either verbal or physical threats, or displayed violent behaviour. Aggressive 
symptoms were also assessed as part of the Brief Psychiatric Rating Scale 
(BPRS) (Overall and Gorman 1962). Individuals were scored positive for AD+Aggr 
if they had made physical or verbal threats, or scored highly on the hostility item 
scored as part of the BPRS. Participants in the UK sample were assessed using 
the Behavioural Pathology in AD Rating Scale (BEHAVE-AD) (Reisberg et al. 
1987) and were coded as ‘AD with aggression’ (AD+Aggr) if they had displayed 
unprovoked physical or verbal aggression. Those who had not displayed these 
symptoms were classified as ‘AD without aggression’ (AD-Aggr).
In all analyses of behavioural symptoms, subjects were excluded from the 
analyses if they had a previous history of mood disorders, bipolar disease, 
unipolar disease or an anxiety disorder. Subjects were also excluded if they did 
not meet criteria for either the presence or absence of each symptom (for 
example, those with incomplete data).
The Clinical Dementia Rating (CDR) Scale (Hughes et al. 1982) and Global 
Deterioration Scale (GDS) (Reisberg et al. 1982) were used to rate severity of 
dementia in the NIMH and UK samples, respectively. The GDS is described in 
section 2.2.2. The CDR offers an alternate means of staging dementia, providing 
ratings on a 7 point scale, with anchor points for unaffected (0), questionable (0.5), 
mild (1), moderate (2), severe (3), profound (4) and terminal (5). For the purposes
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of further analyses GDS and CDR scores were recoded to make them more 
compatible. Combined severity ratings comprised very mild (CDR 0.5, GDS 2) mild 
(CDR 1, GDS 3) moderate (CDR 2, GDS 4) moderately severe (CDR 3, GDS 5) 
severe (CDR 4, GDS 6) and very Severe (CDR 5, GDS 7).
3.2.3 Statistical analysis
Intraclass correlation coefficients (ICC) offer a means of estimating the level of 
correlation between two variables (X and Y) among unordered pairs (e.g. where 
the attribution of siblings to X and Y is arbitrary) and were estimated to assess the 
relationship between AAO among siblings. Intraclass correlation coefficients are 
based on analysis of variance methods (ANOVA), which allow the variation in 
continuous traits (e.g. AAO) to be partitioned into between- and within- subjects 
variation, which in this example is analogous to between- and within- family 
variation in AAO. Intraclass correlations were estimated to quantify the proportion 
of variance in AAO accounted for by within-family (or familial) variation. Data 
originated from families with 2, 3, 4 and 5 affected siblings, which provided 1, 2, 3 
and 4 independent pairs respectively (for example, a family with four affected 
members contributes 3 pairs, comprising the proband with siblings two, three and 
four). Intraclass correlations, using a one-way random effects method, were 
estimated for these four subsets of data in separate analyses using SPSS 12.0.1 
(SPSS Inc. 2003). To combine these four ICCs into one overall estimate of the 
correlation coefficient, the estimates of the intraclass correlation coefficients were 
subjected to Fisher’s z-transformation, with the resulting normal variates having 
the approximate sampling variance of 1/a?(-2), where n is the number of pairs 
(Donner 1986). These four estimates were then averaged to give an overall 
intraclass correlation, weighted by the inverse of sampling variances. The APOE 
s4 allele has been shown to reduce age at disease onset in a dose dependent 
manner (Corder et al. 1993) therefore when considering AAO, separate analyses 
were performed after adjusting AAO according to the number of e4 APOE alleles 
possessed. This was achieved by performing a linear regression model to predict 
AAO using the number of e4 alleles as the independent variable. The residuals 
were stored and used to calculate intraclass correlations as outlined above. SPSS 
12.0.1 (SPSS Inc. 2003) was used to complete these analyses.
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Generalised Estimating Equations (GEE) were used to assess the relationship of 
behavioural symptoms among siblings. The focus of this analysis was to 
determine the association of behavioural symptoms between probands and 
siblings. As there can be multiple pairs of probands and siblings from a single 
pedigree all pairs in the data set cannot be considered to be independent. GEE, as 
implemented in the SAS Proc Genmod (SAS Institute Inc., 1999-2001), were used 
to adjust for the non-independence of pairs in the data. In GEE, the regression 
coefficients in the model are estimated assuming that the observations are 
statistically independent. The standard errors of these coefficients are estimated in 
such a way that takes into account the correlation of the observations within 
families, and they do not tend to be greatly affected if this correlation structure is 
specified incorrectly. A binomial distribution was assumed for the presence or 
absence of behavioural symptoms and hence the logit-link function was used. 
Presence of the behavioural symptom of the proband was treated as the predictor 
variable and the presence of the symptom in the sibling was the outcome variable.
This method is akin to creating a 2x2 contingency table of behavioural symptoms 
for probands (rows) and siblings (columns). It would then be possible to identify 
whether there is a relationship between proband-sibling pairs and their behavioural 
symptoms. Using the 2x2 contingency table an odds ratio could be calculated to 
represent the odds of the sibling displaying the symptom if the proband was 
positive for the behaviour; compared to if the proband had not displayed the 
behaviour. Such an approach assumes that all sibling pairs are independent. The 
GEE method takes into account the non-independence owing to the fact that 
multiple pairs can arise from a single family. In addition, the GEE method allows 
covariates to be included in the analysis. As behavioural symptoms in AD may 
vary as a function of disease stage, sibling disease severity was entered as a 
covariate, along with sibling’s AAO and gender.
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3.3 Results
3.3.1 Characteristics of the sample
Basic characteristics of all affected sibling pair samples can be found in table 3.1. 
Both probands and siblings were predominantly female, 324/452 (71.7%) and 
405/531 (76.3%) respectively. AAO ranged from 65 to 93 years in probands, with a 
mean (sd) of 74.86 (5.76) years. The mean (sd) AAO in siblings was 75.06 (6.05) 
years, ranging from 65 to 97 years. Participants were relatively well distributed 
with regard to severity with 3 (0.4%), 135 (16.6%), 222 (27.4%), 247 (30.4%), 164 
(20.2%) and 41 (5.1%) in the very mild, mild, moderate, moderately severe, severe 
and very severe stages of dementia respectively. Classifications of behavioural 
symptoms in the NIMH, UK and combined sample can be seen in table 3.2.
3.3.2 Familiality of age at onset
Given that family selection was slightly different for analyses of AAO the total 
sample size comprised 307 probands and 381 siblings from the NIMH sample; 90 
probands and 101 siblings from the UK sample; and 62 probands and 76 siblings 
from the NIA sample. The UK sample contained 8 siblings with an AAO less than 
65 (range 61-64 years), the NIMH sample comprised 38 (range 42 to 64 years), 
whilst the NIA sample included 5 (range 57 to 64 years). After including siblings 
who presented with AD before the age of 65 the mean AAO (sd) among siblings 
were 73.48 (7.16), 75.29 (7.39) and 72.95 (7.03) years in the NIMH, UK and NIA 
samples, respectively. The full sample comprised 378 affected sibling pairs, 64 
affected sibling trios, 16 affected sibling quartets and 1 affected sibling quintet, 
contributing 378,128, 48 and 4 independent pairs, respectively. The intraclass 
correlation coefficient (ICC) for AAO among sibling pairs was 0.37 (95% Cl = 0.22- 
0.50, p < 0.001), 0.39 (95% Cl = 0.14-0.60, p < 0.001) and 0.44 (95% Cl = 0.12- 
0.69, p < 0.001) in the NIMH, UK and NIA samples respectively. In the combined 
sample the intraclass correlation was 0.38 (95% Cl = 0.26-0.49, p < 0.001).
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Table 3.1 Basic characteristics of the NIMH, UK and NIA sibling samples used in familiality analysis
NIMH Sample 
Proband Sibling
UK Sample 
Proband Sibling
NIA Sample 
Proband Sibling
Combined Sample 
Proband Sibling
n 287 344 101 115 64 72 452 531
Gender n (%)
Male 78 (27.2) 84 (24.4) 25 (24.8) 21 (18.3) 2 5 (3 9 .1 ) 21 (29.2) 128 (28.3) 126 (23.7)
Female 209 (72.8) 260 (75.6) 76 (75.2) 9 4 (8 1 .7 ) 39 (60.9) 51 (70.8) 32 4 (7 1 .7 ) 405 (76.3)
Mean age at assessment, years 80.95 81.35 82.19 82.85 - - 81.23 81.67
range 68-100 68-101 68-93 69-102 - - 68-100 68-102
missing Ages 0 0 16 22 - - 16 22
Mean age at onset, years 74.70 74.94 76.68 76.52 73.20 73.74 74.86 75.06
range 65-93 65-97 65-89 65-91 65-84 65-95 65-93 65-97
missing A 0 0 0 1 16 20 0 0 16 21
Mean disease duration, years 6.25 6.43 5.36 6.27 - - 6.06 6.40
range 1-27 0.5-24 0.5-17 0.5-20 - - 0.5-27 0.5-24
missing durations 0 1 19 26 - - 19 27
Disease Severity n (%)a
Very Mild (CDR 0.5, GDS 2) 0 (0.0) 0 (0.0) 2 (2.3) 1 (1.0) - - 2 (0.5) 1 (0.2)
Mild (CDR 1, GDS 3) 59 (20.6) 48 (14.1) 10 (11 .6 ) 18 (18.4) - - 69 (18.5) 66 (15.0)
Moderate (CDR 2, GDS 4) 84 (29.3) 115 (33 .7 ) 11 (12.8) 12 (12 .2 ) - - 95 (25.5) 127 (28.9)
Moderately Severe (CDR 3, GDS 5) 94 (32.8) 103 (30.2) 32 (37.2) 18 (18.4) - - 126 (33.8) 121 (27.6)
Severe (CDR 4, GDS 6) 37 (12.9) 55 (16.1) 28 (32.6) 44 (44.9) - - 65 (17.4) 99 (22.6)
Very Severe (CDR 5, GDS 7) 13 (4 .5 ) 20 (5.9) 3 (3.5) 5 (5 .1 ) - - 16 (4 .3 ) 25 (5.7)
Missing 0 3 15 17 15 20
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH Sample and Global Deterioration Scale (GDS) in the UK Sample
Table 3.2 Classification of behavioural symptoms in the NIMH, UK and combined sibling samples.
NIMH Sample________UK Sample_____ Combined Sample
Proband Sibling Proband Sibling Proband Sibling
Psychosis
n 287 344 101 115 388 459
AD with Psychosis n (%) 154 (58.6) 185 (60.9) 51 (62.2) 50 (56.8) 205 (59.4) 235 (59.9)
AD without psychosis n (%) 109 (41.4) 119(39 .1 ) 31 (37.8) 38 (43.2) 140 (40.6) 157 (40.1)
Unspecified - Mild delusions 0 0 3 8 3 8
Unspecified - History of psychiatric illness 2 8 2 0 4 8
Unspecified - Incomplete data 22 32 14 19 36 51
Minor Depression
n 287 344 101 115 388 459
AD with Minor Depression n (%) 85 (33.5) 91 (31.2) 43 (57.3) 31 (37.3) 128 (38.9) 122 (32.5)
AD without Minor Depression n (%) 169 (66.5) 201 (68.8) 32 (42.7) 52 (62.7) 201 (61.1) 253 (67.5)
Unspecified - History of psychiatric illness 2 8 2 0 4 8
Unspecified - Incomplete data 31 44 24 32 55 76
Major depression
n 287 344 101 115 388 459
AD with Major Depression n (%) 43 (20.3) 40 (1 6 .6 ) 13 (28 .9 ) 9 (1 4 .8 ) 56 (21.8) 49 (16.2)
AD without Major Depression n (%) 169 (79.7) 201 (83.4) 32 (71.1) 52 (85.2) 201 (78.2) 253 (83.8)
Unspecified - Mild depression 42 51 26 21 68 72
Unspecified - History of psychiatric illness 2 8 2 0 4 8
Unspecified - Incomplete data 31 44 28 33 59 77
Depression & Anxiety
n 287 344 - - 287 344
AD with depression & anxiety n (%) 6 4 (3 1 .1 ) 58 (25.8) - - 64(31 .1 ) 58 (25.8)
AD without depression & anxiety n (%) 142 (68.9) 167 (74.2) - - 142 (68.9) 167 (74.2)
Unspecified - Mild depression/anxiety 35 47 - - 35 47
Unspecified - History of psychiatric illness 2 8 - - 2 8
Unspecified - Incomplete data 44 64 - - 145 179
Aggression
n 287 344 101 115 388 459
AD with aggression n (%) 134 (51.9) 160 (52.3) 32 (44.4) 31 (40.3) 166 (50.3) 191 (49.9)
AD without aggression n (%) 124 (48.1) 146 (47.7) 40 (55.6) 46 (59.7) 164(49.7) 192 (50.1)
Unspecified - Very mild aggression 3 3 12 16 15 19
Unspecified - History of psychiatric illness 2 8 2 0 4 8
Unspecified - Incomplete data 24 27 15 22 39 49
Increasing APOE e4 alleles were associated with reduced AAO in a dose- 
dependent manner. Compared to those with no e4 alleles the regression 
coefficient for those with one z4 allele was 3 = -3.137, p < 0.001, whilst for those 
with two s4 alleles it was 3 = -6.560, p < 0.001. Intraclass correlations were 
calculated after removing the effects of APOE. Complete APOE data were 
available for 344 affected sibling pairs, 52 affected sibling trios and 6 affected 
sibling quartets. In this sub sample the intraclass correlation for AAO among 
sibling pairs was 0.41 (95% Cl = 0.29-0.52, p < 0.001). After removing the effect of
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APOE on AAO for both probands and siblings the intraclass correlation reduced 
slightly to 0.38 (95% Cl = 0.25-0.49, p < 0.001).
3.3.3 Familiality of psychosis
Classification of psychotic symptoms was possible for 345 (88.9%) probands and 
392 (85.4%) siblings. Three probands and eight siblings did not meet criteria for 
AD+P or AD-P, as they had displayed mild delusional behaviour which was not 
sufficient to meet criteria for AD+P. Forty probands and 59 siblings were excluded 
because they either did not have data regarding psychotic symptoms or had a 
previous history of psychiatric disturbance. The prevalence of psychotic symptoms 
was comparable in the UK and NIMH samples, and among probands and siblings.
Demographic and clinical characteristics of the proband’s siblings can be found in 
table 3.3. There was a significant association between proband psychosis status 
and the occurrence of AD+P in siblings in both the UK and NIMH samples. After 
fitting a GEE-based logit model, the estimated odds ratios for AD+P in siblings 
who had probands with AD+P in the NIMH sample was 3.37 (95% Cl, 2.06-5.51; p 
< 0.001). This finding was replicated in the UK sample, with an OR of 3.10 (95% 
Cl, 1.21-7.96; p < 0.019). In the combined sample the estimated odds ratio was 
3.32 (95% Cl, 2.15-5.13; p < 0.001). A significant association between proband 
psychosis status and the occurrence of AD+P in siblings was observed after 
controlling for sibling disease severity, OR = 3.25 (95% Cl, 2.10-5.02; p < 0.001).
In supplementary analysis, AD+P was significantly more prevalent among female 
siblings compared to males, OR = 1.80 (95% Cl, 1.07-3.02; p < 0.026). Proband 
psychosis status remained a significant predictor of AD+P in siblings after 
controlling for sibling AAO, sibling disease severity and gender, OR = 3.30 (95% 
Cl, 2.12-5.13; p< 0.001).
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Table 3.3 Clinical characteristics of siblings of AD probands with and 
without psychotic symptoms.
Sibling Characteristics
Proband psychosis status 
AD-Psychosis AD+Psychosis
n 165 245
Gender n (%)
Male 43 (26.1) 53 (21.6)
Female 122 (73.9) 192 (78.4)
Mean age at assessment, years 81.38 81.98
range 68-102 68-101
Mean age at onset, years 75.09 75.57
range 65-91 65-97
Mean disease duration, years 6.32 6.46
range 1-24 0.5-21
Disease Severity n (%) a
Very Mild (CDR 0.5, GDS 2) 1 (0.6) 0 (0.0)
Mild (CDR 1, GDS 3) 2 9 (1 7 .8 ) 33 (13 .6 )
Moderate (CDR 2, GDS 4) 49 (30.1) 67 (27.6)
Moderately Severe (CDR 3, GDS 5) 38 (23.3) 75 (30.9)
Severe (CDR 4, GDS 6) 35 (21.5) 55 (22.6)
Very Severe (CDR 5, GDS 7) 11 (6.7) 13 (5 .3 )
Missing 2 2
Psychosis status n (%)
AD-P 88 (57.9) 66 (28.9)
AD+P 64 (42.1) 162 (71.1)
Unknown - Mild Delusions 2 6
Unknown - Insufficient Data 11 11
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH 
Sample and Global Deterioration Scale (GDS) in the UK Sample
3.3.4 Familiality of mood
Minor Depression
Data regarding symptoms of minor depression were available for subjects from the 
NIMH and UK samples. 329 (84.8%) probands and 375 (81.7%) siblings met 
criteria for either AD-D or AD+D. 55 probands and 76 siblings did not have data 
regarding depression. Four probands and eight siblings were classified as 
unknown as they had a previous history of mood disorders, bipolar disease, 
unipolar disease or an anxiety disorder. The prevalence of AD+D was significantly
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higher in UK probands, compared to NIMH probands (x2(1)= 13.89, p < 0.001) and 
UK siblings (x2(1)= 6.32, p=0.012).
Table 3.4 Clinical characteristics of siblings of AD probands with and without minor 
depression.
Sibling Characteristics
Proband minor depression status
AD-Minor Depression AD+Minor Depression
n 238 147
Gender n (%)
Male 58 (24.4) 31 (21.1)
Female 180 (75.6) 116(78.9)
Mean age at assessment, years 81.84 81.85
range 68-102 69-101
Mean age at onset, years 75.7 74.88
range 65-92 65-91
Mean disease duration, years 6.23 6.81
range 1-22 0.5-24
Disease Severity n (% )a
Very Mild (CDR 0.5, GDS 2) 0(0) 0(0)
Mild (CDR 1, GDS 3) 36 (15.3) 18(12.3)
Moderate (CDR 2, GDS 4) 73 (31.1) 39 (26.7)
Moderately Severe (CDR 3, GDS 5) 69 (29.4) 40 (27.4)
Severe (CDR 4, GDS 6) 42 (17.9) 42 (28.8)
Very Severe (CDR 5, GDS 7) 15(6.4) 7 (4.8)
Missing 3 1
Minor Depression status n (%)
AD-Minor Depression 160 (73.7) 76 (57.1)
AD+Minor Depression 57 (26.3) 57 (42.9)
Unspecified - History of depression 3 3
Unspecified - Insufficient Data 18 11
Major Depression status n (%)
AD-Major Depression 160 (86.5) 76 (79.2)
AD+Major Depression 25 (13.5) 20 (20.8)
Unspecified - Mild Depression 32 35
Unspecified - History of depression 3 3
Unspecified - Insufficient Data 18 12
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH 
Sample and Global Deterioration Scale (GDS) in the UK Sample
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Demographic and clinical characteristics of the proband’s siblings can be found in 
table 3.4. AD+D in probands was significantly associated with AD+D in siblings in 
the NIMH sample, OR = 2.07 (95% Cl, 1.21-3.55; p=0.008). AD+D in probands 
was associated with over a two-fold increase of AD+D in siblings from the UK 
sample, however this result did not meet criteria for statistical significance, OR =
2.39 (95% Cl, 0.89-6.45; p=0.086). An odds ratio of 2.17 (95% Cl, 1.36-3.46; p < 
0.001) was observed in the combined UK and NIMH sample. In the combined 
sample sibling’s disease severity, gender and AAO were entered into the model as 
covariates but did not significantly explain any of the variance in AD+D in siblings. 
Furthermore, AD+D status in probands remained a significant predictor of AD+D in 
siblings after controlling for siblings disease severity, gender, AAO and age at 
collection, OR = 2.16 (95% Cl, 1.34-3.46; p=0.002).
Major Depression
56 probands and 49 siblings met criteria for AD with major depression (AD+MajD), 
201 probands and 253 siblings had displayed no symptoms of depression. 68  
probands and 72 siblings had mild depression but did not meet criteria for 
AD+MajD and were therefore categorised as unknown in analyses of major 
depression. A further 63 probands and 85 siblings were excluded from the 
analysis as they either had insufficient data or had a previous history of psychiatric 
illness.
After excluding families in which the proband had insufficient data, only 4 siblings 
In the UK sample met criteria for AD with major depression (AD+MajD). This 
sample was inadequate for independent hypothesis testing; therefore analysis was 
performed on the combined sample only. Demographic and clinical characteristics 
of the proband’s siblings can be found in table 3.5. Major depression in probands 
was associated with around a two-fold increase in the corresponding symptom 
among siblings, but this result did not meet criteria for statistical significance, OR = 
1.96 (95% Cl, 0.87-4.45; p < 0.106). In supplementary analyses, neither sibling’s 
AAO, gender nor disease severity significantly predicted siblings AD+MajD status.
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Table 3.5 Clinical characteristics of siblings of AD probands with and without major
depression.
Sibling Characteristics
Proband major depression status
AD-Major depression AD+Major depression
n 238 63
Gender n (%)
Male 58 (24.4) 13 (20 .6 )
Female 180 (75.6) 50 (79.4)
Mean age, years 81.84 81.61
range 68-102 71-101
Mean age at onset, years 75.70 74.44
range 65-92 65-88
Mean disease duration, years 6.23 7.19
range 1-22 1-24
Disease Severity n (%) a
Very Mild (CDR 0.5, GDS 2) 0 (0.0) 0 (0.0)
Mild (CDR 1, GDS 3) 36 (1 5 .3 ) 11 (17.5)
Moderate (CDR 2, GDS 4) 73 (31.1) 14 (22.2)
Moderately Severe (CDR 3, GDS 5) 69 (29.4) 20 (31.7)
Severe (CDR 4, GDS 6) 4 2 (1 7 .9 ) 14 (22 .2 )
Very Severe (CDR 5, GDS 7) 1 5 (6 .4 ) 4 (6.3)
Missing 3 0
Major depression status n (%)
AD-Major depression 160 (86.5) 33 (76.7)
AD+Major depression 2 5 (1 3 .5 ) 10 (23 .3 )
Unspecified - History of depression 3 2
Unspecified - Mild Depression 32 12
Unspecified - Insufficient Data 18 5
Minor depression status n (%)
AD-Minor Depression 160 (73.7) 33 (58.9)
AD+Minor Depression 57 (26.3) 23 (41.1)
Unspecified - History of depression 3 2
Unspecified - Insufficient Data 18 5
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH  
Sample and Global Deterioration Scale (GDS) in the UK Sample
Depression and Anxiety
Data regarding AD with depression and anxiety were only available for individuals 
in the NIMH sample. Sixty-four probands and 58 siblings met criteria for 
AD+DepAnx, whilst 142 probands and 167 siblings were classified as AD-DepAnx.
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35 probands and 47 siblings had displayed symptoms of either depression or 
anxiety, but these were not severe enough to meet full criteria for AD with 
depression and anxiety, whilst 2  probands and 8  siblings were classified as 
unknown as they had previous history of mood disorders, bipolar disease, unipolar 
disease or an anxiety disorder. The prevalence of AD+DepAnx was comparable in 
probands and siblings, x20 )= 1-48, p=0.223.
Clinical characteristics of siblings of AD+DepAnx and AD-DepAnx probands can 
be seen in table 3.6. AD+DepAnx in probands was associated with just over a two­
fold increase in AD+DepAnx in siblings, but this result did not reach criteria for 
statistical significance, OR = 2.09 (95% Cl, 1.00-4.38; p < 0.052). In 
supplementary analyses, sibling gender, AAO and disease severity were added as 
covariates, which revealed that male siblings were significantly more likely to have 
displayed depression and anxiety than females, OR = 2.48 (95% Cl, 1.14-5.40; p < 
0.023). Furthermore, when gender was added as a covariate, proband 
AD+DepAnx status significantly predicted AD+DepAnx status in siblings, OR =
2.40 (95% Cl, 1.12-5.12; p < 0.024). Sibling severity and AAO were not associated 
with AD+DepAnx in siblings.
3.3.5 Familiality of aggression
Sufficient data were available to classify 330/388 probands (85.1%) and 383/459 
siblings (83.4%) as either AD+Agg or AD-Agg. 15 probands and 19 siblings were 
classified as unknown for AD with aggression as they had displayed very mild 
aggressive behaviour which could have been provoked, and therefore did not 
meet criteria for AD+Agg or AD-Agg. 43 probands and 57 siblings were classified 
as unknown as they either had a previous history of psychiatric illness or had 
insufficient data. No difference was observed in the prevalence of aggression in 
probands and siblings, x2(1)= 0.013, p=0.908, however a significantly higher 
prevalence of aggression was noted among NIMH families compared to those 
from the UK, x20 )= 4.570, p=0.033. Clinical characteristics of siblings of AD+Agg 
and AD-Agg probands can be seen in table 3.7.
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Table 3.6 Clinical characteristics of siblings of AD probands with and without
depression & anxiety.
Sibling Characteristics
Proband Depression & Anxiety status
AD-Depression & 
Anxiety
AD+Depression & 
Anxiety
n 172 75
Gender n (%)
Male 49 (28.5) 14(18 .7 )
Female 123 (71.5) 61 (81.3)
Mean age at assessment, years 81.35 81.83
range 68-95 72-101
Mean age at onset, years 75.33 74.45
range 65-90 65-88
Mean disease duration, years 6.06 7.38
range 1-21 0.5-24
Disease Severity n (%)a
Very Mild (CDR 0.5, GDS 2) 0 (0 ) 0 (0 )
Mild (CDR 1, GDS 3) 2 3 (13 .6 ) 11 (14.7)
Moderate (CDR 2, GDS 4) 63 (37.3) 18(24)
Moderately Severe (CDR 3, GDS 5) 49 (29) 29 (38.7)
Severe (CDR 4, GDS 6) 21 (12.4) 14(18.7)
Very Severe (CDR 5, GDS 7) 13(7 .7 ) 3 (4 )
Missing 3 0
Depression/Anxiety status n (%)
AD-Depression & Anxiety 97 (78.2) 31 (63.3)
AD-Depression & Anxiety 27 (21.8) 18(36 .7 )
Unspecified - History of depression 3 2
Symptoms too mild to meet criteria 22 12
Unspecified - Insufficient Data 23 12
Minor Depression status n (%)
AD-Minor Depression 115(74 .2 ) 43 (62.3)
AD+Minor Depression 40 (25.8) 26 (37.7)
Unspecified - History of depression 3 2
Unspecified - Insufficient Data 14 4
Major Depression status n (%)
AD-Major Depression 115(85.2 ) 43 (78.2)
AD+Major Depression 20 (14.8) 12(21.8)
Unspecified - Mild Depression 20 14
Unspecified - History of depression 3 2
Unspecified - Insufficient Data 14 4
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH 
Sample and Global Deterioration Scale (GDS) in the UK Sample
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In the NIMH sample aggression in probands was associated with a significant 
increase in AD+Agg prevalence among siblings, OR = 2.35 (95% Cl, 1.47-3.75; p 
< 0.001). This finding replicated in the UK sample, OR = 2.75 (95% Cl, 1.01-7.44; 
p=0.047). The combined sample yielded an odds ratio of 2.38 (95% Cl, 1.56-3.63; 
p < 0.001). When entered as covariates sibling disease severity, gender, AAO and 
current age did not contribute to the model, whilst proband aggression status 
remained a significant predictor of AD+Agg in siblings after controlling for all 
covariates, OR = 2.33 (95% Cl, 1.52-3.57; p < 0.001). A summary of the 
Generalized Estimating Equation models for all behavioural symptoms can be 
seen in table 3.8.
Table 3.7 Clinical characteristics of siblings of AD probands with and without 
aggressive symptoms.
Sibling Characteristics
Proband Aggression status
AD-Agg ression AD+Aggression
n 196 194
Gender n (%)
Male 44 (22.4) 44 (22.7)
Female 152 (77.6) 150 (77.3)
Mean age at assessment, years 81.67 81.94
range 68-99 69-102
Mean age at onset, years 75.35 75.56
range 65-97 65-92
Mean disease duration, years 6.27 6.42
range 0.5-24 0.5-20
Disease Severity n (%) a
Very Mild (CDR 0.5, G D S 2) 0 (0.0) 1 (0.5)
Mild (CDR 1, GDS 3) 3 2 (1 6 .6 ) 2 5 (1 3 .0 )
Moderate (CDR 2, G DS 4) 62 (32.1) 50 (25.9)
Moderately Severe (C D R  3, G D S 5) 44 (22.8) 64 (33.2)
Severe (CDR 4, G DS 6) 42 (21.8) 44 (22.8)
Very Severe (CDR 5, G DS 7) 1 3 (6 .7 ) 9 (4.7)
Missing 3 1
Aggression status n (%)
AD-aggression 108 (60.0) 71 (38.6)
AD+aggression 72 (40.0) 113(61 .4 )
Unspecified - Very mild aggression 7 2
Unspecified - Insufficient Data 9 8
a Severity was rated using the Clinical Dementia Rating Scale (CDR) in the NIMH 
Sample and Global Deterioration Scale (GDS) in the UK Sample
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Table 3.8 Summary of generalised estimating equation models for behavioural symptoms.
NIMH Sample UK Sample Combined Sample
OR1 95% Cl OR1 95% Cl OR1 95% Cl
OR1 | 
Sibling 
Severity
95% Cl
OR11 Sibling 
Severity, 
AAO, Gender
95% Cl
Psychosis 3.37** 2.06-5.51 3.10* 1.21-7.96 3.32** 2.15-5.13 3.25** 2.10-5.02 3.30** 2.12-5.13
Minor Depression 2.07** 1.21-3.55 2.39 0.89-6.45 2.17** 1.36-3.46 2 .2 2** 1.39-3.54 2.16** 1.34-3.46
Major Depression - - - - 1.96 0.87-4.45 1.96 0.87-4.40 1.88 0.84-4.21
Depression/Anxiety 2.09 1.00-4.38 - - 2.09 1.00-4.38 2.07 0.99-4.33 2.40* 1.12-5.12
Aggression 2.35** 1.47-3.75 2.75* 1.01-7.44 2.38** 1.56-3.63 2.32** 1.52-3.54 2.33** 1.52-3.57
1 Odds Ratio's (OR) represent the risk that each symptom will occur in siblings if the proband has displayed the symptom, 
compared to if the proband has not displayed the symptom.
* p < 0.05
** p < 0.01
3.4 Discussion
3.4.1 Summary of findings
The UK, NIMH and NIA siblings were similar to the non-family based sample 
reported in chapter 2 in terms of AAO, age of assessment, disease duration, 
gender ratio and disease severity. Symptoms of aggression, psychosis and 
depression were common in both the NIMH and UK families, with comparable 
prevalence rates to those reported in the non-family based sample reported in 
chapter 2. A significant familial effect on age at disease onset was observed in the 
three independent samples of sibling pairs. The APOE e4 allele was associated 
with a lower AAO. However, the familial effect on AAO remained significant after 
controlling for APOE e4 status. Significant familial aggregation was noted with 
symptoms of psychosis and aggression in the NIMH siblings, which also replicated 
in the independent sample collected in the UK. In the NIMH sample, minor 
depression clustered in families more often that would be expected by chance, 
whilst a trend towards familiality was observed among the UK sibling pairs. Neither 
depression and anxiety, nor major depression, were significantly related among 
sibling pairs in univariate analyses. However, depression and anxiety showed 
some evidence of familiality in a model including gender. Perhaps the most 
notable result was the strong relationship between psychotic symptoms observed 
among sibling pairs with AD. Those with psychotic probands were over three times 
as likely to develop symptoms of psychosis, compared to siblings of non-psychotic 
probands. This finding was highly significant in both the UK and NIMH sample, 
reducing the possibility of a type II error.
3.4.2 Discussion of findings in relation to previous literature
Strong evidence was found for familial effects on AAO in AD, which was not 
attributable to APOE. This supports previous findings by Tunstall and colleagues 
(2000) who noted familial influence on AAO in a sample which contained data from 
a large proportion of the UK siblings used here. The results also support the 
conclusion drawn by Warwick-Daw and Colleagues (2000) who suggested that 
there are a number of unidentified genes which exert a sizable effect on AAO in 
AD.
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The findings in relation to psychotic symptoms offer support to what has been 
observed previously in AD, however it should be noted that there is considerable 
overlap between the UK sample and that used by Tunstall and colleagues (2000), 
whereas the previous report of familial aggregation of psychosis in AD by Sweet 
and colleagues (2000b) includes a proportion of the NIMH siblings used in this 
analysis. In fact, only 8 % of probands, and 10% of the siblings in the NIMH sample 
were exclusive to the analyses reported here. Sweet and colleagues included 
individuals diagnosed with possible AD and those with a disease onset less than 
65 years; as such 30% of probands and 31% of siblings selected by Sweet and 
colleagues were not used in the analysis presented here. It is interesting to note 
that the familial influence on psychotic symptoms remained prominent in analyses 
restricted to sibling pairs with late-onset probable, or definite, AD. This, along with 
the highly comparable effect sizes noted in the UK and NIMH sample, imply that 
the finding of familiality of psychosis in AD is robust.
Using a different method to the one used here, Tunstall and colleagues (2000) 
reported familiality of aggressive symptoms in AD, represented by a slight 
elevation in pairwise concordance for aggression among sibling pairs compared to 
what would be expected by chance. This is the first study to statistically assess the 
relationship between aggressive symptoms among relatives suffering with AD. 
Siblings of those with aggressive symptoms were more than twice as likely to 
display aggression. The relationship was less marked than that observed with 
psychosis, however the finding appears to be robust, replicating in the UK sample.
Three variables were used to assess the behavioural component of mood in the 
sibling pairs. In the main analyses only the broad definition of depression showed 
significant evidence of familial aggregation, with the prevalence of depression 
doubling in siblings of those with AD+D. This effect did not replicate in the smaller 
UK sample, however there was a trend in the same direction. The familial effect 
appears to be small; as such the UK sample may have been inadequately 
powered to detect this effect. No significant familial effects were noted with major 
depression. Likewise analysis of the combined depression and anxiety variable did 
not initially reveal statistically significant evidence for familial aggregation.
However, after including gender as a covariate, depression and anxiety in
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probands was associated with a significant two-fold increase in siblings. Using an 
overlapping sample, Tunstall and colleagues reported a moderate familial 
influence on mood. Others have reported a relationship between family history of 
depression and the prevalence of mood disturbances in AD (Butt and Strauss 
2001; Lyketsos et al. 1996; Pearlson et al. 1990; Strauss and Ogrocki 1996). 
These studies strongly suggest a genetic influence in the aetiology of depressive 
symptoms in AD. The findings here offer some suggestive evidence in support of 
the previous findings, but the results are far from conclusive.
3.4.3 Implications and future research
It is important to consider whether familiality observed in studies such as this 
represents increased genetic liability. As discussed in section 3.1.1, familiality 
represents the total effect of genetic heritability and shared environment among 
relative pairs; however this analysis is not able to differentiate between these two 
effects. Some have suggested that shared environment effects are limited in later 
life (Sweet et al. 2002; Tunstall et al. 2000), which is supported by several twin 
studies which have reported limited shared environment effects when assessing 
the risk of developing AD (Gatz et al. 1997; Pedersen et al. 2004; Pedersen et al. 
2001; Raiha et al. 1996). Sullivan, Neale and Kendler (2000) provided a meta­
analysis of five family based studies of major depression, not related to AD, and 
found shared environment to have a negligible effect in explaining susceptibility to 
the disease. It therefore seems reasonable to assume that shared environment 
does not exert a substantial influence on depression observed in AD, although it 
cannot be completely ruled out. Familial aggregation of psychosis, aggression and 
age at disease onset may also be explained by environmental influences shared 
between family members in these analyses. However, as already discussed, 
genetic variation has been shown to modify AAO (Meyer et al. 1998) and 
susceptibility to psychotic and aggressive symptoms in AD (Sweet et al. 1998), 
illustrating that genetic variation may account for elements of clinical 
heterogeneity. It therefore seems more plausible to assume that genetic effects 
are the most important contributor to familiality, however further study is required 
to confirm this.
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Conclusions from the findings in relation to AAO should be made with caution. 
Methods of sample ascertainment in sibling pair collections raise the possibility 
that siblings with a similar AAO are more likely to be sampled together, as they are 
more likely to be living with the disease at the same time. The optimal estimate of 
familiality would be gained through collection of population based studies with 
complete ascertainment of affected family members. It is encouraging that the 
familial effect remained strong in the NIMH sample, which was collected over a 
wider time frame than the NIA and UK siblings, with a total period of collection 
lasting over 6  years. As such sampling bias among NIMH sibling pairs would be 
expected to have less influence on familiality estimates.
Given the limitations outlined, these findings provide evidence that age at disease 
onset and behavioural components of AD aggregate within families. The evidence 
regarding AAO and psychosis are perhaps the most convincing, displaying the 
strongest familial influence. Future studies may seek to further unravel the genetic 
aetiology of clinical heterogeneity in AD. Although replication in larger, population 
based twin and family samples would be advantageous these, and previous, 
findings provide adequate justification for studies aiming to map genes associated 
with clinical variation observed in AD. The findings in relation to aggression and 
depression were not as strong, indeed minor depression was the only mood 
related variable assessed to show significant familial aggregation. However, due to 
issues of power, these findings do not preclude a genetic influence on mood state 
in AD.
It is likely that familial effects identified here are genetically underpinned; hence 
genetic variation may modify AAO, psychotic symptoms, and to a lesser extent 
mood and aggression in AD. Alternatively these clinical characteristics may 
provide suitable ‘candidate phenotypes’ to assist in the delineation of more 
homogeneous subsets for future research. A number of authors have already 
performed genetic association studies to search for genes associated with the 
clinical variation observed in AD. They have generally focused on candidate genes 
for other neuropsychiatric disorders, for example dopamine (Craig et al. 2004b; 
Holmes et al. 2001; Sweet et al. 1998) and serotonin (Assal et al. 2004; Holmes et 
al. 1998a; Lam et al. 2004; Nacmias et al. 2001) receptor genes. Some positive
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associations have been reported, but the findings to date are not entirely 
consistent. Linkage analysis offers an alternative to genetic association studies 
and can provide a powerful first step in identifying regions which are likely to 
harbour loci associated with disease phenotypes. The family based samples used 
in this chapter originate from a number of linkage studies of LOAD, therefore offer 
an opportunity to search for genes associated with clinical variation showing 
familial aggregation. In chapter 4, AAO, psychosis, aggression and minor 
depression will be used as covariates in the linkage analysis of affected relative 
pairs from the NIMH, UK and NIA samples. The primary goal is to identify genetic 
regions which are likely to contain genes which could modify the clinical 
presentation of AD, or alternatively increase susceptibility to genetically 
homogeneous forms of the disease characterised by different clinical 
presentations.
3.4.4 Methodological critique
This study suffers from a number of limitations which are worthy of discussion.
First, there were concerns regarding the power of this sample to detect familial 
effects, which was particularly a problem when the prevalence of the behavioural 
components was low (e.g. major depression, depression and anxiety). As such it is 
difficult to draw firm conclusions from these analyses. However, it should be noted 
that this is among one of the largest samples to date which has been used to 
assess the familiality of clinical features in AD. In addition, power to detect familial 
effects may have been reduced by creating binary variables to determine 
presence or absence of behavioural components. If one assumes that clinical 
variation observed in AD is a quantitative trait, it would be beneficial to construct a 
continuous measure of behavioural components. Indeed, Tunstall and colleagues 
reported a significant familial effect on current mood state when mood was rated 
on a quantitative scale using a sample much smaller than the one reported here. 
This approach also negates the requirement for researchers to define criteria for 
presence or absence of particular symptoms. These data were collected for a 
genome screen of AD; therefore data regarding behavioural symptoms was limited 
and largely incompatible with defining quantitative measures of aggression, 
psychosis and mood. This study offers a good insight into the familial influence on
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clinical variation observed in AD. However, this field would be advanced by the 
collection of large well powered family based samples, where the primary goal was 
to determine familial aggregation of clinical variation.
This study relies largely on information obtained using a retrospective interview 
with the AD sufferers informant. It is possible that certain informants may have a 
particular propensity to report certain symptoms more than others. If the same 
informant was used for multiple members of the same family this may falsely 
inflate the correlation between siblings. However, reviewing the limited data 
available it appears that the informant often differed for each sibling within a family 
(i.e. it was usually the participants next of kin), which is likely to limit the extent to 
which reporting bias affected familiality estimates. Unfortunately, insufficient data 
were available to assess statistically the effect of reporting bias by informants. It is 
noteworthy that all the behavioural components displayed either a trend towards, 
or significant, familial influence. However, given previous findings, there was an a 
priori assumption that these symptoms would aggregate within families, thus these 
concerns may be unfounded. In addition, the familial effects on psychosis and 
AAO where much stronger than those for other symptoms, hence they are less 
likely to have resulted merely from a reporting bias.
This study employs the behavioural components identified in the UK non family 
based sample in chapter 2 , to inform the categorisation of behavioural symptoms. 
This could represent a flaw in the current study design. Ideally, factor analysis 
would have been performed directly in the sibling pair sample, adjusting for family 
effects. Consequently, the familiality of factor scores could have been assessed 
directly as a quantitative trait. However, the data collected for the sibling pair 
samples was not originally intended for this purpose. It was therefore less than 
ideal for factor analytical procedures (e.g. the assessment of a number of common 
symptoms including, euphoria, disinhibition, sleep and appetite disturbances was 
either limited or absent). It is possible that the behavioural components identified 
in chapter 2 were not appropriate to transfer into the affected sibling pair sample, 
as the participants used for the PCA comprised primarily sporadic, non familial, 
cases of AD. However, there is no evidence, either in chapter 2 or the literature 
(Haupt et al. 1992; Holmes and Lovestone 2002), to suggest that behavioural
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symptoms differ among those with and without a family history of dementia. In 
addition, the prevalence of behavioural symptoms reported in the UK and NIMH 
sibling pairs was comparable to those reported in the sample used in chapter 2 . 
Furthermore, the behavioural components identified in chapter 2 have been 
reported elsewhere on numerous occasions, using different rating scales and 
study populations. As such they can be regarded as robust behavioural 
components commonly observed in AD. It therefore seems reasonable to 
generalise findings from the UK non family based dataset to the sibling pair 
sample.
3.4.5 Conclusions
Principal components analysis identified three components which represent the 
broad range of behavioural symptoms commonly observed among AD sufferers. 
These findings were used to guide the characterisation of behavioural symptoms 
in a sample of affected sibling pairs, with the primary goal of assessing the familial 
influences on the clinical presentation of AD. Strong evidence was found to 
suggest that the presence of psychotic symptoms and age at disease onset in AD 
are familial. Likewise, aggression and depression showed some evidence of 
familial aggregation. The correlation between ages at onset among siblings was 
largely independent of the APOE z4 allele. These findings support the hypothesis 
that genetic factors, at least in part, contribute to the clinical differences observed 
among AD sufferers. They also provide justification for studies aiming to map 
genes associated with the phenotypic heterogeneity observed in AD.
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Chapter 4 
Linkage analysis of late-onset Alzheimer’s disease
4.1 Introduction
4.1.1 Genetics background
Linkage analysis provides a means of localising regions that may harbour genetic 
variants which increase susceptibility to disease. The human genome consists of 
a sequence of approximately 3,000 million bases. Long molecules of double 
stranded DNA located in the nucleus of every cell form chromosomes. In general, 
humans inherit 23 chromosomes, containing a copy of the human genome, from 
each parent. These comprise 22 pairs of autosomes, and a pair of sex 
chromosomes, X and a Y in males and two X’s in females.
DNA provides the genetic blueprint which is used to produce the proteins that form 
part of the structure, and perform most of the cellular activities, of living organisms. 
Genes are segments of DNA that specify the amino acid sequence of proteins. 
They account for roughly 3% of the DNA sequence in the human genome and 
occur in approximately the same physical genomic location in all human beings 
(International Human Genome Sequencing Consortium 2004). The remaining DNA 
sequence is thought to be non-coding and is often referred to as ‘junk DNA’, 
however it is now known that some of these regions are involved in the regulation 
of nearby coding sequences (Dicks and Sawa 2003). The entire human genome 
is currently thought to consist of approximately 20,000 to 25,000 genes 
(International Human Genome Sequencing Consortium, 2004; Stein 2004). Linear 
chains of amino acids are used to make up proteins. There are 20 such amino 
acids that are used as ‘building blocks’. As such an enormous number of different 
and diverse proteins can be constructed. The structure of DNA allows accurate 
copies to be made which can be passed on from parents to offspring. The 
accuracy of replication is crucial as changes in the DNA sequence disrupt the 
coding sequence. This can lead to proteins which differ in structure and function, 
which can have a potentially harmful effect on the cell and the organism.
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During reproduction a single cell, called the zygote, is formed from two gametes, 
the ovum and the sperm. Gametes are formed by a special type of cell division 
known as meiosis, which gives rise to cells which, rather than containing two sets 
of all chromosomes (diploid) have a single (haploid) set of the 2 2  autosomes and a 
sex chromosome. Therefore, the resulting zygote comprises the correct number of 
23 diploid chromosomes. Two chromosomes in the zygote are said to be 
homologous if they belong to the same chromosomal family (e.g. both 
chromosome 1). Homologous chromosomes are similar in both length and 
sequence meaning that humans possess two copies of every gene -  one from 
each parent. During meiosis crossing over of genetic material can occur, achieved 
by the exchange of genetic information between homologous chromosomes of 
paternal and maternal origin. As a result alternating segments of paternal and 
maternal DNA are produced, which are then passed onto the next generation 
(Sham and McGuffin 2002).
Ancestral mutations lead to variation which occurs at numerous positions, or loci, 
across the genome, meaning that the DNA sequence can take different forms. 
These different forms are called alleles (e.g. a<\, 32, a3, a4 and so on). Since human 
cells are diploid there are two alleles at each locus. A pair of alleles is called a 
genotype (e.g. ai/ai, ai/a2, a2/a4 etc). If the two alleles at a locus are identical then 
the individual is said to be homozygous (e.g. a-i/a-i, 82/82) for that genotype, if they 
are different they are said to be heterozygous (e.g. ai/a2). Changes in the DNA 
sequence can occur through the process of mutations. Allelic variations in the 
DNA sequence are called polymorphisms, which can take the form of 
substitutions, deletions, translocations and insertions. Substitutions refer to 
replacement of one base pair by another, deletions and insertions occur when one 
or more base pairs are deleted or inserted from the DNA sequence. DNA can also 
be translocated from one segment of the sequence to another. It is such mutations 
within genes which give rise to the genetic variability observed within the 
population. Mutations can cause, or increase, susceptibility to particular diseases, 
which are then passed down in families from generation to generation.
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The basic nature of the gene was defined by Gregor Mendel over a century ago. 
He observed that many traits in plants and animals are heritable and coined the 
term ‘gene’ to refer to discrete units of information transmitted from parent to 
offspring. Mendel proposed the laws of dominance, segregation and independent 
assortment. Mendel’s law of dominance stated that hereditary units passed on 
from each parent could be either dominant or recessive. Both dominant and 
recessive alleles could be inherited by offspring; however the dominant trait will 
mask the expression of the recessive trait. For example, if ai is dominant and a2 is 
recessive, then homozygotes ai/ai and heterozygotes a<i/a2 have identical 
phenotypes. The trait coded for by the recessive allele is only observed among 
those with the homozygous a2/a2 genotype. As such, autosomal dominant disease 
would occur in the offspring of those with an a-i/a2 mother and a2/a2 father at an 
affected/unaffected ratio of 1:1. The offspring of two unaffected ‘carriers’ of a 
recessive disease gene (e.g. ai/a2) would be expected to display a ratio of 
unaffected/affected individuals of 3:1. However, Mendelian segregation ratios are 
not observed in many genetic disorders, and they also do not generalise to 
continuously distributed traits such as height. As such Mendel’s law of dominance 
needs a slight conceptual modification to account for penetrance, which refers to 
the probability of a given phenotype conditional on a particular genotype (Cardno 
and McGuffin 2002). Those carrying a genotype which conveys a penetrance to a 
particular trait of 1 will inevitably express the corresponding phenotype, conversely 
a genotype with a penetrance of 0 will have no effect on the trait. Under Mendel’s 
law of dominance particular genotypes always have a penetrance of 0 or 1. 
However, this is generally not the case for complex disorders, with penetrance 
usually lying between 0 and 1. As such, genetic variation at a particular locus may 
increase the probability that a particular trait or phenotype will be displayed, but 
will not make it inevitable. Mendel’s law of segregation stated that during the 
formation of reproductive cells, a parent’s paired hereditary units are randomly 
separated; each gamete containing only one of the two traits. Hence all individuals 
obtain one randomly selected gene from each parent. Finally, he proposed the law 
of independent assortment which suggested that genes were inherited 
independently of each other. However, this was later proven to be incorrect.
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4.1.2 An introduction to genetic linkage analysis
Mendel’s law of assortment states the transmission of alleles at two or more loci 
are independent. It has since been shown that this is only true for loci on separate 
chromosomes. Some alleles are inherited together more often than would be 
expected by chance. Within families genes which are located in close proximity to 
one another tend to be transmitted together. This provides an opportunity for a 
form of research called ‘genetic linkage analysis’. Linkage analysis measures the 
co-segregation of specific marker alleles and a disease phenotype within individual 
families. Markers are usually short tandem repeat polymorphisms (STRs). STRs 
are highly polymorphic and are therefore more informative for linkage (Oetting et 
al. 1995). If a particular marker genotype co-segregates with a disease within 
families it is possible that mutations at this marker, or a locus nearby, increase 
susceptibility to the disease. Linkage analysis has the particular advantage that it 
does not require any prior knowledge of the pathophysiological mechanisms of the 
disorder. As such it has proven hugely successful in mapping mutations 
responsible for Mendelian diseases (Risch 2000) and has also been used in the 
study of genetically complex disorders.
Linkage analysis makes use of genetic markers spread across the genome. Such 
markers are DNA polymorphisms which have two or more alleles in the population 
of interest. They are anchored to a specific locus and their order and location can 
be identified using a genetic map. Linkage analyses can be performed using two 
loci, (i.e. two marker loci, or one marker locus and the proposed disease locus), 
which is called twopoint (or single point) linkage analysis. Alternatively, a number 
of marker loci spread across a chromosome can be analysed simultaneously, 
referred to as multipoint linkage analysis.
Linkage analysis can be performed by formulating specific inheritance models 
(parametric) or by employing methods that do not require disease models to be 
predefined (model-free). Parametric methods are model dependent and require 
researchers to specify the mode of transmission (e.g. dominant or recessive), 
penetrance of the susceptibility locus, marker and disease frequencies. On the 
whole they are a powerful means of testing for linkage; however the power is
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drastically reduced if the model parameters are mis-specified (Clerget-Darpoux et 
al. 1986), which can often lead to false positive results. This is a particular concern 
in complex diseases where genetic models are difficult to determine. In the 
absence of accurate parameters model-free methods are more robust; however 
they have less power to detect linkage if in fact the correct disease model is known 
(Holmans 2003). Model-free methods can also be performed using samples of 
affected relative pairs, rather than complex pedigrees which are preferred for 
parametric methods. Due to difficulty in ascertaining large pedigrees, especially in 
diseases of late-onset, relative pair approaches are often advantageous as they 
allow a greater proportion of the population to be sampled.
Model-free methods using relative pairs rely on information about alleles shared in 
the pedigree. If two individuals inherit the same allele from a common ancestor it is 
said to be shared ‘identical by descent’ (IBD). As each individual carries two 
alleles at a marker locus, a pair of individuals can either share 0, 1 or 2 alleles. In 
outbred populations it is possible to determine the prior probabilities that a pair of 
relatives will share 0, 1 or 2 alleles IBD. For example, if a mother and father 
possess genotypes ai/a2 and 83/84, respectively, at locus A, assuming 
independent assortment of alleles their offspring can possess the following 
genotypes with equal probability: ai/a3, a-i/a4, 82/83 or 82/84. It therefore follows that 
two siblings have the probabilities 0.25, 0.50, 0.25 of sharing 0,1 or 2 alleles IBD 
respectively. It is possible to calculate prior IBD sharing probabilities for any given 
pair of relatives. As already noted, alleles that are in close proximity have a higher 
chance of being transmitted together from one generation to the next than alleles 
at loci which are unlinked (e.g. far apart). Hence, relatives co-segregating the 
same genetic disorder will have a higher probability of sharing alleles IBD at, or 
near, the locus influencing susceptibility to the disease. By genotyping markers in 
chromosomal regions of interest a test for linkage between the markers and the 
disease phenotype can be performed. To search for regions of interest genetic 
markers can be selected at set intervals which cover large chromosomal regions, 
or even the whole genome.
Unfortunately, determining alleles shared IBD is often difficult when samples are 
restricted to sibling or relative pairs. A lack of information means it is sometimes
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not possible to infer whether 0, 1 or 2 alleles are shared IBD with certainty when 
only sibling pairs are genotyped. In some cases, IBD can remain ambiguous even 
when parental genotypes are available. For example, it is difficult to determine 
IBD sharing among siblings where one parent is homozygous for a particular 
allele, or if both parents have the same genotype. When IBD cannot be 
determined explicitly allele frequencies are employed to give the best estimate of 
the IBD sharing probabilities. The use of multiple markers provides more accurate 
IBD information.
The LOD score is a commonly used measure of linkage. It is defined as the logio 
of the ratio between two probabilities, L Ha  and Lho. Where, l_Hois the probability of 
the data under the null hypothesis, i.e. assuming that the there is no excess allele 
sharing. I_ha is the probability of the data under the alternative hypothesis, i.e. 
given the estimated IBD sharing probabilities. Dependent on the availability of 
marker genotypes the LOD score can be estimated at any point across the 
genome. The maximum LOD score (MLS) obtained across a given region provides 
the best estimate of the gene location. In the presence of a disease gene, the size 
of the MLS depends on the magnitude of the genetic effect and the proximity of 
the disease locus to the nearest point of analysis.
In the context of a full genome screen using sibling pairs, linkage signals are 
declared suggestive when they are expected to occur less than once per genome 
screen and significant if they are expected to occur less than 0.05 times per 
screen. Lander and Krugylak (1995) proposed that a MLS >2.2 is indicative of 
suggestive linkage, whereas a signal can be deemed significant if the MLS 
exceeds 3.6. However, these criteria are based on a particular number ASPs, 
genotyped on an infinite grid of markers and are not directly applicable to most 
studies. However, Lander and Krugylak do suggest that each genome screen 
should report empirically derived significance criteria based on the sample and 
data from that particular study.
A number of concerns are inherent in linkage methods. For example, the mis- 
specification of marker allele frequencies can lead to increased type 1 error rates 
when using model-free methods (Knapp et al. 1993). Issues of power also plague
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linkage studies. For example, to give an 80% chance of identifying a locus with a 
relative risk to siblings of 1.5 (the estimated effect size of APOE in AD) at the 0.05 
significance level a total of 600 sibling pairs would be needed (Myers et al. 2002). 
Family based samples remain difficult and costly to ascertain, especially for 
diseases of late-onset. As such many of the linkage studies of AD reported to date 
have been underpowered.
Heterogeneity and phenocopies present a substantial problem for linkage analysis. 
Heterogeneity, where identical phenotypes arise from different mutations at 
different loci, is a particular concern as many complex disorders are likely to result 
from the combination of many genes and environmental factors. This is likely to 
underpin the lack of, and inconsistent, linkage findings reported in the majority of 
studies of complex diseases (Altmuller et al. 2005; Bertram and Tanzi 2004; 
Gillanders et al. 2004). Phenocopies, subjects with clinically indistinguishable non- 
genetic forms of the disease, can lead to broad, ill defined linkage peak regions or 
increased type 2 error rate, even when using reasonable sample sizes of 500 to 
1000 families (Risch 2000). Large sample sizes reduce the impact that locus 
heterogeneity and phenocopies have on linkage analyses (Schulze and McMahon 
2003). However, adequate sample sizes are often not available, and the impact of 
these factors is still not clear even when large family based samples are 
ascertained. An alternative approach is to include covariates, which are likely to 
reduce the impact of locus heterogeneity and phenocopies on linkage analyses 
(Altmuller et al. 2005; Gillanders et al. 2004; Hamshere et al. 2005).
4.1.3 Methods ofcovariate linkage analysis
Covariates are generally used to reduce the effect of locus heterogeneity and 
phenocopies on linkage evidence by identifying homogenous subsets of the 
disease, or to search for genetic variation which acts as a disease modifier in 
complex disorders. Numerous methods of incorporating covariates in linkage 
analyses have been utilised. At this point, it is important to consider the uses of the 
different methods, and their associated advantages and disadvantages.
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The simplest method of incorporating additional phenotypic characteristics into 
linkage analyses is to perform sample stratification. As such a primary analysis is 
performed using the whole dataset, followed by a secondary analysis on a subset 
according to the covariate of interest. For example, this method has been 
employed to perform linkage analysis of a refined phenotype of AD with psychosis 
(Bacanu et al. 2002). It has been suggested that this approach will reduce the 
impact of locus heterogeneity and phenocopies, however methods which rely on 
sample splitting often lead to substantial reductions in sample size. This is a 
particular concern as sample size is one of the most important factors for 
identifying significant linkage evidence (Altmuller et al. 2001). Furthermore, using 
such an approach makes it difficult to statistically assess the relative difference 
between primary and secondary analyses, as the sample sizes are likely to differ.
An alternative to methods which rely on sample stratification is to perform ordered 
subset analysis (Ghosh et al. 2000; Hauser et al. 2004). This involves ordering 
families in relation to a continuous variable (e.g. age at onset (AAO)) and then 
sequentially incorporating them into the analysis to identify the subset with the 
maximum evidence for linkage at a given set of markers. Using this method a prior 
‘cut point’ for continuous variables is not required (e.g. AAO above or below 65), 
which is an advantage as such cut-offs are usually arbitrary and are not likely to be 
biologically valid. Also, it allows for detection of linkage peaks in subsets, even in 
the presence of heterogeneity in the full sample (Scott et al. 2003). Whilst this 
method is well suited to searching for loci that are strongly linked to disease in a 
small portion of the covariate distribution, it is less suitable for identifying disease 
modifying genes for covariates which are defined categorically. In addition, 
ordered subset analysis is presented with difficulty if the locus is only a risk factor 
among those in the mid range of a covariate distribution, as is the case with APOE 
which exerts its largest effect in those between 60 and 70 years of age.
An alternative approach has been suggested by Devlin and Colleagues (2002) 
who suggested the use of ‘mixture models’ to incorporate covariates into linkage 
analysis. They were primarily concerned with locus heterogeneity which presents 
a problem in the study of complex disease. As such they proposed two methods of 
assigning ASPs to groups who are either ‘linked’ or ‘unlinked’ to a specific region.
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The first method utilises cluster analysis, based on phenotypic information, to 
assign sibling pairs into groups. The other uses estimated IBD information at the 
region of interest to assign sibling pairs to groups. They provide evidence that this 
method leads to a considerable increase in power when the covariate carries 
information about membership to linked and unlinked groups. However, the 
second method of clustering, based on estimated IBD sharing, was shown to 
perform badly when data were drawn from affected sibling pairs, as apposed to 
larger pedigrees, as sibling do not provide adequate IBD information to 
discriminate between linked and unlinked groups. This method is not suited to 
studying disease modifying hypotheses as IBD sharing among families is 
constrained to be greater than, or equal to, 50% (Hamshere et al. 2005).
A number of methods of covariate analysis have been proposed which aim to 
regress the IBD scores among affected pairs onto covariates (Dorr et al. 1997; 
Goddard et al. 2001; Greenwood and Bull 1997, 1999; Olson 1999; Rice et al. 
1999). The method proposed by Greenwood and Bull (1997), and since modified 
extended by Olson (1999) and Goddard and colleagues (2001), uses regression 
methods to assess the dependence of the IBD sharing proportions on covariates. 
These methods have been shown to increase power to detect linkage, provided 
that the covariate reflects underlying locus heterogeneity. These methods also 
allow the inclusion of both categorical and continuous covariates.
An alternative is to treat covariates as quantitative traits. Linkage methods used to 
localise quantitative trait loci (QTL) focus on the within- and between-family 
variance of the trait, and is therefore driven more by the similarity, rather than the 
mean, of covariate values among relative pairs. This provides a distinctly different 
question to approaches that look at the mean variation in the covariate, such as 
ordered subset analysis. Indeed, ordered subsets and QTL analysis of the same 
dataset have been shown to provide contrasting results (Li et al. 2002; Scott et al. 
2003). QTL methods are more specifically a method of identifying loci which are 
directly associated with the variable of interest (e.g. height, A(342 levels) rather 
than a covariate method. As such, QTL methods are less well suited to studying 
covariates, as comparisons cannot be made between the evidence from QTL 
analysis and overall linkage (in the absence of covariates).
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In general covariate linkage methods can be divided into two categories. First 
methods which treat the family as the unit of analysis (e.g. QTL methods) and 
secondly, those that are able to treat the relative pair as the unit of interest (e.g. 
sample splitting and regression based methods). Compared to methods that focus 
on relative pairs, those that treat the family as the unit of interest are more likely to 
be disadvantaged if a number of phenocopies, or locus heterogeneity exist within 
the family. In general, covariate methods of linkage analysis have been shown to 
increase power to detect linkage, especially in the presence of heterogeneity. As 
such, they are likely to provide invaluable insights in the study of complex 
disorders, indeed, covariate linkage methods have already contributed to the 
identification of numerous novel linkage regions and also to the identification of 
susceptibility genes. These findings will be discussed in more detail in section 
4.1.5.
4.1.4 Linkage analysis studies of Iate-onset Alzheimer’s disease
The importance of genetic factors in the aetiology of LOAD has been discussed in 
previous chapters. As such a number of genome screens have been published in 
an attempt to localise susceptibility genes for AD. The evidence suggests that 
LOAD, like many other complex diseases, does not follow a simple mode of 
inheritance. It is therefore difficult to accurately specify a disease model when 
using parametric forms of linkage analysis, which leads to a decrease in power 
(Clerget-Darpoux et al. 1986). Linkage studies of LOAD have therefore relied 
mainly on model-free methods of analysis, which protect against loss of power due 
to mis-specified model parameters. Owing to the Iate-onset nature of Alzheimer's 
disease linkage studies have been largely based on samples of sibling pairs, as 
parents are very rarely available for genotyping.
In 1997 Pericak-Vance and colleagues (1997) reported the first full LOAD genome 
screen, using a sample of 54 large multigenerational families where a substantial 
number of members had Iate-onset AD. They used parametric and model-free 
linkage analysis, and divided the sample into a genomic screening set, comprising 
16 families, and a follow up sample of 38 families. They identified four regions of 
interest, on chromosomes 4, 6, 12 and 20, with the strongest evidence for linkage
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observed over a 30cM region of chromosome 12 (incorporating markers D12S373, 
D12S1057, D12S1042 & D12S390, located between 36cM and 67cM). In addition, 
it appeared that linkage to chromosome 12 was strongest in families where at 
least one individual did not possess an APOE e4 allele, suggesting that APOE and 
the potential chromosome 12 locus might act independently.
Linkage to chromosome 12 by Pericak-Vance and colleagues in 1997 was 
followed up a year later in two independent studies; however, the findings are not 
straightforward to interpret. Firstly, in 1998 Rogaeva and colleagues replicated the 
chromosome 12 linkage in an independent sample, comprising 172 AD patients 
and 146 non-demented relatives taken from 53 families. They genotyped 6 
markers in the region previously implicated on chromosome 12. When the data 
were analysed, assuming a single homogeneous locus on chromosome 12 caused 
AD in all 53 pedigrees, no evidence for linkage was found. However, significant 
evidence for linkage was revealed between D12S358 (26cM) and D12S373 
(35cM) and in a region ~50cM distal to this, between D12S1090 (48cM) and 
D12S96 (68cM) using non-parametric linkage methods. The strongest evidence in 
this study appeared to originate from families in which at least 75% of affected 
members carried one or more APOE z4 alleles.
A further attempt at replication was published by Wu and colleagues in 1998. They 
used a sample of 230 families collected by the National Institute of Mental Health 
(NIMH) AD Genetics Consortium. Each family contained at least 2 affected 
siblings with probable or definite Iate-onset AD (AAO > 60 years). No evidence for 
linkage on chromosome 12 was reported in their full sample. However, moderate 
linkage evidence was observed in a subset of the sibships in which neither pair 
possessed an APOE z4 allele, with a maximum multipoint LOD score of 1.91 
found at marker D12S98 around 24cM (chromosome wide p-value = 0.09, after 
correcting for multiple testing).
Pericak-Vance and colleagues followed up their initial findings by sampling more 
individuals in their original families and genotyping a tighter grid of markers in their 
region of interest (Scott et al. 2000). A total of 26 microsatellite markers were 
genotyped, located between 24cM and 152cM on chromosome 12. Weightings for
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clinical and neuropathological factors, along with sibship size and APOE 
genotyped were also included to address issues of heterogeneity. Moderate 
evidence for linkage was observed at 9 of the 14 markers genotyped in the initial 
region of interest. Evidence for linkage was strongest in families who had at least 
one member with no APOE e4 alleles. However, this is contradictory to their 
previous report in which linkage evidence was strongest in families where at least 
75% of affected members carried one or more APOE z4 alleles.
These preliminary efforts highlight the difficulties in identifying further novel risk 
loci for complex disorders, like LOAD. In review Craddock and Lendon (1998) 
concluded that these three studies offered encouraging evidence of the existence 
of a novel susceptibility gene, or genes, in the chromosome 12 region. These 
studies also highlighted the need for further well powered linkage studies in 
independent samples.
Using largely the same sample as in their earlier chromosome 12 paper (Wu et al. 
1998a), Kehoe and colleagues reported a full genome screen in 1999. They 
employed a model-free method of analysis, incorporating 237 microsatellite 
markers separated by an average distance of 16.3cM. In either the full sample, or 
sub samples characterised by the absence or presence of e4 alleles, 16 peaks 
with a maximum multipoint LOD score £ 1 were reported, which exceeded the 
number that would have been expected by chance. Only peaks on chromosome 1, 
5, 9,10 and 19 gave a MLS > 1 in the full sample. No evidence for linkage was 
found in the region implicated by Pericak-Vance and colleagues in this study, 
although some evidence for linkage was found on 12p, at around 24cM. This was 
also the first published report of suggestive linkage to chromosome 10 
(MLS=2.27).
Further to the initial findings (Kehoe et al. 1999) three articles published in 
‘Science’ \n December 2000 reported significant linkage to Alzheimer's disease, 
and a related phenotype, on chromosome 10. In an extension to the Kehoe and 
colleagues genome screen Myers and colleagues (2000) reported significant 
linkage on chromosome 10 using a widely overlapping, but extended sample 
comprising 168 additional affected sibling pairs, genotyped on a tighter grid of
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markers. The combined sample included 429 sibling pairs diagnosed with 
probable or definite AD, all with an age at disease onset > 65 years. Fifteen 
additional markers on chromosome 10 were genotyped in all sibling pairs, giving a 
total of 26 microsatellite markers with an average interval of 5cM. Non-parametric 
multipoint linkage analysis yielded a peak LOD score of 3.83 at 82cM (between 
D10S1227 and D10S1225). The MLS was higher in the subset of the sample 
where both siblings had at least one APOE e4 allele, compared to sibships in 
which neither member had an APOE e4 allele. This is a likely reflection of the 
increased number of APOE e4 positive sibling pairs in their sample. Allele sharing 
was similarly elevated in both groups, suggesting that stratification by APOE e4 did 
not change the proportion of allelic sharing at the linkage peak. Furthermore, 
Holmans and colleagues (2005) have since reported covariate linkage using this 
sample and did not report a significant effect of APOE on chromosome 10.
A further report of linkage was reported in December 2000 by Bertram and 
colleagues (2000). They presented genetic linkage analysis of 7 markers on 
chromosome 10 in 435 multiplex AD families, in which all affected members had 
an AAO equal to or greater than 50 years. They performed parametric and model- 
free analysis, stratified by AAO and APOE genotype. They found significant 
evidence for linkage at a locus ~40cM distal to that reported previously (Ertekin- 
Taner et al. 2000; Kehoe et al. 1999; Myers et al. 2000). Significant evidence for 
linkage was found around marker D10S583 (115cM) under a dominant and 
recessive model in the full sample, and around marker D10S1671 (124cM) when 
restricting analysis just to those with Iate-onset disease. Model-free linkage 
results yielded similar results, with the strongest signals for markers D10S583, 
D10S1671 and D1 OS 1710 in the Iate-onset families, with a peak linkage score at 
124cM (D10S1710). However, none of the analyses yielded significant findings for 
marker D1 OS 1225 (located around 80cM) that had previously been linked with 
LOAD (Ertekin-Taner et al. 2000; Kehoe et al. 1999; Myers et al. 2000).
Additional support for a chromosome 10 locus was reported in a study using 
plasma amyloid P42 peptide (AP42) levels as a surrogate marker for AD (Ertekin- 
Taner et al. 2000). Autosomal dominant mutations that cause early-onset familial 
AD all increase AP42 in plasma and the brain (Cai et al. 1993; Citron et al. 1992;
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Duff et al. 1996). It is also found to be elevated in unaffected family members of 
patients with Iate-onset AD, whilst heritability estimates for Ap42 are as high as 
73% (Ertekin-Taner et al. 2001). A042, therefore, appears to be a good biological 
marker for AD, and was used in linkage analysis to follow up previously reported 
linkage regions for Iate-onset AD on chromosomes 1, 5, 9,10 and 19 (Kehoe et al. 
1999). Using this method a MLS of 3.93 was found on chromosome 10 around 
81cm, between markers D10S1227 and D10S1211. This finding coincides almost 
directly with the chromosome 10 linkage peak reported previously by Myers and 
colleagues (2000). Maximum multipoint LOD scores in all other genotyped regions 
were less than 0.5. It should be noted that the study was restricted to 10 families, 
focusing on five which had an AD proband with extremely high plasma Ap42 or 
Ap40. Linkage evidence was less striking in the unstratified sample, with a 
maximum multipoint LOD score of 1.82. Therefore, the results cannot be used to 
evaluate the contribution of the chromosome 10 locus to the AD population in 
general.
It should be noted that there is a considerable overlap between the samples used 
by Myers and colleagues and Bertram and colleagues. A total of 188 families were 
included in both analyses. To assess the impact of this overlap Bertram and 
colleagues performed separate analyses for families included in both studies and 
families independent to their investigations. Linkage evidence was most 
pronounced at three of the seven markers in those families who were present in 
the analysis by Myers and colleagues. However, in their analysis of the ‘Myers 
families’ they did not find linkage to D10S1225. They postulated that this 
discrepancy could have arisen from a number of factors, including sampling 
issues, inclusion of genetic information from all relative pairs (as opposed to just 
siblings) or differences in analytic methods. However, in their attempt to confirm 
the previously reported linkage peak, Bertram and colleagues genotyped marker 
D10S1225, leaving an interval of ~30cM to the next genotyped marker. Although, 
this marker was the peak multipoint marker reported in previous studies by Myers 
and colleagues and Erekin-Taner and colleagues, the twopoint LOD scores in 
those studies were only 1.54 and 0.57, respectively. The elevated multipoint score 
in the Myers and colleagues analysis appears to be driven largely by markers 
within 10cM of D10S1225, of which two had twopoint LOD scores of 2.12
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(D10S1220) and 4.85 (D10S1211). A similar interpretation of the Ertekin-Taner 
and colleagues data is also appropriate. It would therefore seem reasonable that 
the analysis by Bertram and colleagues was inadequately placed to attempt 
replication of the proximal linkage peak and it remains unclear whether the two 
reported chromosome 10 peaks are independent. It is also unfortunate that 
Bertram and colleagues did not report the twopoint model-free analysis of the 
‘Myers’ families. It remains a possibility these three linkage signals on 
chromosome 10 result from a single susceptibility gene, indeed varying results 
from linkage analyses were similarly reported on chromosome 19 prior to the 
identification of APOE as a risk factor for LOAD (Liu et al. 1996).
Extensions to these three studies have since been reported to cover the whole 
genome or include additional samples and marker genotypes (Blacker et al. 2003; 
Myers et al. 2002; Pericak-Vance et al. 2000). Myers and colleagues (2002)
(Myers et al. 2002) reported stage 2 of a genome screen following up their prior 
stage 1 analyses (Kehoe et al. 1999). In the second stage 451 affected sib pairs 
were genotyped at a total of 327 microsatellite markers, incorporating an additional 
91 markers mainly located within the 16 regions with a MLS > 1 in stage 1. Ten of 
their stage 1 regions maintained LOD scores in excess of 1. Aside from the 
chromosome 10 finding already reported (Myers et al. 2000) minor linkage peaks 
were observed on chromosomes 5, 9 (2 peaks), 12,19, and X in the full sample, 
with additional loci of interest on chromosomes 1, 6 and 21 when stratification by 
APOE s4 was performed. However, other than the chromosome 10 finding none of 
these linkage regions met published criteria for suggestive linkage (Lander and 
Kruglyak 1995).
Blacker and colleagues (2003) reported a follow up to the linkage evidence 
reported by Bertram and colleagues (2000). They used the AD sample collected 
as part of the National Institute of Mental Health AD genetics initiative, which has 
been widely used in other linkage studies. Therefore, this study contained a 
sample overlap of up to 60% with other published genome screens (Bertram et al. 
2000; Ertekin-Taner et al. 2000; Kehoe et al. 1999; Li et al. 2002; Myers et al.
2000; Myers et al. 2002; Olson et al. 2001; Pericak-Vance et al. 2000). However, 
sample selection and analysis method vary between studies. The sample used by
129
Blacker and colleagues consisted of 437 families. An AAO cut-off of 50 years was 
adopted, however analysis was also performed on a sub sample of 320 families 
where all affected members had an AAO £ 65 years.
They identified one ‘highly significant’ linkage region located in close proximity to 
the APOE locus on chromosome 19, along with 10 regions that met criteria for 
suggestive linkage. Including, 1q23, 3p26, 4q32, 6p21, 6q27, 9q22,10q24,14q22, 
15q26 and 21q22. Only regions on chromosome 1, 9 and 10 showed evidence of 
suggestive linkage in the sub-stratum of families segregating Iate-onset AD. 
Linkage regions on chromosome 3, 14, 15 were restricted to the subset of 117 
families which contained affected individuals with an AAO < 65 years. The other 
regions were identified in the unstratified sample.
Interestingly, Blacker and colleagues also reported a secondary analysis 
performed in families not used in previous reports of linkage. Most regions of 
suggestive evidence identified in the full dataset remained in the sub sample, 
whilst LOD score increases were noted on chromosome 3, 6 and 14. No evidence 
for linkage was observed on either chromosome 9, 10 or 12 in the independent 
families.
It should be noted that 65 cases with possible AD were included in the analysis. 
This was controlled for to some extent in parametric analyses by allowing for a 
phenocopy rate of 20%. However, such concessions are not attributable to 
multipoint model-free analyses, which is a particular concern as linkage evidence 
is known to be sensitive to mis-specification of the phenotype (Whittemore and 
Halpern 2001). It is also noteworthy that Blacker and colleagues used genetic 
maps and inter-marker distances provided by CIDR (www.cidr.jhmi.edu) which in 
some cases differ for those from the Marshfield Centre for Medical Genetics 
(http://research.marshfieldclinic.org/genetics) which have been used in the 
majority of other genome screens to date. It is currently unclear which map is most 
accurate, however parametric/model-free analyses are not generally robust to 
changes in map location, hence, this could account for differing results between 
studies (Daw et al. 2000). The final point of note is that the Blacker and colleagues 
study contained 26 non-Caucasian families, which could lead to problems
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associated with population stratification. However, they did report that analyses 
excluding these families did not differ notably.
Pericak-Vance and colleagues (2000) reported a follow up to their earlier genome 
screen (Pericak-Vance et al. 1997) performing a genome scan using a sample of 
466 families with Iate-onset AD (including 739 sibling pairs) genotyped on a 10cM 
grid of markers. A model-free affected sibling pair (ASP) method was employed, 
along with a complimentary approach using parametric analyses incorporating 
affected relative pairs. The analysis was also stratified into a subset of families that 
contained at least one affected member whose AD diagnosis had been confirmed 
by autopsy. They found interesting results on chromosomes 4, 5, 6, 7, 8, 9,10,
11,12, 13, and 19, with chromosome 9 showing the highest MLS of 2.97, rising to
4.3 in the sub-sample of autopsy confirmed affected individuals. The APOE locus 
on chromosome 19 showed significant linkage, as did a region at around 125cM 
on chromosome 7 with a peak LOD of 1.97. Chromosome 10 only demonstrated a 
LOD score >1 in twopoint parametric analysis of autopsy confirmed cases. The 
peak chromosome 10 marker mapped closer to the peak identified by Myers and 
colleagues than it did to the one identified by Bertrem and colleagues. The 
previous finding on chromosome 12 was not replicated with a MLS < 1 over the 
whole region. As with many full genome screens it is likely many of the interesting 
regions represent false positives, as a number of tests are applied to the data and 
testing sub samples, without correction for multiple testing, ultimately leads to an 
increased type 1 error rate. It should also be noted that the study by Pericak- 
Vance and colleagues (2000) used families with a mean AAO £ 60 years. 
Therefore, it remains possible that a number of affected individuals had an AAO < 
60 years, which are commonly excluded from studies of LOAD and may have a 
different disease aetiology. However, the number of individuals with an AAO < 60 
years was not reported.
The studies reported by Pericak Vance and colleagues, Myers and colleagues and 
Blacker and colleagues remain the largest genome screens reported for Iate-onset 
AD. However, there is considerable sampling overlap between the studies which 
makes the comparison of results difficult. All three analyses have sampled 
different families collected as part of the NIMH AD Genetics Initiative, with only a
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proportion of families selected being unique to each investigation. The studies by 
Pericak-Vance and colleagues and Myers and colleagues both use DNA from AD 
families taken from the Indiana Alzheimer Disease Centre National Cell 
Repository. In addition, the Myers and colleagues study contains a unique sample 
of 94 affected sibling pairs collected in the United Kingdom. Whereas, Pericak- 
Vance and colleagues used data from 216 affected and 164 unaffected family 
members, taken from 62 families recruited as part of the Collaborative Alzheimer 
Project (CAP), which are exclusive to their study. Furthermore, different, but 
overlapping, microsatellite markers have been used in these analyses.
The most consistent signals across samples are located on chromosomes 9 and 
10. Myers and colleagues and Pericak-Vance and colleagues both report linkage 
to marker D9S741, with MLS of 1.8 and 2.97 (raising to 4.31 in autopsy confirmed 
AD samples), respectively. Blacker and colleagues report linkage to a region 12cM 
distal with a peak MLS of 1.3, however this reduces to 0.7 in families not used in 
the Myers and colleagues analysis. Linkage to chromosome 10 is reported at 
59cM (Pericak-Vance et al. 2000), 82cM (Myers et al. 2002) and 135cM (Blacker 
et al. 2003). It would seem unlikely that such a broad linkage region results from 
the presence of one susceptibility gene. Pericak-Vance and Blacker both report 
minor evidence for linkage around chromosome 4q32 and 6q26-27. The locus on 
chromosome 6 also showed linkage evidence in the Blacker and colleagues full 
sample and in the substratum of families independent to their analyses. Linkage to 
this region has also been demonstrated in a more recent reanalysis of the NIMH 
dataset (Olson et al. 2002). Comparisons between the studies are simplified as 
Blacker and colleagues present data arising just from families unique to their 
study. Comparing the results of the genome screens reported by Myers and 
colleagues with the analyses of the families independent to the study reported by 
Blacker and colleagues would suggest that concordant linkage peaks between the 
two studies on chromosome 1, 5, 6, 9 10 and 21 are driven by overlapping 
samples.
Given the interesting, but largely conflicting, results from these analyses it is clear 
that appropriately powered replication studies are required in independent 
samples. To date, the only independent genome screens have come from two
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non-Caucasian family based samples (Farrer et al. 2003; Lee et al. 2004) and one 
non-family based sample collected in Finland (Hiltunen et al. 2001). Hiltunen and 
colleagues (2001) performed a genome screen using linkage disequilibrium 
mapping in a Finnish sample of 47 AD cases and 41 age matched controls. Their 
sample consisted of individuals from a geographically isolated region of Finland, 
where all members have descended from a small group of original founders, which 
makes the use of LD mapping more appropriate. Twenty-one of the 366 
polymorphic microsatellite markers across the whole genome showed association 
with AD (6 of these showed association at a more stringent significance level of 
0.01). Additional genotyping of markers flanking these LD regions identified seven 
chromosomal loci that contained more than one marker associated with AD.
Strong evidence was found on chromosome 6, around marker D6S1017 (~63cM), 
in a region which has been implicated by others (Blacker et al. 2003; Lee et al. 
2004; Myers et al. 2002). Two markers on chromosome 10 were found to be 
associated with AD, however, the LD locus was located ~40cM to 75cM from the 
previously reported linkage evidence, suggesting that these two loci are 
independent (Blacker et al. 2003; Ertekin-Taner et al. 2000; Lee et al. 2004; Myers 
et al. 2002). It is interesting that microsatellite markers located 2.5cM and 1cM 
from the APOE locus did not show significant association with AD. This could have 
resulted from a lack of power, or alternatively may reflect the evolutionary ancient 
nature of the APOE e4 allele, which questions the ability of LD mapping in this 
sample to detect other genetic mutations associated with AD which are of similar 
origin to APOE.
A further genome screen using LD mapping was performed by Farrer and 
colleagues in 2003, using a genetically isolated Israeli-Arab population. Particular 
high prevalence rates of AD have been noted in the Wadi Ara community with an 
overall prevalence rate of 20.5% in those over 60 years of age, raising to over 
50% in those aged 80 years or older. Farrer and colleagues describe familial 
clustering of AD in this population and hypothesise that the increased risk of AD is 
due to genetic factors. To search for susceptibility genes in this sample they 
performed a LD screen between markers spread throughout the genome and AD. 
A screening set of 5 cases and controls from families with the highest AD 
prevalence was genotyped across 375 markers spread throughout the genome.
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Markers showing significant difference in allelic frequency between cases and 
controls were genotyped in an enlarged sample of 100 cases and 100 controls. 
Significant allelic association was noted on chromosomes 2, 9 and 10. The region 
showing association on chromosome 2 was located at ~40cM and had not 
previously been reported in linkage studies, however this region has been 
implicated in the Finnish linkage disequilibrium screen (Hiltunen et al. 2001). 
Significant association was noted with 4 markers on chromosome 9, notably 
alleles with sizes of 244bp or greater were observed in 16.5% of AD cases and in 
none of the controls, resulting in a highly significant association (p < 0.001). This 
finding is of particular interest as this region has also been implicated in all three 
previous genome screens of AD using conventional linkage methods (Blacker et 
al. 2003; Myers et al. 2002; Pericak-Vance et al. 2000). To follow up previous 
reports of linkage Farrer and colleagues also performed intensive analyses of 
chromosomes 10 and 12. They reported significant evidence for allelic association 
at ~59cM and ~80cM on chromosome 10, which could represent a replication of 
the previous findings (Ertekin-Taner et al. 2000; Myers et al. 2000; Pericak-Vance 
et al. 2000), however the most consistent region of allelic association on 
chromosome 10 was observed in a more distal position between 105cM and 
115cM. Four contiguous markers showed evidence of allelic and genotypic 
association in this region, which maps closely to the region of linkage reported by 
Bertram and colleagues (Bertram et al. 2000). Six markers were associated with 
AD on chromosome 12, with the strongest signal observed at ~83cM around the 
linkage region identified by Rogeava and colleagues (1998).
It is interesting that a number of the regions identified in the Israeli-Arab 
community sample have previously been implicated in AD, largely in samples of 
Caucasian origin, suggesting that they may be authentic loci rather than chance 
findings. It should be noted that the sample used was non-Caucasian and largely 
inbred. It is therefore unclear how generalisable these results are to other 
populations. However, previous studies have found success in mapping genes 
responsible for disease susceptibility in Caucasian outbred populations by using 
genetically isolated samples (Baldwin et al. 1995; Frydman et al. 1985).
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A particular concern when assessing the study by Farrer and colleagues arises 
from the relatively small screening sample of 5 cases and controls. Such an 
approach is likely to lack power, leading to an increase in false negatives. This is 
illustrated in their chromosome 12 analyses. During their initial screen this region 
did not warrant further follow up, however due to previous reports of linkage and 
association in this region a number of markers were genotyped in their larger 
sample set, with several showing significant allelic association. Results from these 
analyses are therefore only useful in identifying or replicating regions of interest, 
rather than excluding regions from further study.
A further linkage study of Iate-onset AD has been reported, using a family based 
sample of Caribbean-Hispanic descent (Lee et al. 2004). The strongest evidence 
for linkage was observed on 18q, 10q and 12p in the first stage of their analyses. 
These findings were followed up through fine mapping using a slightly extended 
sample of 527 individuals from 104 families. Maximum multipoint LOD scores of 
3.15 and 2.70 were obtained in their stage 1 analyses, on chromosome 10 and 18 
respectively. The region on chromosome 10 was located around 142cM which is 
somewhat distal to those reported previously, with the closest region of previously 
identified linkage being ~20cM proximal (Bertram et al. 2000; Li et al. 2002). In 
their stage 2 analyses the LOD scores on chromosome 18 increased to 3.65, 
whereas the linkage evidence on chromosome 10 was reduced somewhat, with a 
maximum multipoint LOD score of 2.02. Suggestive evidence for linkage in this 
sample was also observed on chromosome 12 in close proximity to the region 
identified in previous reports (Kehoe et al. 1999; Pericak-Vance et al. 1997)
Reviewing the linkage findings to date provides an illustration of the difficulties in 
replicating linkage and in estimating the location of genes underlying complex 
disorders. Comparing studies reveals a total of 16 regions on 11 chromosomes 
that yield positive signals (p < 0.01) across at least two studies with markers no 
further than 25Mb apart. The strongest evidence seems to be around 5p13-15, 
9p21, 9q22, 10q21-22, 12p11-12 and the APOE locus located around 19q13. 
Perhaps the strongest region of linkage reported to date is on chromosome 10. A 
number of studies, based on different but related phenotypes (e.g. familial AD 
(Bertram et al. 2000; Blacker et al. 2003; Farrer et al. 2003; Lee et al. 2004; Myers
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et al. 2000), AAO in AD (Li et al. 2002) and plasma amyloid (342 peptide (Ertekin- 
Taner et al. 2000)) have reported evidence for linkage to chromosome 10q. The 
peak regions in these studies stretch from ~81cM to ~138cM. Three studies find 
strong evidence for linkage around 81 cM (Ertekin-Taner et al. 2000; Kehoe et al. 
1999; Myers et al. 2000), whereas others have reported linkage to a more distal 
region between 115cM and 138cM (Bertram et al. 2000; Blacker et al. 2003; 
Farrer et al. 2003; Li et al. 2002). Methodological or sampling differences across 
studies could be responsible for discrepant localisation of the two linkage peaks 
which could all be caused by the same gene (Bertram and Tanzi 2004). 
Alternatively, more than one loci could be present, which could either influence 
disease risk or act as a modifier for AAO (Li et al. 2002). At present it is impossible 
to distinguish between these two possibilities, but it seems likely that at least one 
major Iate-onset AD locus resides on chromosome 10q.
Like studies of many complex disorders, issues of power are a persistent problem 
for linkage studies of Iate-onset AD. Family based samples remain difficult and 
costly to ascertain, especially for diseases of Iate-onset, meaning that many of the 
linkage studies of AD reported to date have been underpowered. However, it is 
encouraging that the majority of linkage and association genome screens to date 
have found evidence for a susceptibility gene near the APOE locus (Blacker et al. 
2003; Curtis et al. 2001; Li et al. 2002; Myers et al. 2002; Pericak-Vance et al. 
2000; Zubenko et al. 1998). Further linkage and association studies are clearly 
required to unravel the complex issues surrounding the genetics of Iate-onset AD. 
Linkage studies to date have largely served to highlight that AD is likely to be 
characterised by substantial locus heterogeneity. As discussed earlier, covariate 
analysis can account for locus heterogeneity and aid in the identification of novel 
linkage signals. Hence, recent years have seen an increase in studies which have 
aimed to include aspects of clinical variation as covariates in linkage analysis.
4.1.5 Covariate linkage analysis studies of Iate-onset Alzheimer's 
disease
The inclusion of covariates, as briefly discussed in section 4.1.3, has two distinct 
advantages over standard methods of linkage analysis, both of which are pertinent
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to this thesis. First, inclusion of covariates may facilitate the identification of 
regions which contain disease modifying genes. Second, covariate linkage 
analysis allows for locus heterogeneity owing to the covariates, consequently 
genes that are risk factors for certain ’sub-phenotypes’ of AD are more likely to be 
localised (e.g. genes which cause AD in the very old). It is possible that the clinical 
heterogeneity observed in AD could be responsible for differing linkage and 
association results observed between studies.
The most commonly used covariate at present is AAO. It is hoped that if genetic 
mechanisms that influence AAO can be identified it may be possible to modify 
their processes to prevent or delay disease onset, which is of particular 
importance for Iate-onset disorders such as Alzheimer’s disease. As found in 
section 3.3.2, the APOE zA allele has been shown to reduce AAO in a dose- 
dependent manner (Meyer et al. 1998), however there is substantial evidence 
which suggests that further, unidentified, genes are associated with AAO in AD (Li 
et al. 2002; Tunstall et al. 2000; Warwick Daw et al. 2000).
Olson and colleagues (2001) reported linkage to chromosome 21 when 
incorporating AAO as a covariate. Their sample comprised 252 ASPs with a 
disease onset > 60 years collected as part of the NIMH AD genetic initiative, which 
has previously been used in genome screens of AD (Bertram et al. 2000; Blacker 
et al. 2003; Kehoe et al. 1999; Myers et al. 2000; Myers et al. 2002; Pericak-Vance 
et al. 2000). Sibling pairs with a higher mean AAO and current age showed 
increased evidence for linkage around the region containing the amyloid precursor 
protein (APP) gene. This is of particular interest as APP is known to confer high 
risk of AD to a number of families afflicted with early onset AD (Goate et al. 1991). 
Olson and colleagues (2002) have since extended this analysis, presenting 
findings from a whole genome scan on the same dataset, using the same 
covariates. In addition to the previously reported linkage evidence on chromosome 
21 they reported significant AAO effects on chromosome 14 (increase in LOD of 
1.89, p=0.003). Significant APOE effects were reported on chromosome 9 
(increase in LOD of 1.52, p=0.008) and 14 (increase in LOD of 1.62, p=0.006), 
whilst current age had the largest effects on chromosome 20 (increase in LOD of 
2.69, p < 0.001). Analyses of ‘current age’ and disease duration should be
137
interpreted with caution. Current age reflected age at interview in 33% of the cases 
and age at death in 67% of the sample. Hence, disease duration and current age 
in a proportion of individuals were reliant on when they were ascertained, and it 
makes little sense to suggest that this could be determined by genetic/biological 
factors. Also, cause of death was not taken into account; it therefore remains 
possible that participants may have died of a condition unrelated to their 
dementing illness, which questions the use of duration from disease onset to death 
as a surrogate marker for rate of disease progression.
In a slightly overlapping sample, Li and colleagues (2002) treat AAO as a QTL, 
using a sample of 449 and 174 families affected with AD and Parkinson’s disease 
(PD), respectively. When looking at AD alone they found interesting regions on 
chromosomes 4, 6, 8, 10 (at 139cM, close to marker D10S1237), 13 & 17. 
Interestingly, linkage (MLS=1.55) was also found with AAO in Parkinson’s disease 
at 132cM on chromosome 10. To further investigate this common region they 
combined the AD and PD samples, considering both disorders as a common 
disease in one model, and then considering them separately to distinguish the 
contribution of AAO between AD and PD. They found a peak MLS of 2.62 when 
both diseases were considered together at 133cM (between markers D10S1239 
and D10S1237), indicating that a common modifier for AAO in AD and PD may be 
located on chromosome 10. The peak on chromosome 10 is distal to the more 
commonly observed linkage peak located around 80cM (Ertekin-Taner et al. 2000; 
Kehoe et al. 1999; Myers et al. 2000), but is in close proximity to the linkage region 
at ~130cM (Bertram et al. 2000; Blacker et al. 2003; Farrer et al. 2003)
It is noteworthy that AAO in families has been characterised in different ways. 
Olson and colleagues analysed the relationship between alleles shared IBD in 
ASPs and the total AAO in each sibling pair. In contrast, the variance components 
analysis by Li and colleagues focuses on the relationship between alleles shared 
IBD and the similarity of AAO. These are different questions, both with biological 
relevance. Increases in linkage evidence observed when using AAO mean as a 
covariate could indicate that a gene in the region contributes to AD in a subset of 
the population within a particular AAO range. In contrast, it is possible that 
susceptibility genes give rise to differing levels of disease risk with age, in this
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case increased IBD sharing would be observed in sibling pairs with a closer AAO.
It is also likely that sibling pairs who display more clinically distinguishing factors, 
for example, difference in AAO, represent phenocopies. Use of AAO similarity as a 
covariate is likely to reduce the impact of such phenocopies on analyses.
Holmans and colleagues (2005) used the difference between, and mean, AAO in 
sibling pairs as covariates in a single analysis. A novel measure of rate of decline 
(ROD) (mean and difference) was also considered. The analysis was based on the 
sample and genotypes used in the genome scan published by Myers and 
colleagues (2002). As such, there was some overlap with the samples used for 
previous genome screens of AAO in AD (Li et al. 2002; Olson et al. 2002), 
however a significant proportion of sibling pairs collected in the UK and the Indiana 
Alzheimer’s Disease Centre (IADC), along with additional marker genotypes, were 
unique to their analysis.
The covariate method employed by Holmans and colleagues tested the effect of 
quantitative variables by modelling the IBD sharing probabilities in relation to 
covariates using regression. The most significant finding was on chromosome 21 
in the NIMH sample, where elevated IBD sharing was observed among those with 
increasing AAO, supporting the findings of Olson and colleagues. However this did 
not replicate in the additional non-NIMH sibling pairs. A significant increase in LOD 
with AAO difference was observed on chromosome 12. As in previous analyses 
(Kehoe et al. 1999) increased IBD sharing was also observed on chromosome 12 
in sibling pairs who did not possess an APOE e4 allele, however the AAO effect 
was independent of pairwise APOE e4 status. This effect was driven by sibling 
pairs from the non-NIMH sample; however a small, insignificant, increase in LOD 
(from 0 to 1.14) was noted when analysis was restricted to NIMH sibling pairs. A 
smaller increase in LOD was also reported on chromosome 12 using ROD 
difference in the combined NIMH+UK sample, with a univariate LOD score of 0.36 
being increased to 1.51.
Genome screens which have incorporated AAO as a covariate have generally 
provided rather inconclusive results. Strong evidence for linkage has been 
observed on chromosome 21 in those with a later AAO, which could implicate APP
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as a susceptibility gene for very late-onset AD (>80 years). However, this finding 
failed to replicate in a completely independent sample (Holmans et al. 2005). The 
use of AAO as a covariate has provided further insight into the previously reported 
linkage region on chromosome 10, suggesting that the distal peak observed 
between 130 and 140cM may be related to age at disease onset. Methodological 
issues across studies also make comparisons difficult. For example, Li and 
colleagues and Olson and colleagues treat AAO in sibling pairs differently, asking 
distinct biological questions. Furthermore, Li and colleagues used a method of 
analysis which did not allow a test for overall linkage to be performed (e.g. to test 
for linkage to disease risk). It therefore remains possible that increased IBD 
sharing in their analysis is related to overall disease risk, independent of AAO. 
Indeed, despite finding evidence for overall linkage, Holmans and colleagues 
reported that AAO did not contribute to linkage evidence on chromosome 10.
Holmans and colleagues also incorporated a crude measure of rate of decline in 
their analysis. The most significant effect was found on chromosome 9 (at 103cM) 
when using mean ROD in the NIMH sample, with a univariate LOD score of 1.76 
being increased to 3.58. IBD sharing was greater in those showing an increased 
ROD, an effect that remained significant even after allowing for APOE. However, 
this finding failed to replicate in a sample of sibling pairs collected in the UK. Mean 
ROD was also associated with other suggestive findings on chromosomes 1 (UK 
sample), 2 (NIMH sample) and 8 (NIMH sample). It should be noted that the ROD 
measure used by Holmans and colleagues was only based on two time points, 
which, whilst giving a good general picture of ROD may in some cases be 
inaccurate. In addition, a number of regions where suggestive linkage was found 
in the NIMH sample were not genotyped in the non-NIMH families, precluding 
replication.
Two genome screens have been published to date which have used the presence 
of psychotic symptoms in LOAD as a covariate (Avramopoulos et al. 2005; Bacanu 
et al. 2002). Sample stratification was employed by Bacanu and colleagues (2002) 
to perform linkage analysis on a subset of sibling pairs concordant for AD and 
presence of psychotic symptoms (AD+P). These data were further partitioned into 
sibling pairs where both members possessed at least one APOE e4 allele
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(AD+P+84). Significant linkage was observed on chromosome 2, along with two 
suggestive signals on chromosome 6 and 21. The significant and suggestive 
linkage signals, on chromosome 2 and 21 respectively, were found in the subset of 
siblings who were concordant for AD+P+e4. In the subset of siblings sharing solely 
AD+P only the chromosome 6 finding met criteria for suggestive linkage. By 
restricting their analysis to those sibling pairs who were concordant for AD 
diagnosis, presence of psychotic symptoms and possessing at least one APOE z4 
allele, it was difficult to assess the individual contribution of AD, psychosis and 
APOE e4 genotype. In addition, the method of sample stratification limited the 
sample size to 140 individuals taken from 65 families, resulting in a substantial 
loss of information.
Avramopoulos and colleagues (2005) also used a subset of the sample collected 
as part of the NIMH AD Genetics Initiative. Using a covariate method of linkage 
analysis they found linkage to chromosome 14 in sibling pairs who were non 
psychotic. However, they included families with early onset AD (AAO < 65 years) 
and subsequent analysis indicated that the finding on chromosome 14 was being 
primarily driven by families with at least one member with an earlier AAO.
The studies outlined above represent the only analyses of late-onset AD to date 
which have incorporated phenotypic covariates. Without replication is it difficult to 
draw conclusions from these studies, however they have been successful in 
identifying novel linkage regions. The inclusion of covariates leads to issues of 
multiple testing, which undoubtedly increases the likelihood that a number of these 
regions are false positives. Further analyses of these regions will provide more 
information about the value of covariate linkage studies in AD. Results obtained 
from covariate analyses of other disorders are encouraging. For example, 
covariate linkage analyses have facilitated the successful mapping of susceptibility 
genes in a number of other disorders, including asthma (Van Eerdewegh et al.
2002) and Crohn’s disease (Rioux et al. 2001). The use of covariates has also 
been instrumental in refining, or amplifying, existing linkage peaks and identifying 
novel linkage signals in other disorders, including studies of autism (Shao et al.
2003), schizophrenia (Hallmayer et al. 2005) and prostate cancer (Gillanders et
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al. 2004; Goddard et al. 2001). Promising results in other areas provide adequate 
justification for the use of similar approaches in the study of late-onset AD.
4.1.6 Study Design and aims
Aspects of clinical heterogeneity (e.g. AAO) have previously been used in AD, and 
other disorders, to define suitable covariates for genetic linkage analysis. Clinical 
variation which shows familial aggregation, or genetic heritability, is most likely to 
facilitate mapping of genes which either modify disease presentation or lead to 
genetically homogenous sub-phenotypes. In chapter 3, age at disease onset, 
psychosis, minor depression and aggression were found to aggregate within 
families. Familial clustering of AAO is consistent with previous findings (Li et al. 
2002; Tunstall et al. 2000), and supports the hypothesis that further genetic loci 
which modify AAO remain to be identified (Warwick Daw et al. 2000). The findings 
of familial aggregation of psychosis and aggression are also consistent with 
previous findings (Bacanu et al. 2005; Sweet et al. 2002; Tunstall et al. 2000). 
Given the available data it is not possible to determine if familial aggregation 
results from genetic factors, or shared environment. However, it is reasonable to 
suggest that these symptoms are likely to be genetically modified. The findings 
from the previous chapter regarding the mood component were less reliable; 
however familial aggregation of minor depression was shown in two independent 
samples. As such this chapter will present linkage analysis using a regression 
based method to include covariates representing AAO, psychosis, aggression and 
minor depression.
The method of covariate linkage analysis employed in this chapter is particularly 
useful as it allows the statistical contribution of covariates and APOE to be 
assessed independently. It also incorporates information from relative pairs who 
have not displayed the symptom of interest (e.g. psychosis). Furthermore, it allows 
various hypotheses to be explored. For dichotomous traits, such as psychosis, 
individuals are coded as '+’ if they had displayed the symptom, and if it was 
absent. Therefore, pairwise trait categorisations are restricted to -/-, -/+ and +/+ in 
relative pairs. Given a linkage signal the pattern of IBD sharing among pairs can 
therefore inform the likely role of the loci. For example, in the presence of a
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disease modifying locus, which does not confer risk to AD as a whole, increased 
IBD sharing would be expect in -/- and +/+ relative pairs, with reduced sharing in 
-/+ pairs. However, if the loci increased risk to a disease sub-phenotype, 
characterised by the symptoms of interest (e.g. AD with psychosis), elevated IBD 
sharing would be expected in +/+ relative pairs. Whereas -/+ and -/- pairs would be 
expected to show IBD sharing probabilities similar to those expected in the in the 
absence of linkage. For AAO, a continuous trait, it is possible to characterise 
affected relative pairs according to the pairwise mean AAO, and difference in AAO 
between members of each pair. Linkage observed with mean AAO implies the 
presence of a gene which increases risk of AD within a particular age range. 
Alternatively linkage observed with AAO difference would imply the presence of a 
locus which exhibits different levels of risk according to age. Therefore, those with 
a closer AAO would be likely to share the same genotype and therefore show 
evidence of linkage.
An extended dataset consisting of 513 affected relative pairs (ARPs) from the 
NIMH, UK and NIA samples introduced in section 3.2.1 will be used. All of these 
samples have data available regarding AAO and APOE genotype, whilst both the 
NIMH and UK samples are well characterised in terms of behavioural symptoms 
observed in AD. Genotypes from genome screens presented by Myers and 
colleagues (2002) and Blacker and colleagues (2003) will be combined providing 
genome wide coverage, with an average marker spacing of 5.5cM. As such this 
represents one of the largest samples used to date to perform linkage analysis of 
LOAD.
In summary, this chapter is primarily concerned with the following aim:
• To perform linkage analysis of late-onset AD, incorporating the following 
covariates, whilst controlling for the confounding effect of APOE: 
o Mean AAO among affected relative pairs 
o AAO difference between affected relative pairs 
o Psychotic symptoms 
o Symptoms of minor depression 
o Aggressive symptoms
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4.2 Methodology
4.2.1 Sample description.
Data presented here originate from the NIMH, NIA and UK family based samples 
described in chapter 3. A more detailed description of these samples can be found 
in section 3.2.1. Families were selected based on the following criteria: 2 or more 
relatives diagnosed with probable or definite AD according to NINCDS-ADRDA 
diagnostic criteria (McKhann et al. 1984) with onset ages greater than or equal to 
65 years. AAO was defined as the age at which the first symptoms of AD were 
observed. To reduce potential genetic heterogeneity caused by ethnic origin, only 
Caucasian families were selected. Analysis was restricted to affected relatives 
pairs (ARPs) who were genotyped for linkage.
Genotypes came from two overlapping genome screens of late-onset AD 
published by Myers and colleagues (2002) and Blacker and colleagues (2003). A 
total of 651 individuals were selected from 295 families from the NIMH sample.
160 individuals from 75 families collected in the UK had genotypes available for 
linkage and were selected for this analysis, whilst 136 individuals from 64 families 
were selected from the NIA sample. The total sample comprised 513 ARPs. The 
sample were predominantly sibling pairs, but also included 3 half siblings, 22 pairs 
of cousins and 12 pairs of avuncular relationship. Eleven parent-offspring pairs 
were excluded from the analysis as they are uninformative for linkage (i.e. they will 
always share 1 allele IBD).
4.2.2 Genotyping
Genotypes from the Kehoe and colleagues (1999), Myers and colleagues (2002) 
and Blacker and colleagues (2003) analyses were combined. A total of 610 
markers were included, with an average spacing of 5.5cM. These comprised 237 
marker loci with an average spacing of 15cM genotyped by Kehoe and colleagues. 
Myers and colleagues followed up the 16 regions giving a maximum LOD score >
1 by genotyping a further 91 marker loci in the UK, NIA and NIMH sample. As 
such the UK and NIA samples are only genotyped on 11 autosomes (genotypes 
were available for the X chromosome, however these were not used in these 
analyses), and markers were restricted to areas showing a maximum LOD score >
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1 in the genome screen reported by Kehoe and colleagues. More details of the 
chromosomal regions genotyped in the UK and NIA samples can be found in 
appendix 4a. Blacker and colleagues (2003) genotyped 381 markers with an 
average spacing of 9cM. Ninety-nine of the markers genotyped by Blacker and 
colleagues and Myers and colleagues were overlapping. Markers were selected 
from the CHLC (http://lpq.nci.nih.gov/CHLC/index.htmh and CEPH 
(http://www.cephb.fr/cqi-bin/wdb/ceph/svsteme/forme) databases and marker 
positions were determined from the Marshfield maps 
(http://research.marshfieldclinic.org/qenetics). Marker positions for those not 
included in the Marshfield maps were obtained through the deCode genetic maps 
(Kong et al. 2002). Where positions of markers could not be mapped accurately 
due to scarcity of synonymous markers within both maps, the physical distances 
obtained from the UCSC website (http://genome.ucsc.edu/) were used to map the 
markers relative to each other.
4.2.3 Description of variables used in covariate linkage analysis
AAO, psychosis, aggression and minor depression all showed evidence of familial 
clustering in section 3.3 and were therefore included as clinical covariates. Minor 
depression was taken to represent the mood dimension rather than major 
depression or depression/anxiety, as it showed the most evidence of familial 
clustering. Also, minor depression was the most prevalent mood related symptom, 
and data regarding depression/anxiety were not available for the UK sample. It 
was therefore considered that analysis of minor depression offered the optimal 
means of identifying genetic variation associated with mood in AD. AAO data were 
available for all samples; however data regarding other clinical features were only 
available for those in the NIMH and UK families. All clinical covariates were 
defined as described in section 3.2.2. Several studies have reported an 
association between aggressive symptoms and severity of dementia (Cummings 
1997; Kloszewska 1998; Lopez et al. 2003; Senanarong et al. 2004). In section 
2.3, symptoms of aggression were found to be more prevalent and severe among 
those with moderately severe to severe dementia, compared to those in the mild to 
moderate stages of disease development. It is therefore likely a proportion of 
those in the earlier stages of the disease will go on to develop aggressive
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symptoms as the disease progresses. Therefore, those in the mild to moderate 
stages of dementia who had not displayed symptoms of aggression (GDS 2-4 and 
CDR 0.5-2 in UK and NIMH samples, respectively) were classified as unknown 
and only used in the estimation of allele frequencies and determining IBD sharing 
within families.
Paulsen and colleagues (2000) reported an increase in new psychotic symptoms 
of just 1.8% in the fourth year following onset of AD, suggesting that if they are to 
develop in the course of an individual’s illness they will usually appear within 4 
years of onset. Therefore, individuals with a disease duration > 4 years who had 
not developed psychotic symptoms were categorised as ‘Alzheimer’s with no 
psychosis’ (AD-P). Those with disease duration < 4 years who had not presented 
psychotic symptoms were coded as ‘unknown’, and were only used in the 
estimation of allele frequencies and determining IBD sharing within families.
4.2.4 Statistical analysis
Genotyping error checks A number of methods were used to detect genotyping 
errors. Non-Mendelian inheritance errors were determined for each marker using 
PEDCHECK (O'Connell and Weeks 1998). However this is likely to produce an 
underestimate of the true genotyping error rate in the absence of genotyped 
parents. As such, replicate datasets were simulated as discussed by Myers and 
colleagues (2002). Each simulation was based on the actual people genotyped 
and the allele frequencies at each locus, randomly introducing errors at a chosen 
fixed rate. For a range of given error rates, the average number of non-Mendelian 
errors in the simulated dataset were obtained for each locus. The final stipulated 
error rate was that at which the average number of errors in the simulated dataset 
most closely matched the observed number of errors. Data were also checked 
using the program SIBMED (Douglas et al. 2000) to eliminate genotypes that did 
not give visible inconsistencies but were nevertheless unlikely given the allele 
frequencies and marker maps. In addition it was possible to compare individual 
genotypes for the 99 overlapping markers genotyped separately by Myers and 
colleagues and Blacker and colleagues. The average detectable error rate for
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these markers was 2.6%, ranging from 0.2% to 14.0%. Discrepant genotypes were 
removed from the analysis.
Linkage Analysis The program SPLINK (Holmans and Clayton 1995) was used 
to estimate marker allele frequencies. Estimated multipoint and twopoint affected 
relative pair IBD sharing probabilities were obtained using MERLIN (Abecasis et 
al. 2002). MERLIN uses the relationship information from all individuals to estimate 
IBD sharing probabilities. In comparison to other linkage programs it provides a 
computationally economic means of analysis, allowing the inclusion of large 
pedigrees genotyped at many markers, which was required for this dataset.
Ninety-nine markers overlapped between the datasets provided by Blacker and 
colleagues and Myers and colleagues, these were included in the analysis as 
independent markers separated by an artificial gap of 0.001 cM. This negates the 
requirement for allele numbering to be consistent between studies and allows 
sample specific allele frequencies to be used. The use of overlapping individuals 
typed at similar, or the same markers, in both datasets, meant that many markers 
were likely to be in linkage disequilibrium (LD). Many popular linkage software 
packages, including MERLIN, generate multipoint linkage statistics under the 
assumption of linkage equilibrium between markers. Violation of this assumption 
can falsely inflate linkage statistics when IBD estimates rely on allele frequencies. 
This happens when a limited number of family members have been genotyped, or 
for example, if parental genotypes are unknown (Webb et al. 2005). The distance 
function in MERLIN was used to account for LD between markers. Markers within 
0.5cM were considered to be in LD, representing around 500k base-pairs.
Likelihood formation The multipoint likelihood of the marker data at any 
point in the genome is given as a function of the IBD sharing in the affected 
relatives pairs by:
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Where z. is the (unknown) probability that an affected relative pair share j  alleles
IBD, and are the prior and posterior (conditional on the observed marker
data) probabilities that pair / share j  alleles IBD (Olson 1999; Risch 1990). These 
estimates were obtained every 2cM using MERLIN. p FS is the probability that a
pair of affected full siblings share a given parental allele IBD. As suggested by 
Rice (Rice 1997) and Rice and colleagues (Rice et al. 1999), probabilities of 
sharing maternal and paternal alleles were assumed to be equal and
independent. Then z0 = (1 -  p FS)2, z, = 2 p FS(1 -  p FS) and z2 = p FS2 . Other types of
relative pair, R, can only share 0 or 1 allele IBD. For these, z0 = 1 -  pR, zx = pR and
z2 = 0 (where p R is the IBD probability for affected relative pairs of type R).
Inclusion of categorical covariates Psychosis, minor depression, aggression 
and APOE e4 were treated as dichotomous traits, with individuals being classed 
as '+’ if they displayed the symptom or if they had not. Individuals were classed 
as ‘£4+’ if they had at least one APOE e4 allele and ‘£4- if they did not. As such 
ARPs were classified as £4-/ £4-, z4-/ z4+ or £4+/ £4+ for APOE £4 status. The 
effect of a binary covariate on the IBD sharing probabilities was investigated by 
modelling p R in a logistic regression framework including a 3-level factor/?, with
levels corresponding to the status of the pair with respect to the covariate (-/-, -/+ 
or +/+). As such the inclusion of one covariate represented here by p k is given as:
gOR +a+pk 
J _|_ g 0 R+ a+Pk
where O r is a fixed offset, ensuring that p R takes the correct value for a relative 
pair of type R in the absence of linkage (i.e. all other coefficients in the regression 
= 0). Under the null hypothesis of no covariate effect, a  is a measure of the 
divergence of IBD from the null in the sample as a whole. The subscript k indexes 
the status of the particular relative pair with respect to the covariate. Multiple pairs 
from the same pedigree were analysed as if they were independent, with 
parameters a  and p  in common. To ensure identifiability of the parameters
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P_,_\Nas set to zero (making a  a measure of IBD divergence from the null in -/-
pairs). To ensure that the model makes sense biologically, the degree of IBD 
sharing for the discordant (-/+) pairs was constrained to be less than or equal to 
the maximum IBD in the concordant pairs. One might expect a gene that modified 
the expression of a clinical covariate (e.g. psychotic symptoms) in individuals 
affected with late-onset AD (but not AD risk itself), to present increased sharing in 
-/- or +/+ pairs (or both), with -/+ pairs showing reduced sharing. A gene which 
acts to cause a sub-phenotype of late-onset AD characterised by a particular 
symptoms presence or absence would cause increased sharing in either -/- or +/+ 
pairs, with the effects on IBD in the pairs of other types being unclear (dependent 
on penetrances, gene frequencies etc.). Caution should be applied to the 
interpretation of the allele sharing estimates as differences could arise for a 
number of reasons.
Inclusion of Quantitative Covariates AAO was characterised in terms of the 
mean and difference within ARPs and represented by the regression 
coefficient/?, which measures the relationship between the AAO covariate and 
IBD sharing. When testing AAO, where the variable of interest was the difference 
between the two members of an ARP, maximisation was carried with p  
constrained to be less than or equal to zero. As such, ARPs who showed most 
phenotypic resemblance were constrained to have higher IBD sharing 
probabilities.
LOD scores, test Statistic and significance levels To estimate the LOD score 
in the absence of covariates (e.g. the univariate LOD score), the likelihood was 
maximised with respect to a) a alone and, b) a = 0, at each position x. The LOD 
score was then estimated as the log-iolikelihood for a) divided by the likelihood for 
b). To determine the LOD score give the effect of covariates, the likelihood was 
maximised with respect to c) a  and p , and d) a = /? = 0. The covariate LOD score 
was then estimated as the logiolikelihood for c) divided by the likelihood for d).
The test statistic was then calculated by subtracting the maximum univariate LOD 
score over all values of x from the maximum covariate LOD score for all values of 
x (i.e. the increase in LOD attributable to the covariate of interest).
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The location of the maximum likelihood was allowed to change when the 
covariate was added. This reflects the fact that linkage peaks from standard 
analyses are often some way from the true disease locus (Cordell 2001). Thus, 
incorporating covariates may give a more accurate estimate of the disease locus. 
Chromosome-wide significance levels were obtained by creating n (1000) 
replicate samples, each with the observed values of the covariate randomly 
permuted among ARPs. The likelihood-ratio analysis was performed for each 
replicate sample and the increase in MLS owing to the covariate estimated. The 
significance level was defined as p=(r+1)/(n+1), where r is the number of 
replicates for which the test statistic exceeded the observed value (North et al. 
2002).
For the chosen test statistic, it was not possible to obtain a genome-wide 
significance level for covariate effects, as this depends not only on the increase in 
LOD score given by the covariate, but also on the linkage evidence present in 
univariate analyses. For example, an increase in LOD score from 2 to 3 is more 
significant than from 0 to 1, because the former is likely to occur by chance (in the 
absence of covariate effects) only in a linkage peak region, whereas the latter 
could occur anywhere on the chromosome. Separate analyses were performed 
including the following as covariates: AAO (mean and difference), psychosis, 
minor depression and aggression. APOE was included as a covariate in all 
analyses. Analyses were restricted to autosomal chromosomes due to software 
limitations.
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4.3 Results
Basic characteristics of the sample can be seen in table 4.1.
Table 4.1 Basic characteristics of the family based samples used for linkage analysis.
NIMH
Sample
UK
Sample
NIA
Sample
Combined
Sample
Number of Families 295 75 64 434
Number of Individuals 651 160 136 947
No. of affected members in each family
2 n (%) 247 (83.7) 66 (88.0) 56 (87.5) 369 (85.0)
3 n (%) 36 (12.2) 8(10.7) 8(12.5) 52(12.0)
4 n (%) 11 (3.7) 1 (1-3) 0 (0.0) 12(2.8)
5 n (%) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.2)
Gender n (%)
Male 163 (25.0) 30 (18.8) 46 (33.8) 239 (25.2)
Fem ale 488 (75.0) 130 (81.3) 90 (66.2) 708 (74.8)
Mean age at assessment, years 81.16 82.07 - 81.31
range 68-101 69-97 - 68-101
Mean age at onset, years 74.64 76.30 73.49 74.73
range 65-97 65-91 65-95 65-97
missing AOO 29 20 0 49
Mean disease duration, years 6.51 5.58 - 6.36
range 0 -27 0-17 - 0-27
Psychosis
AD + P, n (%) 334 (66.8) 76 (74.5) - 410(68.1)
AD - P, n (%) 166 (33.2) 26 (25.5) - 192 (31.9)
Unspecified, AD-P & Duration < 4yrs 52 19 - 71
Unspecified 99 39 - 138
Minor Depression
AD + D, n (%) 171 (32.1) 44 (41.1) - 215(33.6)
AD - D, n (%) 362 (67.9) 63 (58.9) - 425 (66.4)
Unspecified 118 53 - 171
Aggression
AD + Agg, n (%) 285 (68.2) 43 (55.1) - 328 (66.1)
AD - Agg, n (%) 133 (31.8) 35 (44.9) - 168 (33.9)
Unspecified, AD-D & GDS < 5 131 26 - 157
Unspecified 102 56 - 158
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AAO data was available for 94.8% of all samples. The mean AAO (sd) was 74.73
(5.90). The mean AAO (sd) was 77.44 (6.22), 74.09 (5.37) and 71.82 (5.38)
among those with 0, 1 or 2 z4 alleles respectively. The total sample comprised 102
e4-/e4- pairs, 20 z4+tz4- pairs and 331 z4+/z4+ pairs. Pairwise classification of
psychosis, minor depression and aggression can be found in table 4.2.
Table 4.2 Pairwise symptom classifications among relative pairs in the UK, NIMH and combined 
sample.
Total Pairs Number of -/- Pairs (%)
Number of 
+/- Pairs (%)
Number of 
+/+ Pairs (%)
Psychosis
UK Sample 41 6(14 .6 ) 10(24.3) 25 (60.9)
NIMH Sample 266 42 (15.7) 83 (31.2) 141 (53.0)
Combined Sample 307 48 (15.6) 93 (30.2) 166 (54.0)
Minor Depression
UK Sample 57 25 (43.8) 22 (38.5) 10 (17.5)
NIMH Sample 296 144 (48.6) 111 (37.5) 41 (13.8)
Combined Sample 353 169 (47.8) 133 (37.6) 51 (14.4)
Aggression
UK Sample 28 6(21 .4 ) 13 (46.4) 9(32.1)
NIMH Sample 204 21 (10.2) 78 (38.2) 105 (51.4)
Combined Sample 232 27(11 .6) 91 (39.2) 114 (49.1)
The following sections detail covariate linkage results for analyses including AAO, 
psychosis, depression and aggression.
4.3.1 Covariate linkage analysis with age at onset
Multipoint LOD score graphs are shown in figure 4.1 for all chromosomes with a 
LOD score increase owing to AAO greater than, or equal to, 1 and a total 
multipoint LOD score including covariates greater than, or equal to, 2. The 
corresponding linkage results are summarised in table 4.3. A summary of linkage 
results for all chromosomes can be found in appendix 4b.
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Table 4.3 Summary of linkage results after including pairwise AAO mean, difference and APOE. Results 
are shown for all chromosomes with a total maximum LOD score 2:2  and an increase in LOD attributable to 
AAO £ 1
Chromosome Sample Number of Pairs
Univariate
LOD
Incr. Mean 
AAO
Incr. Diff 
AAO Incr. APOE
Incr. 
Mean | 
APOE
Incr. 
Diff | 
APOE
1 Full 521 0.73 1.58 (+) p=0.039
0.07
p=0.806 1.06
1.28 (+) 
p=0.093
0.47
p=0.510
1 NIMH 380 0.87 2.00 (+) p=0.024
0.00
p=1.000 1.04
1.48 (+) 
p=0.144
0.06
p=0.736
1 UK+NIA 141 0.54 0.17p=0.846
0.38
p=0.478 1.38
0.13
p=0.427
0.02
p=0.477
2 Full 511 0.37 1.33 (+) p=0.150
1.37
p=0.212 0.74
1.37 (+) 
p=0.048
0.80
p=0.217
2 NIMH 380 0.37 1.33 (+) p=0.137
1.01
p=0.366 0.74
1.37 (+)
p=0.126
0.50
p=0.494
2 UK+NIA 131 0.06 0.16p=0.854
0.99
p=0.294 0.36
0.18
p=0.306
1.16
p=0.057
12 Full 523 0.13 0.24p=0.847
0.79
p=0.496 1.00
0.03
p=0.658
0.51
p=0.294
12 NIMH 380 0.04 0.32p=0.694
0.88
p=0.290 0.81
0.13
p=0.654
0.21
p=0.593
12 UK+NIA 143 0.65 0.14p=0.828
1.71
p=0.046 0.06
0.14
p=0.396
2.12
p=0.014
14 Full 528 0.03 0.47p=0.668
1.18
p=0.281 0.39
0.19
p=0.393
2.14
p=0.058
14 NIMH 380 0.33 0.87p=0.271
0.74
p=0.344 0.34
0.63
p=0.303
0.98
p=0.204
14 UK+NIA 148 0.03
0.24
p=0.726
0.30
p=0.574 0.85
0.06
p=0.429
0.85
p=0.162
19 Full 529 1.47
0.48
p=0.203
1.36
p=0.016 - - -
19 NIMH 380 0.95
0.34
p=0.390
1.02
p=0.058 - - -
19 UK+NIA 149 1.41
0.73
p=0.219
0.66
p=0.174 - - -
21 Full 521 0.39
1.45 (+) 
p=0.033
0.00
p=1.000 1.35
0.95 (+) 
p=0.514
0.00 
p=1.000
21 NIMH 380 0.07
2.26 (+) 
p=0.008
0.00
p=1.000 1.74
0.89 (+) 
p=0.356
0.00
p=1.000
21 UK+NIA 141 0.99
0.00
p=0.999
0.00
p=0.999 0.69
0.05
p=0.604
0.00
p=0.999
The six columns of maximum LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the analysis, the increases 
given by including 2) mean AAO, 3) AAO difference, 4) APOE genotype. The increase in MLS given by 
including 5) mean AAO and 6) AAO difference after allowing for APOE effects.
(+) in the mean AAO column indicates increased IBD sharing with increasing AAO, (-) indicates increased 
IBD sharing in pairs with lower mean AAO.
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The largest increase in LOD with mean AAO was observed on chromosome 21 in 
the NIMH sample where a univariate LOD of 0.07 increased to 2.33 at 14cM, 
chromosome-wide p-value = 0.008. Pairs with increasing AAO showed elevated 
IBD sharing. The maximum LOD score was lower than previously reported 
(Holmans et al. 2005; Olson et al. 2001). Neither AAO difference, nor mean, had 
an effect on the maximum LOD score on chromosome 21 in the UK+NIA sample. 
As such the effect in the combined sample was smaller, with a univariate LOD of 
0.38 increasing to 1.83, at 14cM, after including AAO mean as a covariate. 
However, the effect of mean AAO in the full sample still met criteria for 
chromosome-wide significance, p=0.033. Holmans and colleagues reported a 
maximum LOD score of 3.62 when including AAO mean as a covariate (NIMH 
sample only), which is somewhat larger than the maximum LOD score identified in 
this analysis. To further investigate this difference a separate, sibling pair only, 
analysis was performed incorporating just the sample and marker genotypes used 
by Holmans et al. The results were largely comparable, indicating that differences 
between these two analyses did not result from the use of different analytical 
methods (e.g. IBD sharing was estimated using MAPMAKER/SIBS by Holmans 
and colleagues, whereas MERLIN was used in this analysis. Also, ARPs were 
incorporated here, whereas Holmans and colleagues restricted analyses to 
affected sibling pairs). (Multipoint maximum LOD score graphs for these analyses 
can be found in appendix 4c). The dataset used in this chapter incorporates 
genotypes from 2 extra markers on chromosome 21, along with additional 
genotypes for 4 markers which where unique to this analysis. Marker D21S2052 
(located at 24.7cM), was unique to this analysis and was in the region of elevated 
linkage reported by Holmans and colleagues. The univariate twopoint LOD score 
for this marker was 0 in the NIMH sample, rising to 0.31 after including mean AAO 
as a covariate. Of the other 7 markers located between 9cM and 29cM on 
chromosome 21, 6 showed an increase in LOD > 1 after the inclusion of AAO 
mean. Removal of marker D21S2052 from the multipoint analysis broadened the 
linkage peak; however it only had a marginal effect on the magnitude and location 
of the MLS obtain after including AAO as a covariate (peak MLS with AAO mean 
of 2.33 at 14cM before removing marker D21S2052, compared to 2.47 located at 
14cM after it was removed). As such it is likely that the reduction in linkage 
evidence, compared to that found in the analysis reported by Holmans and
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colleagues, was due to the inclusion of relative pairs, additional families, family 
members and marker genotypes in the linkage region. Further details and twopoint 
LOD scores can be found in appendix 4c.
A maximum LOD score of 3.86 was observed on chromosome 1 in the combined 
sample after including APOE, AAO mean and AAO difference. Mean AAO was 
associated with an increase in LOD from 0.73 to 2.30 around 32cM (chromosome- 
wide p-value = 0.039), with pairs presenting with a higher mean AAO displaying 
elevated IBD sharing. The increase in LOD attributable to AAO difference was 
0.07. Inclusion of APOE as a covariate resulted in a LOD score increase of 1.06 
around 34cM. The AAO effect resulted primarily from those in the NIMH sample, 
where an increase in LOD from 0.87 to 2.87 (chromosome-wide p-value = 0.024) 
was observed after including AAO mean as a covariate. This did not replicate in 
the UK+NIA sample, with a maximum LOD score of 0.63 observed after including 
mean AAO.
On chromosome 2 a maximum LOD score of 2.60 was observed when including 
AAO mean, difference and APOE. This represented an increase of 2.23 over the 
maximum univariate LOD score. Both AAO difference and mean resulted in LOD 
score increases > 1. The maximum LOD score when including AAO mean was at 
258cM, with elevated IBD sharing observed in pairs with a higher mean AAO. The 
maximum LOD score when including AAO difference was 1.74 at 122cM; pairs 
with a closer AAO demonstrated increased IBD sharing at this locus. Neither the 
increase attributable to AAO mean nor difference met criteria for chromosome- 
wide significance, p=0.150 and p=0.212 respectively. However, after including 
APOE in the model AAO mean had a significant effect on linkage evidence, 
p=0.048, in the combined sample. It is notable that the increase in linkage 
evidence attributed to AAO mean on chromosome 2 was restricted to the NIMH 
sample, whereas increases in the maximum LOD score when including AAO 
difference appeared to be consistent across the NIMH and UK+NIA samples, with 
increases of 1.01 and 0.99, respectively.
On chromosome 14 the maximum univariate LOD score was 0.03, which 
increased to 2.64 when including AAO mean, difference and APOE. The main
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effect appeared to result from the inclusion of APOE and AAO difference, which 
resulted in a LOD score increase of 2.53. Elevated IBD sharing was observed 
among pairs who were discordant for possessing an APOE z4 allele and those 
with a closer age at disease onset. The increase in lod attributable to AAO 
difference did not meet criteria for chromosome-wide significance, p=0.281.The 
increase in LOD attributable to AAO mean was minimal in the combined, NIMH 
and UK+NIA samples.
Interestingly, the inclusion of AAO difference led to a chromosome-wide 
significant increase in LOD close to the APOE locus on chromosome 19, with a 
univariate LOD score of 1.47 raising to 2.83 (p=0.016) in the combined sample. 
Relative pairs with a closer AAO showed elevated IBD sharing. This effect 
appears to be consistent between the NIMH and UK+NIA samples. When 
incorporating AAO difference the LOD score increased from 0.95 to 1.97 (at 80cM) 
and from 1.41 to 2.07 (at 70cM) in the NIMH and UK+NIA samples, respectively. 
However, these effects did not meet criteria for chromosome-wide significance 
when considered alone, p=0.058 and p=0.174 for the NIMH and UK+NIA samples 
respectively. An increase in LOD of 1.41 to 2.14 was also noted with mean AAO 
around 66cM in the UK+NIA sample, with pairs presenting with a lower age at 
disease onset showing elevated IBD sharing. However, this effect did not meet 
criteria for chromosome-wide significance, p=0.219. The overall LOD score when 
including both AAO difference and mean as covariates was 2.69 in the UK+NIA 
sample, representing an increase of 1.28 over the univariate LOD score (p=0.185)
. The maximum LOD score increase attributable to mean AAO in the NIMH sample 
was 0.34 (p=0.390).
Maximum multipoint LOD scores of 2.45 and 4.23 were observed on 
chromosome 9 and 10, respectively, after including AAO mean, difference and 
APOE as covariates. However, the univariate LOD score on chromosome 9 was 
2.32 and 3.44 on chromosome 10. As such the increases in LOD attributable to 
AAO mean and difference were <0.1.
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Figure 4.1 Multipoint maximum LOD score graphs for chromosomes where a total 
LOD score > 2 and an increase attributable to AAO mean or difference > 1 were 
observed.
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The effect of mean AAO on IBD sharing on chromosomes 1 and 21 were further 
investigated by splitting the sample according to mean AAO and analysing the 
resulting sub samples. The results are shown in table 4.4. On chromosome 1 IBD 
sharing rose steadily with mean AAO at 32cM, with the majority of linkage 
evidence coming from those with a mean AAO greater than 80 years. Linkage 
evidence on chromosome 21 at 14cM appeared to solely come from relative pairs 
with a mean AAO in excess of 80 years.
Table 4.4 Variation in IBD and maximum LOD score with mean AAO for chromosomes with significant 
mean AAO effects
Chromosome 21 - Full Sample Chromosome 21 - NIMH Chromosome 1 -NIMH
Mean 
AAO range N IBD LOD N IBD LOD N IBD LOD
65-69.9 89 0.45 0 62 0.43 0 62 0.44 0
70-74.9 196 0.51 0.03 146 0.50 0 146 0.45 0
75-79.9 158 0.49 0 122 0.47 0 122 0.57 0.70
80-84.9 61 0.58 0.58 40 0.68 1.93 40 0.67 1.54
85+ 17 0.75 1.69 10 0.75 1.09 10 0.67 0.35
4.3.2 Covariate linkage analysis with psychosis
Multipoint LOD score graphs are shown in figure 4.2 for chromosome 6 and for all 
chromosomes with a LOD score increase greater than, or equal to, 1 and a total 
multipoint LOD score including covariates greater than, or equal to, 2. These 
results are also summarised in table 4.5. A summary of results including psychosis 
and APOE for all chromosomes can be found in appendix 4d. Pairwise 
classifications for psychosis can be seen in table 4.2 for the NIMH, UK and 
combined sample.
Increases in maximum LOD score >1 attributable to the inclusion of psychosis 
were observed on chromosomes 2, 7, 15 and 18. On chromosome 2 a univariate 
maximum LOD score of 0.30 was increased to 2.42 (p=0.074) after the inclusion of 
psychosis in the NIMH sample. Increased IBD sharing was observed among pairs 
concordant for displaying psychotic symptoms with estimated IBD sharing 
probabilities of 0.52, 0.39 and 0.59 among -/-, -/+ and +/+ pairs, respectively. The 
maximum LOD score reduced to 1.68 after including an additional 37 relative pairs 
from the UK sample, representing an increase in LOD due to psychosis of 1.24,
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p=0.271. In the NIMH and combined sample the peak LOD scores after the 
inclusion of psychosis were around 106cM and 110cM, respectively.
The largest, and most significant, increase in LOD score was observed on 
chromosome 15, where a univariate maximum LOD score of 0.20 was increased 
to 2.80 (p=0.007) around 80cM after psychosis was included as a covariate. 
Relative pairs who were concordant for the absence of psychotic symptoms 
provided the most evidence for linkage, with IBD estimates of 0.71, 0.42 and 0.52 
among -/-, -/+ and +/+ pairs, respectively. No marker genotypes were available for 
those in the UK sample on chromosome 15; therefore analysis was restricted to 
266 relative pairs from the NIMH sample.
Table 4.5 Summary of linkage results after including psychosis and APOE. Results 
are shown for all chromosomes with a total maximum LOD score > 2 and an increase in 
LOD attributable to psychosis > 1. In addition, results for chromosome 6 are shown.
Chromosome Sample Number of Univariate Pairs LOD
Incr.
Psychosis
Incr.
APOE
Incr. 
Psychosis | 
APOE
2 NIMH 266 0.30 2.12 (+) p=0.075 0.35
1.90 (+) 
p=0.164
2 NIMH+UK 303 0.45 1.24 (+) p=0.271 0.34
0.99 (+) 
p=0.507
6 NIMH+UK 303 1.09 0.58p=0.249 1.11
0.77
p=0.092
7 NIMH 266 0.60 2.25 (+/-) p=0.015 0.32
2.00 (+/-) 
p=0.028
15 NIMH 266 0.20 2.60 (-) p=0.007 0.08
2.54 (-) 
p=0.017
18 NIMH 266 0.02 1.49 (-)p=0.200 1.14
1.23 (-) 
p=0.237
The four columns of maximum LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the 
analysis, the increases given by including 2) Psychosis, 3) APOE genotype, 4) the 
increase in MLS given by including psychosis after allowing for APOE effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing 
was elevated in -/- pairs, (+/-) indicates that IBD sharing was elevated in both -/- and +/- 
pairs (compared to +/- pairs)
NB: Genotypes were not available in the UK sample for chromosomes where only 
NIMH results are shown
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Increases in maximum LOD score of 2.25 and 1.49 were observed on 
chromosome 7 and 18. On chromosome 7 a maximum LOD score of 2.85 after 
the inclusion of psychosis was observed. This increase reached criteria for 
chromosome-wide significance, p=0.015, and remained significant after controlling 
for APOE e4 status (MLS increase controlling for APOE = 2.00, p=0.028). 
Consistent with a disease modifying hypothesis, IBD sharing was elevated in pairs 
concordant for absence and presence of psychotic symptoms, with IBD sharing 
estimates 0.67, 0.44 and 0.56 observed among -/-, -/+ and +/+ pairs, respectively. 
On chromosome 18 a peak LOD score of 1.51 was observed around 106cM after 
incorporating psychosis. Linkage evidence was also elevated after including 
APOE, which resulted in an increase in the maximum LOD score from 0.02 to 
1.16. However, neither the increase in LOD attributable to psychosis nor APOE 
met criteria for chromosome-wide significance, p=0.200 and p=0.383, respectively.
Bacanu and colleagues (2002) previously reported a genome screen using a 
subset of the NIMH sample presented here. They used sibling pairs who were 
concordant for AD, psychosis and possessing at least one APOE £4 allele and 
reported significant linkage to chromosome 2 and two suggestive linkage peaks 
on chromosomes 6 and 21. The significant linkage peak on chromosome 2 was 
~50cM proximal to the linkage region identified in this chapter. The maximum LOD 
scores on chromosomes 6 and 21 reported here, after including psychosis status, 
were 1.67 and 0.52 respectively. As such these analyses do not appear to offer 
support for the AD+P linkage evidence identified by Bacanu and colleagues. 
Supplementary analyses were performed to assess these discrepancies.
Bacanu and colleagues reported a LOD score of 3.52 around marker D2S1356 
when analysing a subset of 42 siblings concordant for AD, presence of psychotic 
symptoms and possessing at least one APOE £4 allele (AD+P+£4). The peak LOD 
score was <0.5 when they restricted their analysis to those with just AD+P (i.e. not 
stratified by APOE £4 status). In the NIMH sample assessed in this chapter the 
maximum LOD score observed after including psychosis status at this locus was 
0.69, increasing to 1.03 after including APOE, which does not support the previous 
report of linkage to AD+P+£4 in this region.
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Figure 4.2 Multipoint maximum LOD score graphs for chromosomes where a 
total LOD score > 2 and an increase attributable to psychosis > 1 were observed. 
In additon the multipoint plot for chromosome 6 is shown.
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The chromosome 2 locus was further investigated by performing an analysis 
restricted to just the markers used by Bacanu and colleagues. A subset of 51 
sibling pairs classified as concordant for psychosis and possessing at least one z4 
allele were identified. Using just these affected sibling pairs and a reduced set of 
markers as in the Bacanu study, multipoint linkage analysis of chromosome 2 was 
performed. Elevated evidence for linkage was found around D2S1356. However it 
should be noted that this effect was less marked than in the Bacanu study (MLS=
1.84 at marker D2S1356, 64cM). This region was reanalysed incorporating the 11 
additional markers genotyped on chromosome 2 (of which 6 markers lay within 
25cM of the reported psychosis peak) and the MLS was greatly reduced to 0.84 at 
61cM.
A peak LOD score of 4.01 was observed in the NIMH sample on chromosome 21 
when incorporating APOE and psychosis as covariates, which was consistent with 
the findings of Bacanu and colleagues. However, the increase in LOD attributable 
to psychosis status after controlling for APOE z4 was only 0.08, chromosome-wide 
p value = 0.282. This indicates that a susceptibility locus for psychotic symptoms is 
unlikely to reside on chromosome 21, and it seems more likely that the previous 
report of suggestive linkage is due to an interaction between APOE and a potential 
genetic risk locus on chromosome 21.
In the analysis by Bacanu and colleagues the only result to show suggestive 
linkage in the subset sharing only AD+P (i.e. APOE z4 was not incorporated in the 
analysis) was observed on chromosome 6. When the analysis reported in this 
chapter was restricted to genotypes and individuals from the stage 2 genome 
screen reported by Myers and colleagues (2002), the inclusion of psychosis status 
led to an increase in the MLS from 0.60 to 2.62 (chromosome-wise p value = 
0.011) at the same locus as identified previously. Increased IBD sharing was 
observed among -/- and +/+ pairs, with IBD sharing estimates of 0.57 and 0.63 
respectively, compared to 0.42 among discordant pairs. The full analysis 
presented in this chapter incorporates 2 new markers and additional marker 
genotypes at 2 markers within this linkage region. Furthermore, an additional 59 
relatives pairs were included in the full analysis. Consequently, the maximum LOD 
score when including psychosis reduced to 1.67, representing an increase of 0.58
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over the maximum univariate LOD score of 1.08, chromosome-wide p value = 
0.249. Additional maximum LOD score graphs for chromosome 6, restricted to 
marker genotypes used in the genome screen reported by Myers and colleagues, 
can be found in appendix 4e.
4.3.3 Covariate linkage analysis with aggression
Multipoint LOD score graphs are shown in figure 4.3 for all chromosomes with a 
total maximum LOD score £ 2 and an increase due to aggression £ 1. Covariate 
linkage results for analyses of aggression and APOE are summarised in table 4.6. 
Further details can be found in appendix 4f. Pairwise classifications for aggression 
can be seen in table 4.2 for the NIMH, UK and combined sample. Increases in 
maximum LOD score £1 attributable to inclusion of aggression were observed on 
chromosomes 3, 7, 9 and 12.
The largest LOD score increase attributable to aggression was observed on 
chromosome 7 where a univariate maximum LOD score of 0.27 increased to 1.97 
around 56cM. Increased IBD sharing was observed among concordant pairs, with 
IBD sharing estimates of 0.51, 0.35 and 0.51 for -/-, -/+ and +/+ pairs, respectively. 
The maximum LOD score also increased from 0.55 to 2.12 at 22cM on 
chromosome 3, with elevated IBD sharing among pairs concordant for 
aggression. However, increases in linkage evidence attributable to aggression on 
chromosomes 3 and 7 were not statistically significant, p=0.152 and p=0.108. 
Analyses on chromosomes 3 and 7 were restricted to those in the NIMH sample 
as linkage genotypes were not available for those in the UK families.
The most significant increase in MLS attributable to aggression was observed on 
chromosome 9. In the NIMH sample a univariate LOD of 2.12 increased to 3.64 
at 80cM, chromosome-wide p value = 0.017. This effect reduced slightly when 
incorporating an additional 28 UK relative pairs, but remained significant (total 
MLS = 3.61, increase in MLS due to aggression = 1.43, chromosome wide p value 
= 0.019). Increased IBD sharing was observed in pairs in which neither member 
had displayed symptoms of aggression, with IBD sharing estimates of 0.77, 0.49 
and 0.55 in -/-, -/+ and +/+ pairs respectively. The effect appeared stronger after
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including APOE status into the model. The increase attributable to aggression was
1.85 after including APOE e4 status, resulting in a total MLS after incorporating 
aggression and APOE of 4.09.
An increase of 1.20 was observed on chromosome 12 in the combined sample 
when including aggression. The inclusion of APOE e4 status also resulted in a 
maximum LOD score increase of 1.47. As such, the increase in LOD attributable 
to aggression after controlling for APOE e4 status was 0.79, which did not meet 
criteria for chromosome wide significance, p=0.143.
Table 4.6 Summary of linkage results after including aggression and APOE. Results 
are shown for all chromosomes with a total maximum LOD score £ 2 and an increase in 
LOD attributable to aggression > 1
Chromosome Sample Number of Univariate Pairs LOD
Incr.
Aggression
Incr.
APOE
Incr. 
Aggression | 
APOE
3 NIMH 204 0.55 1.57 (+/-) p=0.152 0.70
0.91 (+/-) 
p=0.317
7 NIMH 204 0.27 1.71 (+/-)p=0.108 0.34
1.43 (+/-) 
p=0.241
9 NIMH 204 2.12 1.53 (+/-) p=0.017 0.22
2.03 (+/-) 
p=0.017
9 NIMH+UK 232 2.18 1.43 (+/-) p=0.019 0.06
1.85 (+/-)
p=0.021
12 NIMH 204 0.12 1.25 (+/-) p=0.308 1.59
0.67 (+/-) 
p=0.127
12 NIMH+UK 229 0.13 1.20 (+/-) p=0.339 1.47
0.79 (+/-) 
p=0.143
The four columns of maximum LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the 
analysis, the increases given by including 2) Aggression 3) APOE genotype, 4) The 
increase in MLS given by including aggression after allowing for APOE effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing 
was elevated in -/- pairs, (+/-) indicates that IBD sharing was elevated in both -/- and +/- 
pairs (compared to +/- pairs)
NB: Genotypes were not available in the UK sample for chromosomes where only 
NIMH results are shown
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Figure 4.3 Multipoint maximum LOD score graphs for chromosomes where a 
total LOD score > 2 and an increase attributable to aggression > 1 were 
observed.
4.3.4 Covariate linkage analysis with depression
Multipoint LOD score graphs are shown in figure 4.4 for all chromosomes with a 
total maximum LOD score > 2 and an increase due to depression greater than 1. 
Covariate linkage results for analyses of depression and APOE are summarised in 
table 4.7. Further details can be can be found in appendix 4g. Pairwise 
classifications for depression can be seen in table 4.2 for the NIMH, UK and the 
combined sample. Increases in maximum LOD score >1 attributable to inclusion of 
depression were observed on chromosomes 3, 10, 19 and 21.
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Table 4.7 Summary of linkage results after including depression and APOE. Results 
are shown for all chromosomes with a total maximum LOD score £ 2 and an increase 
in LOD attributable to aggression £ 1
Chromosome Sample Number of Univariate Pairs LOD
Incr.
Depression
Incr.
APOE
Incr. 
Depression | 
APOE
3 NIMH 295 0.78 1.15 (+) p=0.225 0.35
0.80
p=0.367
10 NIMH 296 2.27 1.26 (+) p=0.081 0.19
1.07 (+) 
p=0.089
10 NIMH+UK 351 2.45 0.63p=0.221 0.22
0.66
p=0.217
19 NIMH 296 0.96 1.56 (+/-)p=0.080 - -
19 NIMH+UK 353 1.04 1.47 (+/-) p=0.115 - -
21 NIMH 296 0.07 1.96 (+/-) p=0.079 1.47
1.20
p=0.034
21 NIMH+UK 351 0.27 2.19 (+/-) p=0.034 0.99
1.23 (+/-) 
p=0.040
The four columns of maximum LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the 
analysis, the increases given by including 2) Depression 3) APOE genotype, 4) The 
increase in MLS given by including depression after allowing for APOE effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing 
was elevated in -/- pairs, (+/-) indicates that IBD sharing was elevated in both -/- and 
+/- pairs (compared to +/- pairs)
NB: Genotypes were not available in the UK sample for chromosomes where only 
NIMH results are shown
The largest and most significant increase in LOD attributable to depression was 
observed on chromosome 21. In the NIMH sample the univariate LOD increased 
from 0.07 to 2.02 at 3cM, chromosome-wide p value = 0.079. The effect became 
stronger after adding in 55 relative pairs from the UK sample, with a LOD score 
after incorporating depression of 2.47 observed in the combined NIMH+UK sample 
(MLS increase attributable to depression = 2.19, chromosome-wide p value = 
0.034). The peak also moved to 25cM, although linkage evidence was still 
elevated around 3cM where an MLS of 1.93 was observed. Compared to -/+ pairs 
increased IBD sharing was noted in -/- and +/+ pairs. The depression peak in the 
combined samples was 11cM distal to the linkage peak identified with mean AAO 
in section 4.3.1. To further investigate the concordance of these results a
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combined analysis was performed incorporating AAO and depression. In the 
linkage sample, AAO did not differ among those classified with and without 
depression, t(633)=-1.235, p=0.217. The multipoint LOD score graph for 
chromosome 21 including depression and AAO can be seen in figure 4.5. The 
inclusion of depression and mean AAO resulted in increases in MLS of 2.09 
(chromosome-wide p value = 0.027) and 1.93 (chromosome-wide p value = 0.013) 
respectively, both around 20cM. Given that the effects of depression and mean 
AAO were not related, a combined maximum LOD score when both were added 
as covariates of 3.95 was observed.
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Figure 4.4 Multipoint maximum  LOD score graphs for chromosomes where a 
total LOD score > 2 and an increase attributable to depression > 1 were 
observed.
The increase in LOD attributable to depression on chromosome 19 was about 
22cM distal to the APOE locus. The increase owing to depression was 1.47 in the 
combined sample, resulting in a maximum LOD score of 2.50. Increased IBD 
sharing was observed among pairs concordant for depression status, with IBD
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sharing probabilities of 0.58, 0.45 and 0.61 among -/-, -/+ and +/+ pairs 
respectively. However, this effect did not meet criteria for chromosome-wide 
significance, p=0.115.
Interestingly depression status resulted in a MLS increase of 1.26 on 
chromosome 10 in the NIMH sample, which approached chromosome wide 
significance, p=0.081. In the subset of 351 relative pairs with depression and 
APOE data the univariate LOD on chromosome 10 was 2.45, which was lower 
than that in the full, unstratified, sample. The maximum LOD score in the NIMH 
sample after including depression increased to 3.53. The linkage peak was at 
72cM which is proximal to the linkage peak identified using part of this sample by 
Myers and colleagues (2002). After including data from 55 relative pairs from the 
UK sample the increase in LOD due to depression reduced to 0.63, chromosome 
wide p value = 0.221.
Finally, the increase in LOD attributable to depression on chromosome 3 was 
1.15 resulting in a maximum LOD score including depression of 1.93 
(chromosome-wide p value = 0.225). The peak was at 112cM which was ~90cM to 
the linkage peak identified with AD and aggression reported in section 4.4.3.
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Figure 4.5 Multipoint maximum LOD score graph for chromosomes 21 
including AAO mean and depression as covariates.
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4.4 Discussion
4.4.1 Summary of findings
Covariate linkage analysis was performed in a large sample of relative pairs 
affected with late-onset AD, incorporating age at disease onset, psychosis, 
aggression and depression. Nine novel linkage regions were identified. Increases 
in linkage evidence, which reached criteria for chromosome wide significance, 
were observed on chromosomes 1, 2 and 21 when mean AAO was included as a 
covariate in linkage analysis. The inclusion of AAO difference led to an increase in 
MLS on chromosome 12 in the UK+NIA sample which met criteria for chromosome 
wide significance. In addition, a significant increase in LOD close to the APOE 
locus in the combined sample was noted with AAO difference. Significant 
increases in LOD were found after the inclusion of psychosis (chromosomes 7 and 
15), aggression (chromosome 9) and depression (chromosome 21). Furthermore, 
numerous other linkage signals with covariate increases > 1 were identified which 
failed to reach criteria for chromosome wide significance.
4.4.2 Discussion of linkage findings in relation to age at onset
The most significant finding was with AAO mean on chromosome 21 p. This is 
consistent with previous analyses which have incorporated AAO as a covariate in 
genome screens of late-onset AD. Holmans and colleagues (2005) used a subset 
of the sample reported in this chapter and found stronger evidence for linkage than 
identified here. The decrease in LOD score between the two analyses was 
attributable to the inclusion of extra families, individuals and marker genotypes, but 
was mainly owing to one marker. Olson and colleagues (2001) also reported 
increased evidence for linkage in this region. The magnitude of effect was 
comparable to the one reported in section 4.3.1 when restricting analyses to just 
those in the NIMH sample. It should be noted that Olson and colleagues included 
many families which overlapped with those used here. They reported linkage 
evidence ~13cM distal to the peak identified in this analysis and the one reported 
by Holmans and colleagues, thus, it was closer to the APP locus. This discrepancy 
could be due to a number of reasons. First, the Olson study was restricted to 
genotypes from the stage one genome screen reported by Kehoe and colleagues 
(1999), whereas this analysis includes data from the stage 2 genome screen
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reported by Myers and colleagues (2002). Second, Olson and colleagues included 
individuals with an AAO above 60 and required that all individuals had data 
regarding current age. Despite individuals in the UK and NIA samples having a 
similar distribution of AAO to those in the NIMH sample, linkage evidence 
decreased when including these families.
Modest evidence of linkage was observed ~14cM distal to the NIMH mean AAO 
linkage peak in univariate analysis of the UK+NIA sample (MLS= 0.99). APOE 
status also increased linkage evidence on chromosome 21 in this dataset; 
consistent with previous findings elevated IBD sharing was observed in relative 
pairs with no APOE e4 alleles (Kehoe et al. 1999; Myers et al. 2002). This is of 
interest as evidence suggests that the APOE e4 allele reduces AAO in a dose 
dependent manner. These findings suggest a role for APP, or a gene in this region, 
in the genetic susceptibility for AD. However, as pointed out by Olson and 
colleagues, the absence of e4 alleles in those showing most evidence for linkage 
on chromosome 21 may not represent an interaction at the biological level, as 
genetic variation at this locus does not appear to confer risk to AD until very late in 
life. Individuals with APOE e4 alleles may have developed lz4 type AD’ prior to the 
age when genetic variation at the chromosome 21 begins to exert its effect.
The inclusion of depression as a covariate also increased linkage evidence at this 
locus. Elevated IBD sharing was observed among relative pairs in which both 
members were concordant for either the presence or absence of depression. The 
effects of depression and AAO appeared to be additive. It is possible to draw a 
number of conclusions from the linkage evidence on chromosome 21: (a) 
increased linkage evidence may result from epistasis between the APOE locus 
and the region on chromosome 21, (b) a gene in this region may increase 
susceptibility to AD among those > 80 years of age, (c) a gene in this region 
modifies susceptibility to mood disturbances in AD. A combination of these three 
scenarios is possible. For example, genetic variation in this region may increase 
susceptibility to very late-onset AD, which modifies the risk of developing 
symptoms of depression.
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The second largest increase in linkage evidence attributable to AAO was observed 
on chromosome 1. This finding was novel and was not reported in previous 
analyses including AAO (Holmans et al. 2005; Li et al. 2002; Olson et al. 2002). 
Similar to chromosome 21, increased IBD sharing was observed among pairs with 
a higher mean AAO, with the effect becoming particularly noticeable among those 
with a mean AAO > 80 years. The finding was much stronger in the NIMH sample; 
however a very small effect was noted in the UK+NIA families. The effect 
attributable to AAO mean was mediated slightly by APOE, as such the effect of 
adding mean AAO after controlling for APOE was smaller, failing to meet 
chromosome wide significance.
Despite the known effects of APOE on AAO in AD, mean AAO did not have an 
effect on linkage in either the NIMH or UK+NIA sample around the APOE locus on 
chromosome 19. However, increases in LOD attributable to AAO difference were 
noted in both samples around the APOE locus. As a result the increase in LOD in 
the combined sample reached criteria for chromosome-wide significance. The 
effect was small, which is consistent with the findings in section 3.3.2 that suggest 
APOE accounts for only a small proportion of the familial effect on AAO.
The only other notable increase in linkage evidence attributable to AAO difference 
was on chromosome 12 in the UK+NIA sample. This finding was ~30cM proximal 
to the linkage peak identified by Pericak-Vance and colleagues (1997). This 
finding was not replicated in the NIMH families. Consequently, this finding was not 
significant in the combined sample, indicating that it might represent a false 
positive. The linkage peak on chromosome 12 with mean AAO in the NIMH 
sample was smaller than the one reported by Holmans and colleagues, and as 
such it did not meet criteria for chromosome wide significance.
Holmans and colleagues reported increased evidence for linkage on chromosome 
6 and 15, which are not supported here after including additional markers 
genotypes and individuals. The maximum LOD score on chromosome 15 in the 
Holmans study was around marker D15S165, at ~20cM. It is notable that the 
analysis reported here incorporated additional marker genotypes for marker 
D15S165, along with genotypes from two additional markers on chromosome 15.
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Similarly additional marker genotypes in the region previously identified on 
chromosome 6 were exclusive to this analysis, resulting in a decrease in linkage 
evidence.
The other major study of AAO in AD was reported by Li and colleagues (2002). 
Their analysis included data from a subset of families ascertained by the NIMH 
and NIA, which overlapped somewhat with those used in this chapter. As noted in 
section 4.1.5, their analysis differs to the one reported here, in that it treated AAO 
as a quantitative trait. As such Li and colleagues considered IBD sharing between 
pairs of relatives and AAO as the independent and dependent variables, 
respectively. Therefore, they were unable to test for overall linkage to AD. They 
reported evidence for linkage around marker D10S1237, at 139cM. Despite finding 
evidence for a highly significant linkage peak on chromosome 10 between 75cM 
and 86cM, the results from this chapter do not support the conclusion that the 
chromosome 10 loci is related to AAO. Li and colleagues also reported linkage 
peaks on chromosomes 4, 6, 8, 13 and 18. Those on 4, 8 and 13 did not replicate 
in this sample. Increases in linkage evidence were observed with AAO difference 
on chromosomes 6 and 18 which corresponds to those reported by Li and 
colleagues. However the maximum LOD scores on these chromosomes were less 
than 2, and did not meet criteria for chromosome wide significance.
4.4.3 Discussion of linkage findings in relation to psychosis
The strongest evidence for linkage to psychosis in AD was observed on 
chromosomes 15. Increased IBD sharing was observed among pairs in which 
neither member had displayed psychotic symptoms, which could be consistent 
with a sub-phenotype hypothesis. The increased evidence for linkage provided by 
psychosis status was independent of APOE. This provides evidence that a gene 
may be located in this region that is linked to a sub-phenotype of AD characterised 
by the absence of psychotic symptoms. In addition, the inclusion of psychosis as a 
covariate led to a significant increase in linkage evidence on chromosome 7. 
Increased IBD sharing was observed among pairs concordant for either the 
presence or absence of psychotic symptoms, whilst IBD sharing was decreased in 
pairs discordant for psychosis status. This finding is consistent with a disease
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modifying hypothesis; however association studies would be required to confirm 
this. It is notable that the previous two analyses (Avramopoulos et al. 2005; 
Bacanu et al. 2002) which have performed genome screens, incorporating 
information regarding psychotic symptoms, have not reported increased linkage 
evidence in these regions. However, this could be attributable to methodological 
differences between these studies. For example, Bacanu and colleagues (2002) 
relied on sample stratification to incorporate data regarding psychotic symptoms 
into linkage analysis. As such, investigations were limited to sibling pairs in which 
both members had AD with psychotic symptoms. In this chapter increased linkage 
evidence was noted on chromosomes 7 and 15 among those without psychotic 
symptoms, which would not have been detected using the analysis method 
adopted by Bacanu and colleagues. Avramopoulos and colleagues treated 
hallucinations and delusions separately. It is therefore difficult to compare their 
results to those reported here, where hallucinations and delusions were viewed as 
symptoms of a larger behavioural component represented by psychosis.
Evidence from this genome screen does not support the previous findings, which 
suggested that a susceptibility locus for AD+P resides on chromosome 2 or 21 
(Bacanu et al. 2002). This study suggests that the previous significant linkage 
signal identified on chromosome 2, found when analysis was restricted to sibling 
pairs where both members had psychotic symptoms and at least one e4 allele, 
may represent a false positive. After incorporating additional marker genotypes in 
this region there was no evidence of linkage, either with APOE z4 status or 
psychosis. Supplementary analyses, which were more comparable with those 
reported by Bacanu and colleagues, did identify a linkage peak with APOE on 
chromosome 2. However, the signal was greatly reduced when additional markers 
were genotyped close to the linkage peak. There was evidence for a potential 
locus on chromosome 21 when psychosis and APOE £4 status were included in 
the analysis. However, the majority of the increase in MLS was accounted for by 
APOE e4 status which agrees with previous findings in studies using part of this 
sample (Kehoe et al. 1999; Olson et al. 2001). Psychosis did not have a significant 
effect on linkage. This indicates that a susceptibility locus for psychotic symptoms 
is unlikely to reside on chromosome 21, and it seems more likely that the previous
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report of suggestive linkage is due to an interaction between APOE and a potential 
genetic risk locus on chromosome 21.
Bacanu and colleagues also reported a linkage peak for AD+P on chromosome 6. 
In this chapter, the inclusion of psychosis as a covariate led to a chromosome 
wide significant increase in linkage evidence when analysis was restricted to 
genotypes and families from the stage 2 genome scan reported by Myers and 
colleagues (2002) (‘stage 2’ sample). This was of particular interest as the 
chromosome 6 finding was the only suggestive linkage peak reported by Bacanu 
and colleagues which was independent of APOE e4 status. After the inclusion of 
additional families and markers the evidence for linkage in the absence of 
covariates increased, whilst the maximum LOD score in the model including 
psychosis status was reduced. As such the increase in linkage evidence 
attributable to psychosis reduced substantially; hence, did not meet criteria for 
significance. Given the contradictory results obtained within this sample these 
findings cannot be taken to exclude the possibility that a gene, or genes, in this 
region are implicated in the aetiology of psychosis in AD. However, further 
analyses in independent samples would be needed to investigate this region.
The chromosome 6 locus is of particular interest as evidence for linkage in this 
region has also been identified in studies of schizophrenia and bipolar disorder, 
both of which have prominent psychotic features. For example, a p-value of 
0.00018 was observed at marker D6S474 (~6cM distal to the psychosis peak in 
the ‘stage 2’ sample) using 61 ASPs from 53 pedigrees (Cao et al. 1997). In an 
independent series of ASPs Cao and colleagues observed a p-value of 0.00095 at 
a locus ~2cM proximal to their previous linkage peak, a finding that was later 
replicated by Martinez and colleagues (1999) who observed a p-value of 0.013 at 
marker D6S424 (at 104cM). Further to this a maximum LOD score of 3.10 at 
106.9cM (~6cM proximal to the psychosis peak identified in the ‘stage 2’ sample in 
this chapter) was found in a combined sample, collected at 8 centres, consisting of 
824 independent sibling pairs with schizophrenia (Levinson et al. 2000). Also, the 
locus on chromosome 6 is arguably the most supported region of linkage 
implicated in the development of bipolar disorder. In their genome screen using 
250 pedigrees affected with bipolar disorder, Dick and colleagues provided
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evidence for a major locus on chromosome 6, with a MLS of 3.61 observed 
between D6S1021 and D6S474 (112cM-118cM). Pato and colleagues (2004) have 
replicated this finding in a sample of Portuguese bipolar disorder sufferers, 
reporting suggestive evidence for linkage at the same marker. More recently, 
Lambert and colleagues have found evidence for suggestive linkage to bipolar 
disorder in this region in an independent sample of sibling pairs from 135 families 
(Lambert et al. 2005). McQueen and colleagues (2005) have performed a meta­
analysis of 11 studies and concluded that this region on chromosome 6 is the most 
important region in bipolar disorder. It is possible that the similarity of these 
findings in AD, schizophrenia and bipolar disorder could represent a locus that 
influences susceptibility to psychotic symptoms across a number of disorders. 
However, it should be noted that the common psychotic symptoms differ in AD and 
schizophrenia; for example, delusions in AD are typically non-bizarre and simple, 
and seem to differ somewhat from the more complex and bizarre delusions seen 
in patients with schizophrenia (Jeste and Finkel 2000). Hallucinations in AD 
patients are more frequently visual than auditory, which again differs from 
schizophrenia where the reverse is true (Jeste and Finkel 2000).
4.4.4 Discussion of linkage findings in relation to depression and 
aggression
Linkage analyses incorporating symptoms of depression and aggression in AD 
have not been reported previously. Significant increases in linkage evidence were 
observed on chromosomes 21 with depression, and chromosome 9 with 
aggression. The finding on chromosome 9 is of particular interest as this region 
has been implicated in numerous genome screens using the NIMH AD sample 
(Blacker et al. 2003; Myers et al. 2002; Pericak-Vance et al. 2000). In addition, 
Holmans and colleagues observed increased IBD sharing among sibling pairs with 
a faster rate of decline close to this locus. This is of interest as symptoms of 
aggression are generally believed to be a marker for a more rapid disease 
progression (Levy et al. 1996a; Lopez et al. 1999). However, linkage evidence on 
chromosome 9 appeared to be coming solely from those without symptoms of 
aggression, which is not consistent with the hypothesis that this region harbours a 
gene which is implicated in the development of a more severe form of AD
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characterised by rapid disease progression and symptoms of aggression. In 
addition to the chromosome wide significant increase in LOD attributable to 
depression on chromosome 21 already discussed, a non-significant increase in 
LOD on chromosome 19 was also observed after including depression as a 
covariate. The peak was ~30cM from the APOE locus, located at ~60cM, therefore 
is unclear whether this reflects a role for APOE in the development of depression 
in AD.
Linkage evidence in AD is arguably most consistent on chromosome 10, with 
many studies finding evidence for linkage in this region. It is interesting that the 
covariate effects on this chromosome were limited. It is noteworthy that highly 
significant evidence for linkage in the combined sample was observed in univariate 
analyses of this region. As such, one would have to conclude that a genetic 
susceptibility locus for AD may reside on chromosome 10, which is unlikely to be 
restricted to specific disease sub-phenotypes included in these analyses. 
Furthermore, this region is not likely to be implicated in the modification of AAO 
(as suggested by Li and colleagues), psychotic symptoms, depression or 
aggression in AD. However, it should be noted that covariates will have the most 
effect when they are able to differentiate between those with high and low IBD 
sharing. In the presence of a high univariate linkage signal, where the majority of 
pairs have high IBD sharing, the power of covariates to exert an effect is likely to 
be limited.
4.4.4 Implications and future research
Linkage signals identified from this type of analysis could be explained in a 
number of ways. Firstly, linkage signals could represent disease modifying genes, 
which could influence susceptibility to psychotic symptoms in the presence of 
neurodegeneration caused by AD. For example, Psychotic symptoms have 
already been associated with the serotonin receptor genes, 5 -HT2A and 5 -HT2C, 
which are not associated with the risk of developing AD, hence are hypothesised 
to act as disease modifying genes (Assal et al. 2004; Holmes et al. 1998a; Lam et 
al. 2004; Nacmias et al. 2001). Alternatively, by including clinical information as a 
covariate, ‘phenocopies’ which do not share the same genetic aetiology will have
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less effect on linkage results. For example, Bacanu and colleagues (2002) argue 
that AD+P represents a ‘purer form of AD’ that will be more useful in determining 
genuine linkage with the disease itself. It is particularly useful that the method of 
covariate linkage analysis used in this chapter gives some indication of which 
hypothesis is most likely to be correct for any given locus. The results from these 
analyses also demonstrate the utility of covariate linkage methods, both for the 
detection of linkage in the presence of locus heterogeneity and also in the 
identification of homogenous subgroups of patients who are likely to show linkage 
to a given loci. This information should be taken into account when performing 
further analyses based on linkage results from this study. For example, future 
studies of APP in late-onset AD should consider the role in the very elderly (e.g. 
those with an AAO £ 80), whilst also taking into account the occurrence of 
depressive symptoms during the course of the illness.
There were numerous examples where the inclusion of covariates led to an 
increase in LOD > 1, which did not reach criteria for chromosome wide 
significance. It is unfortunate that a number of these regions resided on 
chromosomes which were only genotyped in the NIMH sample. Genotyping these 
regions in the UK and NIA samples, or in other independent datasets, will 
undoubtedly provide a clearer picture of how they are implicated in AD and with 
the covariates used in this chapter.
4.4.5 Methodological critique
There are a number of important factors to consider when interpreting the results 
from these analyses. First and foremost, these investigations are largely of an 
exploratory nature. As such, no adjustments for multiple testing were performed. 
Significance testing was performed at a chromosome-wide level. In theory it is 
possible to extrapolate these significance levels to the whole genome, in a 
Bonferroni style test, by multiplying by the total number of chromosomes 
investigated, adjusting for the length of the chromosome where the effect was 
observed. However, it was considered that this would have been too conservative 
for this explorative investigation. Furthermore, the inclusion of covariates 
undoubtedly increases the overall probability of type I error due to number of 
analyses performed on the same dataset. Olson and colleagues (2001) suggest
177
careful prior selection of covariates as one method to limit the problems caused by 
multiple testing. Two methods of limiting the number of covariates tested were 
employed here. First, analyses were limited to a small number of behavioural 
components, guided by the principal components analysis reported in chapter 2, 
rather than numerous individual symptoms. Second, linkage analysis was further 
restricted to aspects of phenotypic variation which showed evidence of familial 
clustering in chapter 3. Despite the use of these strategies a total of 5 covariates 
(AAO mean and difference, psychosis, depression and aggression) were analysed. 
As such one may choose to apply a Bonferroni adjustment to the chromosome or 
genome wide significance levels obtained for each covariate. This approach would 
be highly conservative and was therefore not adopted for these analyses.
However, these considerations emphasise the need to replicate these findings in 
independent samples.
As mentioned in section 3.4, another possible limitation of this study stems from 
the data used to categorise individuals in terms of behavioural components. These 
data were primarily collected for use in a genome screen for late-onset AD; 
therefore limited information was available covering the presence, type and 
severity of behavioural symptoms. The Brief Psychiatric Rating Scale, BEHAVE- 
AD and the MOUSEPAD offer a good overview of behavioural disturbances. 
However, since data were collected at one time point in disease development, 
which varied between individuals, the possibility that behavioural components for 
some individuals may have changed overtime, and were therefore mis-specified 
in this study, cannot be ruled out. It is reassuring that using these data it was 
possible to demonstrate familial aggregation of behavioural components (see 
section 3.3). It appears that the combination of clinical (e.g. AAO, psychosis etc.) 
and genetic information may offer vital clues in the search for genes associated 
with the development and progression of AD; therefore future collections of AD 
samples should aim to acquire information on behavioural symptoms experienced 
by disease sufferers longitudinally over the course of the illness.
The logistic regression approach employed in this study makes efficient use of 
covariate data within the context of an affected relative pair linkage design, as data 
from all informative related individuals contribute to the analysis. This contrasts with
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the frequently used method in which a primary analysis is undertaken with the whole 
dataset followed by a secondary analysis on a subset selected according to the 
covariate. For example, this method was used by Bacanu and colleagues (Bacanu et 
al. 2002) in their genome screen of AD with psychosis. However, this approach 
overlooks a considerable amount of data, as the unselected individuals are either 
excluded totally or they remain in the analysis with phenotype designated as 
‘unknown’. Either way, a direct comparison between the results is hindered, as the 
sample sizes for the main and secondary analyses differ (Hamshere et al. 2005). For 
example, Bacanu and colleagues identified a significant linkage peak on chromosome 
2 in sibling pairs concordant for AD, psychosis and possessing at least one z4 allele. 
However, by performing analysis on a sample substratum it was difficult to determine 
whether the increased evidence for linkage resulted from AD alone, psychosis or an 
interaction with the APOE locus. The logistic regression approach also provides useful 
information about the underlying genetic effect. By comparing the pattern of IBD 
sharing among discordant and concordant pairs for each covariate, it is possible to 
make inferences about whether linkage regions contain genetic variation which is 
likely to modify disease progression or whether it contains a gene, or genes, which 
increase susceptibility to a specific disease sub-phenotype.
4.4.6 Conclusions
Familial aggregation of psychosis, depression, aggression and age at disease 
onset were reported in chapter 3 of this thesis, suggesting that aspects of clinical 
variation commonly observed in AD are genetically influenced. In this chapter a 
number of novel linkage regions have been identified after including clinical 
covariates in linkage analysis. This further supports the hypothesis that disease 
presentation in AD is genetically modified, or that clinically homogeneous sub­
phenotypes exist which will be useful in untangling the complex genetics of late- 
onset AD. The strongest evidence for linkage was observed with mean AAO on 
chromosome 21. In addition, four significant increases in linkage evidence were 
observed after including psychosis, aggression and depression. While it is likely 
that a number of these loci represent false positives, future linkage and 
association analyses of these regions should consider incorporating the relevant 
phenotypic information. The obvious next step is to screen these regions for 
functional candidate genes which may be implicated in the susceptibility to AD, 
sub-phenotypes or disease modification.
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Chapter 5
General discussion
Late-onset Alzheimer’s disease (LOAD) is a clinically heterogeneous disorder. 
There is substantial evidence that LOAD is highly heritable, however, other than 
APOE, the identification of further susceptibility genes has remained problematic. 
Some have suggested that aspects of clinical variation may offer an appropriate 
means of delineating homogeneous disease subtypes which could be useful for 
genetic analysis (Sweet et al. 2003). This approach is becoming increasingly 
popular in genetic investigations and has facilitated the identification of 
susceptibility genes in studies of asthma (Van Eerdewegh et al. 2002) and Crohn’s 
disease (Rioux et al. 2001). A growing number of linkage (discussed in section 
4.1.4) and association studies (discussed briefly in section 1.3) have sought to 
identify genes associated with AD. However, studies which have aimed to 
determine which aspects of clinical variation are likely to be genetically modified 
have been relatively scarce (discussed in sections 3.1.4 and 3.1.5). This thesis 
has employed a more comprehensive approach to studying the genetic aetiology 
of clinical variation observed in AD. First, principal components analysis was used 
to elucidate behavioural components, or groups of symptoms which are likely to be 
related. These components were then used to inform the classification of 
behavioural symptoms in a sample of relative pairs, with the initial goal of 
determining which aspects of the clinical phenotype in AD are genetically 
influenced. A method of covariate linkage analysis was then used to search for loci 
linked to aspects of the disease phenotype showing evidence of familial clustering.
5.1 Summary of findings
The main aim in chapter 2 was to determine if the variety of behavioural symptoms 
observed in AD could be explained by a lesser number of components.
Behavioural disturbances among a sample of 1,120 individuals suffering with AD 
were characterised using the Neuropsychiatric Inventory (NPI) (Cummings 1997). 
These data were then submitted to principal components analysis. This represents
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the largest study of its type reported to date. Three components were identified 
which largely accounted for the 12 symptoms covered by the NPI, these were: 
‘frontal lobe dysfunction’, ’psychosis’ and ‘mood’. They remain relatively stable 
after controlling for disease severity and in analysis restricted just to those in the 
later stages of disease development. Furthermore, the component structure was 
largely comparable to a number of previous reports (Aalten et al. 2003; Fuh et al. 
2001; Mirakhur et al. 2004; Spalletta et al. 2004), providing further evidence that 
robust constructs had been identified which could reflect common underlying 
neuropathology. The identified components were independent of gender, current 
age, years in education, number of APOE z4 alleles and family history of 
dementia. However, higher frontal lobe dysfunction component scores were 
associated with a lower AAO, whilst higher scores were reported for all 
components among those with more severe cognitive impairment.
It is likely that components identified through this kind of analysis have a closer 
biological link to the underlying causative mechanisms than symptoms which are 
categorised based on psychiatric classification systems. Research into the familial 
aggregation of behavioural symptoms is limited; however, the available evidence 
suggests that psychosis, depression and agitation in AD could be genetically 
influenced (Bacanu et al. 2005; Sweet et al. 2002; Tunstall et al. 2000). Similarly, a 
number of studies have suggested that AAO in LOAD may be heritable (Daw et al. 
1999; Li et al. 2002; Tunstall et al. 2000). However, before searching for loci 
involved in the aetiology of clinical variation, further research were required to 
expand earlier family based studies. In chapter 3 of this thesis, data from the 
principal components analysis were used to inform the categorisation of symptoms 
in a large series of sibling pairs. As such individuals were rated for psychosis, 
aggression, depression with anxiety, minor and major depression, with the primary 
aim of determining whether these symptoms clustered in families more often than 
would be expected by chance. The familial influence on age at disease onset was 
also investigated.
A moderate correlation between ages at disease onset among siblings was 
observed. Furthermore, this effect was consistent across three independent 
samples of sibling pairs and was independent of the effects conferred by the
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APOE e4 allele. Of the behavioural symptoms assessed psychosis showed the 
strongest evidence for familial aggregation. Consistent with previous findings 
(Bacanu et al. 2005; Sweet et al. 2002), psychotic symptoms in probands were 
associated with over a three-fold increase in risk for developing psychosis in AD 
affected siblings. This effect was noted in both samples with available data. 
Significant familial influences were also observed for symptoms of aggression and 
minor depression. The results regarding major depression and depression with 
anxiety were less consistent. Both of these in probands were associated with 
around a two-fold increase in risk among siblings with AD. However, the effects on 
the whole were not statistically significant. This may have reflected a lack of 
power, given that both of these symptoms had a relatively low prevalence.
AAO, psychosis, aggression and minor depression showed the strongest evidence 
of being genetically influenced. As such they may be markers for more 
homogeneous disease subtypes or may be modified by genetic variation which 
does not increase susceptibility to the disease as a whole. Linkage analysis 
provides a means of searching for regions which are likely to contain loci linked to 
a particular phenotype. In chapter 4, age at disease onset (mean and difference 
among relative pairs), psychosis, aggression and minor depression were used as 
covariates in linkage analysis. Samples from two overlapping genome screens, 
presented by Myers and colleagues (2002) and Blacker and colleagues (2003), 
were combined to provide one of the largest samples used for linkage analysis of 
LOAD reported to date. A number of novel linkage signals were identified. Three 
peaks were observed with mean AAO, on chromosomes 1, 2 and 21. The linkage 
peak on chromosome 21 was in close proximity to the ones previously reported in 
overlapping samples (Holmans et al. 2005; Olson et al. 2001), and was largely due 
to increased IBD sharing probabilities among those aged over 80. Likewise, the 
linkage signals on chromosome 1 and 2 were driven by relative pairs with a later 
mean AAO. Linkage obtained with AAO difference has different, but equally 
important, biological implications. For example, one may expect to observe linkage 
among relative pairs with a similar AAO if different disease susceptibility 
genotypes give different rates of increase of disease risk with age. AAO difference 
led to a significant increase in LOD close to the APOE locus on chromosome 19 in 
the full sample. Also, it was associated with a significant increase in linkage
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evidence on chromosome 12 in the UK+NIA sample, although this effect was not 
observed in analysis restricted to NIMH relative pairs.
The inclusion of behavioural covariates led to four chromosome wide significant 
increases in LOD. Two of these regions were attributable to psychosis, which 
would appear consistent with the findings in chapter 3 suggesting that the genetic 
influences on psychosis among AD sufferers are greater than those for aggressive 
and mood related disturbances. Specifically increases in linkage evidence were 
observed on chromosome 7 and 15 with psychosis, chromosome 21 with 
depression and chromosome 9 with aggression. Interestingly, the linkage peak 
observed with depression on chromosome 21 was in close proximity to the region 
showing increased linkage among pairs with a higher mean AAO, suggesting that 
a gene, or genes, in this region may be implicated in the development of late-late 
onset AD and the aetiology of depressive symptoms. No evidence was found to 
support the previously reported linkage peaks with psychotic symptoms in AD on 
chromosomes 2 and 21 (Bacanu et al. 2002), or on chromosome 14 
(Avramopoulos et al. 2005). Chromosome 10 is arguably the most consistent 
region of linkage for late-onset AD reported to date (Bertram et al. 2000; Blacker et 
al. 2003; Ertekin-Taner et al. 2000; Farrer et al. 2003; Li et al. 2002; Myers et al.
2000). The data from these analyses come from two overlapping genome screens 
which both report linkage in this region, as such highly significantly linkage 
evidence was found on chromosome 10. However, none of the covariates had an 
effect on linkage in this region, hence it is likely that chromosome 10 harbours a 
gene, or genes, which increases risk of AD as a whole, irrespective of age at 
disease onset or behavioural disturbances.
5.2 Implications and future research
These findings have implications for those seeking to delineate the genetic 
underpinnings of AD. In particular, they underscore the utility of using covariates in 
genetic analysis to identify potentially homogeneous subsets of the disease. 
Further, they highlight the possibility that the clinical presentation of AD may be 
genetically modified.
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This has particular implications as gaining a better understanding of the factors 
associated with behavioural symptoms and age at disease onset may lead to the 
achievable target of disease modification. Due to the late onset nature of AD, 
therapies which could delay the onset of symptoms, even if only briefly would have 
a major impact on public health. Indeed, one study has suggested that an 
intervention which could delay the onset of AD by just 2 years would result in 
nearly 2 million fewer cases of the disease in the United States over the next 50 
years, whilst a delay of 5 years would reduce prevalence by a half (Brookmeyer et 
al. 1998). Behavioural symptoms, as discussed in section 2.1.2, are associated 
with many serious consequences, not only for the individual with AD (Burns et al. 
1990b; Neumann et al. 2001; Rosen and Zubenko 1991; Spalletta et al. 2004), but 
also in terms of additional caregiver distress (Kaufer et al. 1998) and the impact on 
the economy (Steele et al. 1990). As such, the development of effective therapies 
to control these symptoms is of great importance. The identification of genes 
associated with the processes of disease development in AD is likely to offer 
useful insights into the aetiology of the clinical differences observed between 
patients. This may facilitate the development of therapeutic interventions aiming to 
modify disease presentation. Furthermore, it may serve as a means of identifying 
those at high risk of developing certain symptoms, which could assist the 
appropriate management of the illness by caregivers and clinicians.
It is likely that the analysis of disease sub-phenotypes will lead to the identification 
of loci which only account for a relatively small proportion AD cases. However, it 
remains likely that their identification would greatly advance our understanding of 
the pathophysiological disease process in AD as a whole. The findings from this 
thesis could be used to inform future genetic association studies aiming to find risk 
alleles which influence the clinical presentation of AD, and also for genes which 
increase disease susceptibility as a whole.
A number of studies have already been reported which have sought to identify 
genes associated with behavioural symptoms in AD. The most popular approach 
has been to search for genetic variation that modifies the clinical presentation of 
AD, rather than for genes which increase susceptibility to a disease sub­
phenotype characterised by specific clinical features. As such they generally
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compare the effect of genetic variation in samples of AD sufferers with and without 
clinically distinguishing features (e.g. AD cases with and without psychosis). 
Researchers have focused on genes that are associated with AD (e.g. APOE) or 
other psychiatric illnesses (e.g. dopamine and serotonin receptor genes).
The APOE e4 allele is associated with more rapid disease progression, greater 
amyloid and neurofibrillary tangle burden, increased atrophy of the temporal lobes 
and more profound cholinergic loss in the frontal cortex (Gomez-lsla et al. 1996; 
Kanai et al. 1999; Lehtovirta et al. 1996b; Soininen et al. 1995). Behavioural 
symptoms are also associated with numerous neuropathological changes 
(Cummings 2000) and cholinergic deficits (Garcia-Alloza et al. 2005). As such, it is 
reasonable to hypothesise that APOE may play a role in the aetiology of 
behavioural disturbances in AD. In chapter 2 of this thesis none of the behavioural 
components identified through principal components analysis were associated with 
the APOE e4 allele (see section 2.3.3)
Other studies which have investigated the effect of APOE on behavioural 
symptoms have generally reported contradictory results. A number of studies have 
reported an association between psychosis in AD and APOE (Cacabelos et al. 
1997; Forsell et al. 1998; Ramachandran et al. 1996). Many of these have relied 
on relatively small samples and have reported trends, rather than statistically 
significant differences (Cacabelos et al. 1997; Forsell et al. 1998). However, an 
association between APOE and psychotic symptoms has been reported in 
longitudinally assessed (Scarmeas et al. 2002) and large cross sectional samples 
(Harwood et al. 1999). Despite these findings the majority of studies have not 
reported a relationship between APOE and psychosis. These studies have 
generally relied on samples of less than 300 AD sufferers (Hirono et al. 1999; 
Lehtovirta et al. 1996a; Lopez et al. 1997; Lyketsos et al. 1997; Nacmias et al.
2001). Levy and colleagues (1999) used a much larger sample of 605 AD 
sufferers and did not find an association between APOE and psychotic symptoms. 
However, their sample was recruited to test the effect of cholinesterase inhibitors 
on AD progression and as such was heavily biased toward those in the earlier 
stages of dementia. It is possible that APOE increases the susceptibility to 
psychotic symptoms expressed in the later stages of the disease. Indeed,
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Harwood and colleagues (1999) noted that APOE had a stronger effect on 
psychotic symptoms in those in the severe stages of disease development.
There is some evidence to suggest that APOE is associated with the development 
of depressive illness in the absence of dementia, however the findings to date are 
somewhat contradictory (Holmes et al. 1998b; Krishnan et al. 1996; Rigaud et al. 
2001; Zubenko et al. 1996). As such one may speculate that APOE is implicated in 
the development of depressive symptoms in AD. Indeed, such an association has 
been noted in a number of studies (Ramachandran et al. 1996). However, these 
findings have not replicated in larger samples (Holmes et al. 1996). Others have 
reported an association between the APOE z2 allele and depression in AD 
(Holmes et al. 1996), however, numerous other studies have not noted this effect 
(Craig et al. 2005b; Harwood et al. 1999; Hirono et al. 1999; Levy et al. 1999; 
Lopez et al. 1997; Lyketsos et al. 1997; Muller-Thomsen et al. 2002).
In general, the evidence for an association between APOE and behavioural 
symptoms is limited and hindered by a lack of consistent findings. In addition to 
APOE, a number of studies have focused on genes which are implicated in the 
development of other psychiatric conditions, such as schizophrenia. As such, the 
most intensively studies genes in relation to behavioural symptoms in AD are 
dopamine (DRD) and serotonin (5-HT) receptor genes. Numerous polymorphisms 
in DRD1, DRD2, DRD3 and DRD4 have been studied extensively in relation to 
neuropsychiatric illnesses (Sweet et al. 1998). The relationship between DRD 
genes and schizophrenia is complicated, with numerous contradictory findings. 
Meta-analyses and large, multicenter studies appear to support an association 
between polymorphisms in the DRD2, DRD3 and DRD4 genes with schizophrenia 
(Abdolmaleky et al. 2005). Sweet and colleagues (1998) were the first to report a 
relationship between behavioural symptoms in AD and variation within the 
dopamine receptor genes, reporting a significant excess of DRD1 B2/B2 
homozygotes among those with symptoms of aggression and psychosis. They 
also reported that psychotic symptoms, but not aggression, occurred more 
frequently among patients who were homozygous for either DRD3 allele. These 
findings have been replicated in an independent sample (Holmes et al. 2001).
More recently, Craig and colleagues (2005c) have performed analysis of the
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DRD3 polymorphism using a much larger sample of 416 individuals with LOAD. In 
contrast to previous findings they reported that DRD3 was not associated with the 
presence of either delusions or hallucinations. It is difficult to draw conclusions 
from these three studies. It would appear that DRD1 is implicated in the 
modification of behavioural symptoms in AD. However, the role of DRD3 is less 
clear, with current research suggesting that its role in symptom development is 
likely to be limited.
Others have sought to investigate common polymorphisms in the 5-HT2A and 5- 
HT2c serotonin receptor genes (102 T/C and Cys23Ser polymorphisms, 
respectively) in relation to behavioural symptoms observed in AD. These 
polymorphisms have been implicated the aetiology of a number of psychiatric 
conditions, including psychosis (Abdolmaleky et al. 2005; Gutierrez et al. 1996; 
Williams et al. 1997), bipolar affective disorders (Arranz et al. 1997), and eating 
disorders (Nacmias et al. 1999). Reduced serotonergic activities have also been 
linked to depression and psychosis among dementia sufferers (Chen et al. 1996; 
Lanctot et al. 2001), whilst, aggressive symptoms in AD have been associated 
with 5-HT2A receptor loss at post-mortem (Procter et al. 1992). Despite not 
showing an association with disease risk as a whole, polymorphisms in the 5 -HT2A 
and 5 -HT2c serotonin genes have been shown to increase risk of developing 
psychotic symptoms during the course of AD (Assal et al. 2004; Holmes et al. 
1998a; Lam et al. 2004; Nacmias et al. 2001). However, it should be noted that the 
data is somewhat contradictory, with two studies reporting the C102 allele 
increases risk of developing psychotic symptoms (Holmes et al. 1998a; Nacmias 
et al. 2001), whilst others have found the T102 allele to confer increased risk 
(Assal et al. 2004; Lam et al. 2004). In addition, others have reported that the long 
variant of an insertion/deletion polymorphism in the promoter region of the 
serotonin transporter gene (5-HTTPR) is associated with an increased risk of 
developing aggressive and psychotic symptoms in AD (Sukonick et al. 2001). 
However, Assal and colleagues (2001) failed to replicate these findings in an 
independent sample.
Others have hypothesised that the catechol-O-methyltransferase (COMT) gene 
may be associated with the presence of behavioural symptoms. COMT resides on
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chromosome 22q11.2 and has been postulated as a functional candidate gene for 
schizophrenia (Glatt et al. 2003) due to is role in encoding a protein that 
enzymatically inactivates dopamine (Axelrod and Tomchick 1958). A number of 
authors have investigated the relationship between psychotic symptoms in AD and 
COMT (Borroni et al. 2004; Sweet et al. 2005). Borroni and colleagues reported 
that the widely studied G to A substitution in codon 108/158 of COMT (RS4680) 
was associated with the development of psychotic symptoms, despite not 
influencing risk for AD as a whole. Following this report, Sweet and colleagues 
(2005) have reported an investigation of four polymorphisms, namely RS4680, 
ERE6, RS737865 and RS165599. They reported a significant association between 
the RS4680 polymorphism and psychosis among females, but not males. In 
haplotype analysis they reported a highly significant association of a four locus 
haplotype with psychotic symptoms in AD among females, which appeared to 
result from the additive effects of alleles at ERE6 and RS737865 which were in 
very high linkage disequilibrium.
Craig and colleagues (2004a) recently reported that the tryptophan hydroxylase 
(TPH) gene, located on chromosome 11, is associated with aggression in AD. A 
bi-allelic polymorphism in intron 7 of TPH has previously shown association with 
both suicidality (Bellivier et al. 2004) and aggressive behaviour (Manuck et al.
1999). However, the effect reported by Craig and colleagues was largely confined 
to males, suggesting that TPH may have gender specific effects. An earlier report 
found no association between TPH and AD (Wang et al. 2001), suggesting that it 
may modify susceptibility to aggressive symptoms after disease onset. Further to 
this, Craig and colleagues (2004b) have also reported an association between 
psychosis and genetic variation within the interleukin 1p (IL-1 p) gene, located on 
chromosome 2q. They focused on a polymorphism in the promoter region which 
has previously shown association with schizophrenia (Katila et al. 1999; Zanardini 
et al. 2003), but not AD (Ehl et al. 2003). Using a sample of 424 probable AD 
sufferers they reported a significant association with IL-1 (3 and the presence of 
hallucinations and delusions separately, and with a combined phenotype of 
delusions or hallucinations. These findings are of particular interest as cytokines 
such as IL-1 p have been reported to influence levels of numerous 
neurotransmitters, such as serotonin and dopamine (Wichers and Maes 2002),
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which have been implicated in the development of psychosis in AD (Garcia-Alloza 
et al. 2005). They also support the hypothesis that common aetiological pathways 
exist in AD with psychosis and schizophrenia (Sweet et al. 2003).
It is clear from the research to date that the inclusion of clinical covariates in 
genetic association studies is likely to increase our ability to identify loci implicated 
in the development, and progression, of Alzheimer’s disease. Current association 
based investigations of behavioural problems in AD support the findings from 
chapter 3 of this thesis, which suggest that the variation commonly observed 
among AD sufferers is, at least in part, genetically influenced. To date studies 
have largely focused on candidate genes for other major psychiatric disorders, 
such as schizophrenia. It is notable that none of the genes which have already 
shown association with behavioural symptoms are in regions of linkage identified 
in chapter 4 of this thesis. Analysis of genes in these regions is likely to reveal 
further loci which are implicated in the processes of disease development in AD. 
To date, studies have tended to view behavioural symptoms in isolation. More 
success may be obtained by looking at behavioural components, rather than 
individual symptoms. In addition, the majority of studies have investigated the 
relationship between genetic variation and psychotic symptoms in AD, with a 
lesser number focusing on symptoms of depression and aggression. Symptoms of 
anxiety, disinhibition and euphoria, and disturbances in circadian rhythm and 
appetite have been largely overlooked.
Together with the near completion of the human genome project, the ever 
increasing efficiency and lowering costs of high throughput genotyping, ensure 
that the coming years will undoubtedly be a productive time for those investigating 
the genetics of complex disorders. The findings from this programme of research 
serve to highlight the utility of including clinical covariates in genetic analyses of 
AD, providing adequate justification for future studies with the a priori goal of 
identifying genetic variation associated with clinical heterogeneity. They also have 
implications for prospective large scale collections of samples intended for use in 
genetic studies of AD as a whole. Such studies are likely to benefit from 
comprehensively characterising the disease phenotype, using established
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measurement tools. Such data is likely to prove useful in secondary analyses of 
these datasets.
Future studies may seek to identify other distinguishing factors of AD that may be 
useful for delineating more homogenous disease sub-phenotypes. For example, a 
large proportion of those with AD also have substantial co-morbid 
cerebrovasucular pathology (Humpel and Marksteiner 2005). AD with less 
cerebrovasucular disease may represent a ‘purer form’ of the illness which may be 
useful for genetic analyses. Alternatively, researchers may seek to draw on 
“endophenotypes”, or measurable components of the illness, which lie along the 
pathological pathway of the disease (Gottesman and Gould 2003). These can take 
the form of neurophysiological, biochemical, neuroanatomical, cognitive and 
neuropsychological measures (Leboyer et al. 1998). In comparison to disease 
status as a whole, such intermediate phenotypes may be more closely linked to 
the biological function of genes. Of particular interest maybe the use of biological 
markers obtained through use of advanced neuroimaging, such as magnetic 
resonance imaging (MRI) or single photon emission computed tomography 
(SPECT).
As pointed out by Lovestone and Hardy (2002) there is now an urgent need to 
replicate findings in relation to clinical variation in independent, well characterised 
samples. The NIMH families used in this thesis has been used extensively to 
perform linkage analyses using numerous covariates including AAO (Holmans et 
al. 2005; Li et al. 2002; Olson et al. 2001, 2002), rate of decline (Holmans et al. 
2005) and psychosis (Avramopoulos et al. 2005; Bacanu et al. 2002). The findings 
from this thesis offer promise to those searching for genes implicated with age at 
disease onset, psychosis and to a lesser extent aggression and mood 
disturbances in AD. As such, there is now a growing need, not only for further 
prospective association studies, but also for the current linkage findings to be 
replicated in independent family-based samples.
1
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5.3 Conclusions
Genetic variation is likely to play a role in the clinical heterogeneity commonly 
observed in AD. This observation supports the view that AD is a syndrome with 
multiple contributing aetiologies. Linkage analysis has identified numerous regions 
which are likely to contain genes which influence the development of behavioural 
disturbances occurring as part of the illness and the age at disease onset. Further 
study is required to genetically dissect these regions. The identification of genes 
associated with clinical features of AD, is likely to increase our understanding of 
the disease as a whole, which could ultimately lead to the development of more 
effective therapeutic interventions.
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Appendices
2a Rotated component loadings after controlling for disease 
severity (GDS)
Component loadings for the NPI after controlling for GDS and years in education the 
full sample (n=1120).
Item Com ponent 1 Com ponent 2 Component 3
Delusions 0.78
Hallucinations 0.78
Agitation/Aggression 0.66
Depression/Dysphoria 0.82
Anxiety 0.74
Euphoria 0.63
Apathy 0.42
Disinhibition 0.74
Irritability 0.67
Aberrant Motor Behaviour 0.52
Sleep disturbances 0.44
Appetite abnormalities 0.33
Eigenvalue 2.89 1.14 1.07
% of Variance 24.11 9.54 8.94
NB: Values less than 0.3 are not shown
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2b Distribution of component scores before and after log 
transformations
Component 1 - “Frontal lobe dysfunction”
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3a DSM-IV criteria for a major depressive episode
A. Five (or more) of the following symptoms have been present during the same 
2-week period and represent a change from previous functioning; at least one 
of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad or empty) or observation made by others 
(e.g., appears tearful)
2. Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated by either subjective account or 
observation made by others)
3. Significant weight loss when not dieting or weight gain (e.g. a change of 
more than 5% of body weight in a month), or decrease or increase in 
appetite nearly every day. Note: in children, consider failure to make 
expected weight gains.
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or retardation nearly every day (observable by 
others, not merely subjective feelings of restlessness of being slowed down)
6. Fatigue or loss of energy nearly every day
7. feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being 
sick)
8. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others)
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide.
B. The symptoms do not meet criteria for a Mixed Episode.
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hypothyroidism).
E. The symptoms are not better accounted for by Bereavement, i.e., after the loss 
of a loved one, the symptoms persist for longer than 2 months or are 
characterized by marked functional impairment, morbid preoccupation with 
worthlessness, suicidal ideation, psychotic symptoms, or psychomotor 
retardation.
Taken from the “Diagnostic and statistical manual of mental disorders: DSM-IV”
(American Psychiatric Association 1994)
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3b Cornell scale for depression in dementia
Scoring: 0 absent 1 mild or intermittent 2 severe
Have you noticed him/her showing an anxious
expression, ruminating, or worrying? 0 1 2
Showing a sad expression, sad voice, or being tearful? 0 1 2
Not reacting as positively as usual to pleasant events? 0 1 2
Being easily annoyed or short tempered? 0 1 2
Showing restlessness, hand wringing, or hair pulling? 0 1 2
Slowing of movements, slow speech, slow reactions 0 1 2
Complaining of many physical problems? 0 1 2
To be less involved in usual activities? 0 1 2
To be eating less than usual? 0 1 2
To show weight loss? 0 1 2
Fatiguing easily or being unable to sustain activities? 0 1 2
Being generally worse in the morning, in terms of
mood or behaviour? 0 1 2
Falling asleep later than usual? 0 1 2
Waking many times during the night? 0 1 2
Waking early in the morning? 0 1 2
Saying he/she feels life is not worth living, talking
of suicidal wishes, or making a suicide attempt? 0 1 2
Talking about blaming himself/herself, or talking
about poor self-esteem or feelings of failure? 0 1 2
Appearing to expect the worst? 0 1 2
Speaking as though convinced he/she suffers from
poverty, physical illness or loss, when this is clearly 0 1 2
not the case?
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3c DSM-IV criteria for generalised anxiety disorder
A. Excessive anxiety and worry (apprehensive expectation), occurring more days 
than not for at least 6 months, about a number of events or activities (such as 
work or school performance).
B. The person finds it difficult to control the worry.
C. The anxiety and worry are associated with three (or more) of the following six 
symptoms (with at least some symptoms present for more days than not for 
the past 6 months). Note: Only one item is required in children.
1. Restlessness or feeling keyed up or on edge
2. Being easily fatigued
3. Difficulty concentrating or mind going blank
4. Irritability
5. Muscle tension
6. Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep)
D. The focus of the anxiety and worry is not confined to features of an Axis I 
disorder, for example, the anxiety or worry is not about having a Panic Attack 
(as in Panic Disorder), being embarrassed in public (as in Social Phobia), 
being contaminated (as in Obsessive-Compulsive Disorder), being away from 
home or close relatives (as in Separation Anxiety Disorder), gaining weight (as 
in Anorexia Nervosa), having multiple physical complaints (as in Somatization 
Disorder), or having a serious illness (as in Hypochondriasis), and the anxiety 
and worry do not occur exclusively during Posttraumatic Stress Disorder.
E. The anxiety, worry, or physical symptoms cause clinically significant distress 
or impairment in social, occupational, or other important areas of functioning.
F. The disturbance is not due to the direct physiological effects of a substance 
(for example, a drug of abuse, a medication) or a general medical condition 
(for example, hyperthyroidism) and does not occur exclusively during a Mood 
Disorder, a Psychotic Disorder, or a Pervasive Developmental Disorder.
Taken from the “Diagnostic and statistical manual of mental disorders: DSM-IV”
(American Psychiatric Association 1994)
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4a Chromosomal regions genotyped in the UK and NIA samples.
Summary of chromosomal regions genotyped in the UK and NIA samples
Chromosome
Number of markers 
genotyped in 
UK+NIA sample
Chromosomal region 
genotyped in NIMH 
Sample (cM)
Region(s) genotyped in 
the UK and NIA 
samples (cM)
1 19 8.9 - 274.5 10.8-65.5, 125.5 -161.1
2 13 3.8-251.9 7.6-103.2
5 10 0.0-195.5 7.8 - 64.7
6 7 9.2-187.2 53.8 - 88.6
9 18 0.0-163.8 29.5- 142.5
10 18 4.3-170.9 59.0- 135.2
12 9 6.4-165.7 6.4 - 50.9
13 3 8.9-110.6 67.7 -82.9
14 8 9.4-138.2 9.4 - 66.8
19 7 0.0-100.6 56.7-100.0
21 11 3.0 - 57.8 3.0 - 57.8
NB: Chromosomes that are not shown were not genotyped in the UK or NIA samples
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4b Summary table for linkage analyses including Age at Onset and
APOE for all chromosomes.
Chromosome Sample Number of Univariate Pairs LOD
Incr. Mean 
AAO
Incr. Diff 
AAO
Incr.
APOE
Incr. Mean 
| APOE
Incr. Diff 
| APOE
1 Full 521 0.73 1.58 (+) 0.07 1.06 1.28 (+) 0.47
1 NIMH 380 0.87 2.00 (+) 0.00 1.04 1.48 (+) 0.06
1 UK+NIA 141 0.54 0.17 0.38 1.38 0.13 0.02
2 Full 511 0.37 1.33 (+) 1.37 0.74 1.37 (+) 0.80
2 NIMH 380 0.37 1.33 (+) 1.01 0.74 1.37 (+) 0.50
2 UK+NIA 131 0.06 0.16 0.99 0.36 0.18 1.16
3 NIMH 379 0.77 0.83 0.27 0.54 0.40 0.45
4 NIMH 379 0.40 0.49 0.13 0.94 0.02 0.00
5 Full 511 1.31 0.01 0.00 0.42 0.08 0.00
5 NIMH 380 1.36 0.02 0.00 0.60 0.00 0.00
5 UK+NIA 131 0.31 0.02 0.07 0.62 0.00 0.00
6 Full 523 0.72 0.30 0.93 0.80 0.04 0.26
6 NIMH 380 0.48 0.24 1.34 1.38 0.10 0.15
6 UK+NIA 143 1.15 0.14 0.03 0.22 0.01 0.04
7 NIMH 380 0.38 0.24 0.98 0.66 0.23 0.72
8 NIMH 379 0.75 0.02 0.59 0.82 0.00 0.50
9 Full 532 2.32 0.03 0.00 0.07 0.07 0.00
9 NIMH 380 3.32 0.24 0.00 0.14 0.32 0.00
9 UK+NIA 152 1.05 0.01 0.00 0.47 0.03 0.00
10 Full 523 3.44 0.01 0.00 0.76 0.00 0.02
10 NIMH 380 2.17 0.21 0.05 0.51 0.15 0.21
10 UK+NIA 143 1.42 0.34 0.00 0.21 0.28 0.00
11 NIMH 379 0.86 0.31 0.43 0.70 0.01 0.07
12 Full 523 0.13 0.24 0.79 1.00 0.03 0.51
12 NIMH 380 0.04 0.32 0.88 0.81 0.13 0.21
12 UK+NIA 143 0.65 0.14 1.71 0.06 0.14 2.12
13 Full 511 0.11 0.20 0.07 1.01 0.00 0.00
13 NIMH 380 0.19 0.23 0.12 0.89 0.00 0.00
13 UK+NIA 131 0.00 0.07 0.07 0.17 0.01 0.14
14 Full 528 0.03 0.47 1.18 0.39 0.19 2.14
14 NIMH 380 0.33 0.87 0.74 0.34 0.63 0.98
14 UK+NIA 148 0.03 0.24 0.30 0.85 0.06 0.85
15 NIMH 380 0.07 0.53 1.16 0.13 0.43 1.22
16 NIMH 380 0.11 0.47 0.30 0.51 0.26 0.04
17 NIMH 380 1.13 0.17 0.00 0.25 0.20 0.00
18 NIMH 380 0.16 0.23 1.64 0.66 0.21 1.01
19 Full 529 1.47 0.48 1.36 - - -
19 NIMH 380 0.95 0.34 1.02 - - -
19 UK+NIA 149 1.41 0.73 0.66 - - -
20 NIMH 379 0.35 0.70 0.00 0.33 0.52 0.02
21 Full 521 0.39 1.45 (+) 0.00 1.35 0.95 (+) 0.00
21 NIMH 380 0.07 2.26 (+) 0.00 1.74 0.89 (+) 0.00
21 UK+NIA 141 0.99 0.00 0.00 0.69 0.05 0.00
22 NIMH 379 0.50 0.42 0.37 0.61 0.45 0.56
The six columns of maximum mulitpoint LOD scores refer to (left to right):
1) The maximum mulitpoint LOD score (MLS) when no covariates are used in the analysis, the 
increases given by including 2) mean AAO, 3) AAO difference, 4) APOE genotype. The increase in 
MLS given by including 5) mean AAO and 6) AAO difference after allowing for APOE effects.
(+) in the mean AAO column indicates that IBD sharing increased with increasing AAO, (-) indicates 
increased IBD sharing in pairs with lower mean AAO
NB: Genotypes were not available in the UK + NIA sample for chromosomes where only NIMH results 
are shown
4c Supplementary analyses of chromosome 21 incorporating age at
onset data
Chromosome 21 
NIMH Sample (277 Sibling Pairs)
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Maximum mulitpoint LOD score graphs for chromosome 21. Figure a) shows the 
analysis performed using using sibling pairs and marker genotypes analysed by 
Holmans and colleagues. Figure b) shows the analysis after incorportating 
additional families, individuals, relative pairs and marker genotypes. Markers 
highlighted in green and red were common to both analyses. However, additional 
marker genotypes were available for markers highlighted in green which were not 
used by Holmans and colleagues. The two markers highlighed in blue were not 
included in the analysis reported by Holmans and colleagues.
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Two point LOD scores for chromosome 21 including mean AAO for the NIMH 
sample
Marker cM No Covariates Incr. Mean AAO
D21S1432 1 3.0 0.17 0.73
D21S14322 3.0 0.11 0.63
D21S1201 1 3.0 0.27 0.99
D21S1899 1 9.7 0.02 1.23
D21S1437 1 13.1 0.00 2.19
D21S1437 2 13.1 0.13 1.24
D21S1914 1 19.4 0.00 1.62
D21S1435 1 22.6 0.15 0.83
D21S217 1 22.8 0.00 1.42
D21S2052 2 24.7 0.00 0.31
D21S19091 28.5 0.04 1.26
D21S14401 36.8 0.44 0.01
D21S1440 2 36.8 0.38 0.22
D21S2055 2 40.5 0.05 0.73
D21S2661 45.9 0.00 0.06
D21S18851 52.5 0.00 0.01
D21S14461 57.8 0.00 0.11
D21S1446 2 57.8 0.00 0.09
1 Marker genotypes taken from genome screen reported by Myers et al (2002)
2 Marker genotypes taken from genome screen reported by Blacker et al (2003)
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Multipoint LOD score graphs for chromosome 21, including AAO mean and APOE 
as covariates, after removing marker D21S2052.
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4d S ummary table for linkage analyses including psychosis and APOE
for all chromosomes.
Chromosome Sample Number of Pairs
Univariate
LOD
Incr.
Psychosis
Incr.
Incr. APOE Psychosis | 
APOE
1 NIMH 266 1.11 0.60 1.34 0.48
1 NIMH+UK 303 1.30 0.84 0.75 0.36
2 NIMH 266 0.30 2.12 (+) 0.35 1.90 (+)
2 NIMH+UK 303 0.45 1.24 (+) 0.34 0.99 (+)
3 NIMH 265 0.35 0.54 0.72 0.04
4 NIMH 265 0.25 0.45 0.41 0.20
5 NIMH 266 0.82 0.47 0.09 0.69
5 NIMH+UK 303 0.53 0.76 0.07 1.00
6 NIMH 266 1.03 0.53 1.04 0.71
6 NIMH+UK 303 1.09 0.58 1.11 0.77
7 NIMH 266 0.60 2.25 (+/-) 0.32 2.00 (+/-)
8 NIMH 265 1.40 0.10 0.45 0.13
9 NIMH 266 1.98 0.47 0.01 0.47
9 NIMH+UK 307 1.31 0.71 0.07 0.64
10 NIMH 266 0.96 0.39 0.21 0.18
10 NIMH+UK 303 1.32 0.54 0.15 0.39
11 NIMH 265 0.91 0.10 1.44 0.09
12 NIMH 266 0.25 0.26 1.61 0.25
12 NIMH+UK 303 0.30 0.32 1.09 0.20
13 NIMH 266 0.89 0.06 0.34 0.06
13 NIMH+UK 303 0.91 0.07 0.35 0.06
14 NIMH 266 0.39 0.48 0.12 0.36
14 NIMH+UK 306 0.38 0.49 0.11 0.38
15 NIMH 266 0.20 2.6 (-) 0.08 2.54 (-)
16 NIMH 266 0.15 0.57 0.49 0.05
17 NIMH 266 0.41 0.21 0.52 0.17
18 NIMH 266 0.02 1.49 (-) 1.14 1.23 (-)
19 NIMH 266 1.34 0.56 - -
19 NIMH+UK 307 1.00 0.65 - -
20 NIMH 265 1.38 0.18 0.30 0.19
21 NIMH 266 0.05 0.25 3.87 0.08
21 NIMH+UK 304 0.11 0.41 3.63 0.36
22 NIMH 265 0.27 0.26 0.71 0.17
The four columns of maximum mulitpoint LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the 
analysis, the increases given by including 2) psychosis, 3) APOE genotype, 4) The 
increase in MLS given by including psychosis after allowing for APOE effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing 
was elevated in -I- pairs, (+/-) indicates that IBD sharing was elevated in both -/- and +/+ 
pairs (compared to -/+ pairs)
NB: Genotypes were not available in the UK sample for chromosomes where only NIMH 
results are shown
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4e Supplementary linkage analyses of chromosome 6 incorporating
psychosis data
C h ro m o so m e 6 
NIMH+UK Sample (244 Sibling Pairs)
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Maximum mulitpoint LOD score graphs for chromosome 6. Figure a) shows the 
analysis performed using sibling pairs and marker genotypes from the genome 
screen presented by Myers and colleagues (Myers et al. 2002). Figure b) shows 
the analysis after incorportating additional families, individuals, relative pairs and 
marker genotypes. Markers highlighted in green and red were common to both 
analyses. However, additional marker genotypes were available for markers 
highlighted in green which were not used in analysis (a). Markers highlighed in 
blue were not included in the analysis reported by Myers and colleauges.
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4f Summary table for linkage analyses including aggression and
APOE for all chromosomes.
Chromosome Sample Num ber o f 
Pairs
Univariate
LOD
Incr.
Aggression
Incr.
APOE
Incr. 
Aggression 
| APOE
1 NIMH 204 0.90 0.44 0.28 0.16
1 NIM H+UK 229 1.24 0.46 0.27 0.19
2 NIMH 204 0.32 0.49 0.35 0.33
2 NIM H+UK 229 0.57 0.59 0.20 0.20
3 NIMH 204 0.55 1.57 (+/-) 0.70 0.91 (+/-)
4 NIMH 204 0.19 0.27 0.42 0.23
5 NIMH 204 0.29 0.21 0.65 0.22
5 NIMH+UK 229 0.20 0.55 0.74 0.23
6 NIMH 204 0.97 0.31 1.67 1.20 (+/-)
6 NIMH+UK 229 1.00 0.36 1.60 1.30
7 NIMH 204 0.27 1.71 (+/-) 0.34 1.43 (+/-)
8 NIMH 204 1.02 0.81 0.32 0.86
9 NIMH 204 2.12 1.53 (-) 0.22 2.03 (-)
9 NIM H+UK 232 2.18 1.43 (-) 0.06 1.85 (-)
10 NIMH 204 1.14 0.16 0.03 0.15
10 NIMH+UK 229 0.81 0.29 0.08 0.26
11 NIMH 204 0.55 0.67 1.50 0.06
12 NIMH 204 0.12 1.25 (+/-) 1.59 0.67 (+/-)
12 NIM H+UK 229 0.13 1.20 (+/-) 1.47 0.79 (+/-)
13 NIMH 204 0.09 0.62 0.34 0.71
13 NIMH+UK 229 0.09 0.81 0.35 0.75
14 NIMH 204 0.27 0.82 0.22 0.80
14 NIMH+UK 231 0.25 0.83 0.23 0.80
15 NIMH 204 0.09 0.43 0.05 0.44
16 NIMH 204 0.07 0.30 0.43 0.04
17 NIMH 204 0.59 0.05 0.46 0.00
18 NIMH 204 0.06 0.37 0.90 0.08
19 NIMH 204 0.36 0.08 - -
19 NIMH+UK 232 0.49 0.09 - -
20 NIMH 204 0.74 0.02 0.76 0.02
21 NIMH 204 0.49 0.21 4.59 0.04
21 NIMH+UK 230 0.63 0.04 4.41 0.01
22 NIMH 204 0.14 0.31 0.94 1.20
The four columns o f maximum m ulitpoint LOD scores refer to (left to right):
1) The maximum m ultipoint LOD score (MLS) when no covariates are used in the analysis, 
the increases given by including 2) aggression, 3) APOE genotype, 4) The increase in MLS 
given by including aggression a fte r allow ing fo r APO E effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing was 
elevated in -/- pairs, (+/-) indicates tha t IBD sharing was elevated in both -/- and +/+ pairs 
(compared to +/- pairs)
NB: Genotypes were not ava ilab le  in the UK sample for chromosomes where only NIMH 
results are shown
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4g S ummary table for linkage analyses including depression and
APOE for all chromosomes.
Chromosome Sample Number of Pairs
Univariate
LOD
Incr.
Depression Incr. APOE
Incr. 
Depression 
| APOE
1 NIMH 296 0.69 0.73 1.49 0.00
1 NIMH+UK 351 1.03 0.40 0.93 0.00
2 NIMH 296 0.10 0.53 0.36 0.17
2 NIMH+UK 351 0.20 0.44 0.42 0.65
3 NIMH 295 0.78 1.15 (+) 0.35 0.90
4 NIMH 295 0.37 0.31 0.39 0.09
5 NIMH 295 1.17 0.05 0.22 0.08
5 NIMH+UK 351 0.91 0.08 0.30 0.28
6 NIMH 296 0.82 0.92 0.52 0.57
6 NIMH+UK 351 0.87 0.52 0.42 0.36
7 NIMH 296 0.40 0.49 0.69 0.72
8 NIMH 295 0.64 0.60 0.32 0.84
9 NIMH 296 1.51 0.17 0.00 0.17
9 NIMH+UK 353 1.30 0.60 0.06 0.64
10 NIMH 296 2.27 1.26 (+) 0.19 1.25 (+)
10 NIMH+UK 351 2.45 0.63 0.22 0.66
11 NIMH 295 1.14 0.49 0.45 0.47
12 NIMH 296 0.28 1.03 (+/-) 0.68 0.92
12 NIMH+UK 351 0.28 1.11 (+/-) 0.78 0.91
13 NIMH 296 0.32 0.52 0.41 0.12
13 NIMH+UK 351 0.32 0.46 0.66 0.41
14 NIMH 296 0.26 0.41 0.08 0.33
14 NIMH+UK 353 0.25 0.41 0.03 0.41
15 NIMH 296 0.00 0.34 0.41 0.07
16 NIMH 296 0.09 0.32 1.23 0.00
17 NIMH 296 0.52 0.33 0.37 0.23
18 NIMH 296 0.05 0.99 1.95 0.70
19 NIMH 296 0.96 1.56 (+/-) - -
19 NIMH+UK 353 1.04 1.47 (+/-) - -
20 NIMH 295 0.63 0.88 1.13 0.73
21 NIMH 296 0.07 1.96 (+/-) 1.47 1.20
21 NIMH+UK 351 0.27 2.19 (+/-) 0.99 1.23 (+/-)
22 NIMH 294 0.24 0.85 0.62 0.42
The four columns of maximum mulitpoint LOD scores refer to (left to right):
1) The maximum multipoint LOD score (MLS) when no covariates are used in the analysis, the 
increases given by including 2) depression 3) APOE genotype, 4) The increase in MLS given by 
including depression after allowing for APOE effects.
(+) indicates that IBD sharing was elevated in +/+ pairs, (-) indicates that IBD sharing was 
elevated in -I- pairs, (+/-) indicates that IBD sharing was elevated in both -/- and +/+ pairs 
(compared to +/- pairs)
NB: Genotypes were not available in the UK sample for chromosomes where only NIMH results 
are shown
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